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ABSTRACT OF THE DISSERTATION
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Its purE-purK Operon
by
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Doctor of Philosophy in Chemistry
Washington University in St. Louis
T. Joseph Kappock, Co-Chairperson
Kevin D. Moeller, Co-Chairperson

Acetobacter aceti oxidizes ethanol to acetic acid. While the membranepermeable acetic acid is toxic to many bacteria, A. aceti survives exposure to acetic acid
by tolerating cytoplasmic acidification. The ability to tolerate an acidic cytoplasm
suggests that proteins from A. aceti are unusually suited to function in an acidic
environment. The ability to tolerate an acidic cytoplasm raises additional questions
about biosynthetic pathways that employ acid-labile intermediates. To examine how A.
aceti metabolism may have adapted to function under acidic conditions, a biosynthetic
conversion involving an acid-labile metabolite has been selected for study.
The enzyme N5-carboxyaminoimidazole ribonucleotide mutase (PurE) catalyzes
the reversible intramolecular transfer of the carboxylate of N5-carboxyaminoimidazole
ribonucleotide (N5-CAIR) to the C-4 position of the imidazole ring to form 4-
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carboxyaminoimidazole ribonucleotide (CAIR). A series of mutants was made to explore
the role of two conserved histidines. A pH-rate comparison of AaPurE and the active
mutant AaPurE-H59D was used to identify His59 as the key active site acid/base residue.
The thermostability of Escherichia coli PurE (EcPurE) over a range of pH was also
assessed and compared to AaPurE. AaPurE was found to be significantly more
thermostable than EcPurE over the entire pH range surveyed. Comparison of the pHrate profiles constructed for AaPurE with recently reported pH-rate profiles for EcPurE
indicate that the two do not differ significantly, indicating there has been no adaptive
change in enzyme mechanism. Also reported is a summary and analysis of a number of
crystal structures that have been determined for AaPurE, which suggests a strategy by
which proteins may have become resistant to acid-mediated inactivation.
Initial functional complementation studies using the purE auxotroph PC0135
suggested that AaPurE may require AaPurK to function. We constructed a set of stable
E. coli deletion strains and insertion strains that replace the chromosomal copies of
purEEc or purKEc with their counterparts from A. aceti. Functional complementation
experiments suggest that a third protein, located upstream of purEAa and conserved in
Rhodospirillales, may be involved in the proper functioning of AaPurE.
The nonenzymatic decarboxylation of CAIR and the corresponding
ribonucleoside (CAIR-s) were examined as models for the PurE reaction. The
decarboxylation of CAIR-s was not acid-catalyzed in the pH range examined, and did not
accelerate in lower-polarity solvents.
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Chapter 1
Introduction

1

1.1 Perspective
The formation of carbon-carbon bonds represents some of the most interesting
reactions in biosynthesis. Enzymes have evolved to catalyze many of these reactions
through nucleophilic intermediates that are formed in the near neutral, aqueous
environment of cells. This is especially interesting in the cases of enzymes that lack
cofactors, because they cannot use the Lewis acidity of metals to stabilize reactive
intermediates. To catalyze these reactions, enzymes employ a number of strategies
including: ground state destabilization, transition state stabilization, and the
sequestration of substrate and reactive intermediates from aqueous solvent. Many
enzymes function simultaneously as both acid and base catalysts using distinct
residue(s) in the active site.
One enzyme that catalyzes carbon-carbon bond formation by nucelophilic
attack of a stabilized carbanion (or equivalent) on an electrophilic carbonyl is PurE. PurE
catalyzes the formation of 4-carboxy-5-aminoimidazole ribonucleotide (CAIR), which
represents the sole carbon-carbon bond formed in the de novo synthesis of purine
nucleotides.
PurE. The de novo biosynthesis of inosine monophosphate (IMP) is accomplished
in a total of 10 enzymatic transformations in animals, while bacteria and other
eukaroyotes accomplish this using 11 enzymatic transformations (1). The difference
derives from how 4-carboxy aminoimidazole ribonucleotide is produced in these
pathways (Scheme 1.1). In animals, Class II PurE converts 5-aminoimidazole
ribonucleotide (AIR) + CO2 to CAIR (2). In bacteria, yeast, and plants, the conversion of
2

AIRCAIR requires two distinct steps catalyzed by two separate enzymes, PurK and
Class I PurE (3). PurK catalyzes the carboxylation of the exocyclic amino group of AIR to
form N5-carboxyaminoimidazole ribonucleotide (N5-CAIR), from AIR, ATP and
bicarbonate likely through a carboxyphosphate intermediate (3). Class I PurE then
catalyzes the reversible intramolecular transfer of the carboxylate to the C-4 position of
the imidazole ring to form CAIR (4). The different substrate preferences make Class I
PurEs N5-carboxyaminoimidazole ribonucleotide mutases (EC 5.4.99.18), and Class II
PurEs phosphoribosylaminioimidazole carboxylases (EC 4.1.1.21).

N

N
R

NH2

CAIR

PurK
ADP
Pi, H+

O-

N

PurE (Class II)

N
NH2
R AIR
ATP
HCO3-

O

H+

CO2

PurE (Class I)

N
N
R

O
N
H

O-

N5-CAIR
R = ribose 5-phosphate
Scheme 1.1: Reaction catalyzed by Class I and Class II PurEs
The identity of N5-CAIR as the substrate of Class I PurEs remained obscure until
1994, owing to the unstable nature of N5-CAIR (3). N5-CAIR and an analogue, in which
the ribose 5-phosphate group is replaced with a methyl group, undergo acid-mediated
decarboxylation even at neutral pH (3, 5).
3

The instability of N5-CAIR has inspired attempts to detect substrate channeling
between PurK and PurE in E. coli (6, 7). Channeling has been proposed to occur during
the transfer of another acid-labile intermediate in the purine biosynthesis pathway,
phosphoribosylamine (8), between two successive pathway enzymes. Recent work in
eukaryotic HeLa cells has shown a reversible co-localization of several fluorescently
labeled purine biosynthesis enzymes, detected by fluorescence microscopy under
periods of purine starvation (9).
Acetobacter aceti. A. aceti is a Gram-negative, obligately aerobic, rod-shaped
bacteria which oxidizes ethanol to acetic acid, and is used in the commercial production
of acetic acid. When grown under conditions to optimize the production of acetic acid,
the culture in which A. aceti is grown can reach levels of acetic acid up to 14% w/v (10).
Acetic acid is a membrane-permeable acid, and thus A. aceti has evolved to allow for the
acidification of its cytoplasm as acetic acid is produced (Figure 1.1) (11). This
distinguishes A. aceti from many apparently acidophilic bacteria, which resist external
acidic conditions, but routinely maintain a cytoplasmic pH near neutrality. In this work
the term “acidophilic” will be used to refer to bacteria such as A. aceti that tolerate an
acidic cytoplasm, while the term “acid resistant” will refer to other bacteria that grow in
acidic environments but maintain a relatively neutral cytoplasm. The term
“neutralophile” will refer to bacteria and eukaryotes that grow in neutral environments
and maintain a cytoplasm pH near neutrality.
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Figure 1.1: Changes in the external and internal pH during growth of A. aceti with
ethanol. The intracellular pH was measured with [C14]-acetylsalicylic acid. Internal pH
(filled squares); external pH (open squares); acetic acid (open triangles); optical density
at 546 nm (filled circles). Reproduced with permission from (11).

The effect of an acidified cytoplasm raises several interesting questions, among
them: how does an acidic cytoplasm affect the stability of acid-labile metabolites like
N5-CAIR, how is flux through pathways (like de novo purine biosynthesis) that form acidlabile metabolites affected, and how are enzymes adapted to function under acidic
conditions. It was proposed that enzymes from an acidophile such as A. aceti must be
adapted to function at low pH (12-14). As was previously posited, there are three nonexclusive ways that enzymes may be adapted for such conditions: (1) an enzyme may be
catalytically optimized to function at low pH, (2) a protein may have improved stability
at low pH, (3) a protein may work with the aid of chaperone proteins at low pH.

5

A comparison of crystal structures of proteins from A. aceti and from
neutralophiles have identified a number of characteristics for proteins from A. aceti,
including an increased number of hydrogen bonds, alterations in surface charge, or
changes in the nature and number of salt bridges. A similar preference is observed when
one compares thermophile and mesophile protein crystal structures. This suggests that
there may be shared strategies in the design of proteins suited to extreme conditions.
Proteins studied thus far from A. aceti have not only proven resistant to acid
denaturation, but are also relatively resistant to thermal denaturation (12-14). Many
extremophile proteins have “accidental” cross-resistance to different destabilizers.
Citrate synthase. An ongoing study of the enzyme citrate synthase (CS) from the
bacteria Thermoplasma acidophilum was furthered by the creation, purification, and
characterization of the mutant TM-D317G. This mutant was found to purify with partial
occupancy of oxaloacetate, which hindered kinetic characterization of binding. The
binding affinity for this mutant, and the parental mutants D317G and D317N were
determined under a series of conditions.
1.2 Purpose
To explore these critical carbon-carbon bond forming reactions, the enzyme A.
aceti PurE (AaPurE) and mutants of the enzyme Thermoplasma acidophilum citrate
synthase (TpCS) have been characterized. In Chapter 2, studies of the compound CAIR
and its corresponding ribonucleoside CAIR-s will be reported, including the change in
absorbance in the reaction of CAIR  N5-CAIR over a range of pH. This information

6

allowed for the construction of a pH-rate profile for the enzyme AaPurE and active
mutant AaPurE-H59D (Chapter 3). In Chapter 3, the characterization of several mutants
of AaPurE made to explore the roles of conserved residues His59 and His89 will be
reported along with a summary of crystal structures of several mutants, highlighting a
possible way that proteins from acidophiles are adapted to low pH. In Chapter 4, a
series of stable E. coli deletion strains, and insertion strains that replace the
chromosomal copies of purEEc or purKEc with their counterparts from A. aceti were made
and the growth of these strains examined. In Appendix I, the TpCS mutant TM-D317G
was created and purified. Characterization of this mutant, and the binding affinity the
TpCS mutants D317G and D317N for substrate analogues are also reported.
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Chapter 2
Non-enzymatic decarboxylation of 4-carboxy-5-aminoimidazole
ribonucleotide (CAIR) and 4-carboxy-5-aminoimidazole
ribonucleoside (CAIR-s)
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2.1 Introduction
Although recent studies (1-7) have given much insight into PurE-mediated
reactions, comparatively few studies have addressed the chemistry of 4-aminoimidazole
ribonucleotide (AIR) and carboxylated form (6, 8-11). Understanding the nonenzymatic
chemistry of AIR and 4-carboxy-5-aminoimidazole ribonucleotide (CAIR) is essential to a
full understanding of enzyme action. Much of the work on the nonenzymatic
carboxylation of AIR to CAIR (1) and the nonenzymatic decarboxylation of CAIR to AIR
was performed over 30 years ago (8-10), long before the correct form of the reaction
performed by Class I PurE was known (6). To gain further insight into the reaction
mechanism of PurE, additional work on the nonenzymatic reactions of CAIR or its
nucleoside CAIR-s (1-s) was performed (Figure 2.1). The reactions catalyzed by PurE
(Class I or Class II) have an unknown relationship to non-enzymatic decarboxylation.

Figure 2.1: Compounds used in this study. The product of PurE CAIR(1) and the
corresponding ribonucleoside CAIR-s (1-s)

It was suggested that PurE catalyzes the decarboxylation of CAIR (Figure 2.2 (A))
or N5-CAIR by binding the carboxylate moiety of each in a hydrophobic pocket in the
enzyme active site (2-4). This suggestion was based on analogies to other enzymes that
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catalyze decarboxylation reactions, including thiamine-dependent pyruvate
decarboxylase and biotin-dependent acyl-CoA carboxylases. In the decarboxylases,
deprotonated thiamine attacks an α-keto carboxylic acid. This species then
decarboxylates to form a resonance-stabilized intermediate. In the acyl-CoA
carboxylases, N(1’)-carboxybiotin is produced from biotin, bicarbonate, and ATP. The
N(1’)-carboxybiotin intermediate is then transferred to another active site where CO2 is
produced by decarboxylation.

Figure 2.2: Nonenzymatic decarboxylation of CAIR (A) and 2-(1-carboxy-1hydroxyethyl)-3,4,-dimethylthiazolium (B). A) Nonenzymatic decarboxylation of CAIR
(R1= ribose 5-phosphate) is studied in this work using CAIR and the corresponding
ribonucleoside CAIR-s (R1 = ribose). B) Nonenzymatic decarboxylation of 2-(1-carboxy-1hydroxyethyl)-3,4,-dimethylthiazolium has previously been studied (12, 13), as a model
compound of an isolated intermediate from the thiamine containing enzyme pyruvate
decarboxylase.
Several studies employing compounds resembling the carboxylated substrates of
these enzymes indicate that these enzymes accelerate decarboxylation by sequestration
of the carboxylate moiety in an apolar and aprotic environment (12, 14, 15). Included in
these studies is the decarboxylation of 2-(1-carboxy-1-hydroxyethyl)-3,4,dimethylthiazolium (3, Figure 2.2(B)), used as a model for 2-(1-carboxy-1-hydroxyethyl)12

3,4-thiamine pyrophosphate, an isolated intermediate of pyruvate decarboxylase. The
rate of decarboxylation of this model compound was found to increase in acetatebuffered solutions of constant ionic strength by a factor of ~104 as the percentage of
ethanol was increased from 0 to 100%. Other experiments with a model for of N(1’)carboxybiotin also showed a large increase in the rate of decarboxylation of the anionic
species of the model as the fraction of methanol or acetonitrile increases in mixed
solutions (relative rates in 100% water, methanol, and acetonitrile were 1, 49, and 517)
(15). The large increase in rate for these compounds is attributed to either ground state
destabilization or stabilization of the transition state. In the case of thiamine or biotin
adducts, the negative charge that results from decarboxylation is resonance stabilized
(Figure 2.3). For CAIR, direct decarboxylation would not benefit from such stabilization.

Figure 2.3: The direct decarboxylation of CAIR does not result in a resonance stabilized
anion (A). Model compounds of substrates for enzymes which are proposed to use
carboxylate destabilization result in resonance stabilized anions (B and C).
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Figure 2.4: Decarboxylation of 3-carboxy-benzisoxazoles.

While decreasing solvent polarity has been shown to accelerate the
decarboxylation of many compounds, a notable exception is found with 3-carboxy-4hydroxybenzisoxazole (11). While the rate of decarboxylation of other 3-carboxybenzisoxazoles increases with decreasing solvent polarity (Figure 2.4), 11 maintains a
relatively solvent-independent rate of decarboxylation in water, acetonitrile,
dimethylsulfoxide, dimethylformamide, and dimethylacetamide (16). Studies have
suggested that the cause of this solvent-independent rate is an intramolecular hydrogen
bond between the hydroxyl and carboxylate groups (16, 17). CAIR (1) could form a
similar hydrogen bond between the carboxylate and exocyclic amino group (Figure 2.5).

Figure 2.5: Intramolecular hydrogen bonds. Left, hydrogen bond in 3-carboxy-4hydroxybenzisoxazoles proposed to cause solvent-independent decarboxylation. Right,
possible similar hydrogen bond in CAIR.

An alternate mechanism for decarboxylation involves ring protonation prior to
decarboxylation. A direct ring protonation mechanism has been proposed for many
compounds at low pH including anthranilic acid, pyrrole-2-carboxylic acids, and CAIR-s
14

(Figure 2.6) (18, 19). Protonation at the carbon adjacent to the carboxylate allows for
decarboxylation. The rate of decarboxylation for such a mechanism is dependent on the
concentration of hydronium ion.

Figure 2.6: Ring protonation mechanism for CAIR-s at low pH.

The study of the nonenzymatic decarboxylation of CAIR must account for
nucleobase ionizations (Figure 2.7). CAIR undergoes a total of four ionizations, two
occurring from the 4-carboxy-5-aminoimidazole ring, and two occurring from the
phosphate group of the ribonucleotide. In this study, both CAIR (1) and the
corresponding ribonucleoside CAIR-s (1-s) were used. CAIR-s lacks the sugar phosphate
group, and undergoes only two ionizations.

Figure 2.7: Ionizations of CAIR (1) and CAIR-s (1-s). Ionization constants for carboxylate
and imidazole ring are values reported for CAIR and CAIR-s at 20°C (20). Ionization
constants shown for phosphate group are those reported for the ribonucleotide uridine
monophosphate at 25°C (21).
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In this work the ionization states of the 4-carboxy-5-aminoimidazole ring will
commonly be referred to as anionic (15), zwitterionic (16), and cationic (12) (Figure 2.8).
For clarity, these same terms will also be used in reference to CAIR, and will refer
specifically to a similar protonation state of the 4-carboxy-5-aminoimidazole ring.

Figure 2.8: Illustration of ionization states of 4-carboxy-5-amino-imidazole ring. The
terms anionic (15), zwitterionic (16) and cationic (12) will be used in the text to refer to
these protonation states of the 4-carboxy-5-amino-imidazole ring (R= ribose 5phosphate or ribose).

For several ionization states, many tautomers can be drawn. For instance, the
zwitterion (16) may be in equilibrium with other species (Figure 2.9). Although species
19 may seem implausible, computational studies of the N1-methyl analogue of CAIR
indicated that the C4-protonated form (19 R = methyl) is only 3.1 kcal/mol higher in
energy than the aromatic form (analogous to 16) (2). Additionally, NMR studies of AIR

Figure 2.9: Possible alternate forms of CAIR-s in equilibrium with the zwitterion (16).
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indicate that the C4 proton exchanges rapidly in D2O (kexchange= 0.9 min -1) (22). This
suggests the intermediacy of 19. Species 19 may be stabilized by an internal hydrogen
bond with the iminium ion. This C4 protonated tautomer appears ideal for
decarboxylation, and may provide alternate to direct decarboxylation.

Figure 2.10: Possible mechanism of decarboxylation for C4 protonated tautomer.

The previous study of the nonenzymatic decarboxylation of CAIR and CAIR-s was
performed by Litchfield and Shaw (8, 9). In a pH rate profile of decarboxylation, they
found that the zwitterionic (16) and cationic (12) forms of CAIR, and CAIR-s
decarboxylate, but the anionic form of CAIR (15) does not. They also found that the rate
of decarboxylation was higher for the zwitterionic form than for the cationic from. They
also observed that the rate was accelerated by the presence of anions over the pH range
where the zwitterionic form predominates. They also found evidence of catalysis by
protons at very low pH, implicating a direct ring protonation at pH < 1. They also noted
at a pH value where the anion of CAIR (15) would predominate, that decarboxylation is
catalyzed by formaldehyde.
The last study (8) of the decarboxylation of CAIR and CAIR-s was done prior to
several findings that are key to understanding the relevance to the enzymatic system.

17

These findings include the determination of pH-rate profile for the enzyme suggesting
the involvement of an active site acid (Chapter 3) (2, 3) and the relatively energetically
accessible C-4 tautomer (2). The previous study was also done at a higher temperature
(50 °C) than subsequent enzymatic studies (30 °C). Because the temperature is too high,
we performed experiments to explore at physiologically relevant temperature.
To test the theory that PurE may catalyze the decarboxylation of CAIR by
sequestration of the carboxylate moiety into a hydrophobic pocket, the effects of
solvent polarity on the decarboxylation of CAIR-s were assessed. The effect of
deuterium oxide was also assessed because an observation of a solvent isotope effect
would support a subset of plausible mechanisms.
Standard enzyme activity assays of PurE are measured in the reverse
biosynthetic direction (CAIR  N5-CAIR) (6), by following the change in absorbance of
the reaction mixture using known difference in extinction coefficients (Δε260) for each
nucleotide at pH 8, 7, or 6. The construction of a pH-rate profile for PurE (Chapter 3)
necessitated the determination of Δε260 values for the conversion of CAIR  N5-CAIR at
many pHs. Burst assays were thus designed to measure the Δε260 at all pHs that were
used in the construction of the pH rate profile.
This chapter reports the determination of Δε260 of CAIR N5-CAIR over a range
of pH; these Δε260 will be used in Chapter 3 for the construction of pH-rate profiles of A.
aceti PurE. Also reported in this chapter are the nonenzymatic rate of decarboxylation
of CAIR at several pHs and the activation energy for decarboxylation of CAIR at pH 5.0 or
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6.0 in phosphate buffer. The rate of change in absorbance of the ribonucleoside CAIR-s
has been determined over a range of pH, and the rate of decarboxylation was estimated
by using the Δε260 for the nucleotide when possible. The effect of solvent polarity on the
rate of nonenzymatic decarboxylation of CAIR-s was also determined. The study of the
decarboxylation of CAIR-s also includes the determination of solvent isotope effect at
pH 6.0.
2.2 Materials and Methods
Materials. Unless otherwise noted, all chemicals were obtained from Sigma or
Fisher in the highest purity available. CAIR-s and CAIR were prepared by H. Jiang from 5aminoimidazole-4-carboxamide ribonucleoside (Toronto Research Chemicals) as
described (1, 23). Spectroscopic measurements were recorded on a CARY-100 UV/Vis
spectrometer with a thermostated 6X6 Peltier with a CARY temperature controller.
Data were analyzed using KaleidaGraph 3.5 (Synergy Software).
Determination of ∆ε260 values for CAIR  N5-CAIR. Extinction coefficients are
known at 260 nm at pH 6, 7, and 8 for AIR and CAIR, which allows the computation of
Δε260 values used in PurE activity assays (24). CAIR solutions were standardized by using
endpoint assays at pH 8, in which a large amount of AaPurE (typically 66 µg) was added
to 100 mM Tris HCl pH 8.0 to which small aliquots of CAIR (<0.1 mM) had been added.
The ΔA260 of the resulting burst, corrected for the absorbance of the added enzyme, of
product formation was used to compute the concentration of the stock solution. A
standardized CAIR solution was then subjected to replicate endpoint assays at 30 °C and
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pH values ranging from 4.5 – 9 to determine Δε260 values (Figure 2.1) in a triple buffer
system containing 100 mM Tris-HCl, 50 mM MES, and 50 mM acetic acid (25).
Nonenzymatic decarboxylation of CAIR-s. The initial rate of change of [CAIR-s]
was monitored by the loss of absorbance at 260 nm at 30°C. Experiments were
performed in stoppered, masked, 1 cm path length quartz cuvettes containing a total
final volume of 1.5 mL. Reactions contained 50 µM CAIR-s in 100 mM potassium
phosphate buffer. The reaction was initiated by the addition of CAIR-s from a
concentrated stock solution to a cuvette containing all other components, the cuvettes
had been equilibrated in the cell block for 5 min. The solution in the cuvette was mixed
rapidly by inversion to start the reaction. The pH of the buffer was varied in 0.5 pH unit
increments from pH 2.0 to 6.0, in 0.2 pH unit increments from pH 6.0 to 8.0, and in 0.5
pH unit increments from 8.0 to 9.0. The change in absorbance at 260 nm was monitored
for 5 min. Relative rates in units of (ΔA260/min) were determined from a linear least
squares fit of the data. At pH values for which the Δε260 of CAIR  N5-CAIR is known,
the rate constant for decarboxylation was computed.
Solvent isotope effect on CAIR-s decarboxylation. The decarboxylation of CAIR-s
was monitored by the loss of absorbance at 260 nm at 30°C. Experiments were
performed in stoppered, masked, 1 cm path length quartz cuvette containing a total
final volume of 1.4 mL. Reactions contained 54 µM CAIR-s and 100 mM potassium
phosphate buffer pH 6.8 or 100 mM potassium phosphate buffer pD 6.8 (pH 6.4). The
pD values were determined using a pH electrode previously calibrated in standard H2Ocontaining buffers, using the replationship pD = pH + 0.4 (26). The estimated
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decarboxylation rate was determined from a linear least squares fit of data collected
over 5 min, and the Δε260 for CAIR  N5-CAIR at pH 6.8 (7.91 mM-1).
Effect of mixed solvent on decarboxylation of CAIR-s. Decarboxylation was
monitored by the loss of absorbance at 260 nm over longer periods (>30 min) at 30 °C.
Experiments were performed in stoppered, masked, 1 cm path length quartz cuvette
containing a final total volume of 1.3 or 0.65 mL, depending on the cuvette size.
Reactions contained 50 µM CAIR-s, 25 mM sodium acetate, 10.5 mM acetic acid, and
0.94 M LiCl at 30 °C. The concentration of ethanol was varied from 0 to 90% by mixing
volumes of 1 M LiCl (aq) and 1 M LiCl (ethanol). For calculation of the percentage
ethanol, concentrated buffer (500 mM sodium acetate, 105 mM acetic acid, pH 4.95)
and CAIR-s were considered part of the aqueous volume. To determine the rate of
decarboxylation for each concentration of ethanol, the absorbance time-dependent
data were fit to equation 1 below: OD260 = absorbance at 260 nm, ODf260 = final
absorbance at 260 nm, ΔOD260 = change is absorbance at 260 nm, k = rate of
decarboxylation.
𝑂𝐷

= 𝑂𝐷

+ ∆𝑂𝐷

× 𝑒(

)

Equation (1)

Arrhenius plot for non-enzymatic CAIR decarboxylation. The decarboxylation of
CAIR was monitored at 260 nm at 30, 40, 50 or 60 °C. Experiments were performed in
stoppered, masked, 1 cm path length quartz cuvette containing a total final volume of
1.3 or 0.65 mL, depending on the cuvette size. Reactions contained 50 µM CAIR and
either 50 mM potassium phosphate buffer (pH 6.0) or 50 mM potassium acetate buffer
(pH 5.0). The ionic strength of each buffer was adjusted with potassium chloride to 0.1
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M. Absorbance data were fit to a single-exponential expression. The activation energy
for decarboxylation was determined by plotting the natural logarithms of the first order
rate constants (F) as a function of inverse temperature (x) as governed by equation 2,
with the variables: A, defined as the pre-exponential factor and Ea, defined as the
activation energy.
𝐹 = ln(𝐴) −

𝑥

Equation (2)

CAIR decarboxylation in a triple buffer system. Decarboxylation was monitored
by the loss of absorbance at 260 nm at 30 °C. Experiments were performed in
stoppered, masked, 1 cm path length quartz cuvettes containing a total final volume of
1.3 or 0.65 mL, depending on the cuvette size. Reactions contained 50 µM CAIR when
using the 100 mM Tris-HCl, 50 mM MES, 50 mM acetic acid triple buffer system. These
determinations were performed at pH 5.0, 6.0, 7.0, 7.5 or 8.0. At each pH, individual
trials were also performed at 25 µM CAIR to detect CAIR catalyzed decarboxylation or
with the addition of 0.1 mM EDTA to detect trace metal-catalyzed decarboxylation.
Several trials were run simultaneously, and a holmium standard was included in one cell
to account for slight changes in the calibration of the instrument at 260 nm.
Absorbance data were fit to a single exponential.

2.3 Results
Determination of ∆ε260 for CAIRN5-CAIR/AIR+CO2. Burst assays allowed the
determination of the change in the absorbance of CAIR upon its conversion to N5-CAIR
and/or AIR (Figure 2.11). N5-CAIR is known to decarboxylate rapidly under acidic
22

conditions to form AIR + CO2 (estimated to be ~0.07 s-1 at pH 4.0 and 30 °C) (3). In all
cases, the bursts used for quantitation appeared to be monophasic and reached a stable
endpoint within 2 min. Assuming some decarboxylation of N5-CAIR to AIR occurs during
this period (especially at lower pH values), the flat endpoint implies there is no
substantial difference in ε260 values for N5-CAIR and AIR over the pH range used. Data
collected from pH 8.0–5.0 follow a linear trend; the data for this range of pH were fit to
a linear equation to allow for determination of interpolated extinction coefficients.
Outside this range, extinction coefficients were determined at every pH used in the
construction of the pH-rate profile of PurE (Chapter 3). The values determined by this
method are slightly higher than the values based on published molar absorptivities for
CAIR and N5-CAIR (6, 24), shown as filled squares in Figure 2.11 .

Figure 2.11: Determination of ∆ε260 for the conversion CAIR  N5-CAIR as a function of
pH. Mean values for each pH were determined in at least triplicate (open symbols) with
the indicated standard deviation. The solid line is a fit of the data in the pH 5.0 - 8.0
interval, which yields the expression ∆ε260 = 1.19 × pH – 0.15. Outside this range,
individual ∆ε260 values were determined. Previously reported values for ∆ε260 and
uncertainties are shown for reference (solid squares)(6, 24).
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Nonenzymatic decarboxylation of CAIR – The rate of the decarboxylation of CAIR
was determined at a series of pH values by monitoring the change in absorbance at 260
nm over time. Reactions were performed at 50 µM CAIR. Data were fit to an
exponential decay, and the rate constant was extracted (Table 2.1, second column).
The possibility of catalysis by trace metal ions was examined by the addition of
0.1 mM EDTA to one reaction at each pH (Table 2.1, third column). For most pH values,
the rate constant for the trial containing EDTA was within 2% of the rates determined
for reactions lacking EDTA. This indicates that catalysis by EDTA-chelatable trace metals
does not play a significant role.
The possibility that CAIR could serve as a catalyst for decarboxylation was also
examined by performing one reaction at a reduced concentration of CAIR (25 µM, Table
2.1, fourth column). For all pH values, the rate constant determined at this reduced
concentration is within 3% of the rate constant determined at higher concentration.
This indicates that autocatalysis does not play a significant role.
Table 2.1: kuncatalyzed of CAIR decarboxylation
pH
Rate constant (min-1)a Rate (min-1)b
Rate (min-1)b
0.1 mM EDTA
Reduced [CAIR]
8.0
0.00162 ± 0.00002
0.00161
0.00164
7.5
0.0038 ± 0.0001
0.00420
0.00366
7.0
0.00816 ± 0.00008
0.00820
0.00818
6.0
0.0210
0.0218
0.0215
5.0
0.0235 ± 0.0003
0.0239
0.0234
a
The error shown is standard deviation of rate constants from at least three replicate
trials. No error is reported at pH 6.0 as only two trials were performed. Other errors
were about 1%. bRate constant determined from a single trial.
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Activation energy for CAIR decarboxylation. The rate constants for
decarboxylation of CAIR at 30, 40, 50, or 60 °C in 50 mM potassium acetate buffer (pH
5.0) or 50 mM potassium phosphate buffer (pH 6.0) were determined. The activation
energy at each pH was determined by fitting the natural logarithms of the rate
constants to Eqn 2 (Table 2.2). The error reported for each value is based on the
uncertainty of the slope at each pH. Values were similar to the previously reported
activation energy for CAIR decarboxylation at pH 6.7 (20 ± 2 kcal/mol) (8).
Table 2.2: Activation energy for the decarboxylation of CAIR
pH
Ea(kcal/mol)
5.0
19.1 ± 0.4
6.0
18.9 ± 0.9

CAIR-s decarboxylation. At basic pH, the rate of change in absorbance at 260 nm
(ΔA260 min-1) for CAIR-s is vanishingly small. However, ΔA260 min-1 increases rapidly as
the pH is lowered from 8.0 to 5.0 (open squares, Figure 2.12). A further increase in
ΔA260 min-1 occurs as the pH is lowered from 4.0 to 2.0 (Figure 2.12). These increases
are consistent with either a large increase in the rate of decarboxylation or a large
change in the differential extinction coefficients for CAIR-s and AIR-s. Since the
extinction coefficients for CAIR-s and N5-CAIR-s are unknown, the Δε260 determined for
the nucleotides in Figure 2.11 were used to estimate the rate constants in the pH range
4.5 to 9.0 (filled circles, Figure 2.12).
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Figure 2.12: pH-profile of rate of absorbance change at 260 nm for CAIR-s. Initial relative
rates of change (ΔA260 min-1 mM-1) were determined by a linear fit of absorbance data
recorded over 5 min (open squares) from pH 2.0-9.0. Estimated rates of
decarboxylation (filled circles) were made using the known Δε260 for CAIR N5CAIR/AIR+CO2 (Figure 2.1). Reactions contained 100 mM potassium phosphate buffer
and 54 µM CAIR-s at 30°C.

Deuterium isotope effect. The effect of deuterium oxide solvent on the rate of
decarboxylation of CAIR-s was examined (Table 2.3). CAIR-s was found to decarboxylate
more slowly in deuterium oxide with a kH2O/kD2O = 1.30. This is consistent with the
involvement of a solvent-exchangeable proton in the transition state for the rate
limiting step in decarboxylation. The magnitude of this kinetic isotope effect suggests
that a proton transfer is not the sole rate determining step. Alternatively, it is possible
that the effect is due to a result of a change in the solvation of the anionic (15) and
zwitterionic (16) forms of CAIR-s. The pH at which the solvent isotope effect has been
determined (6.8) is near the pKa of the N3-nitrogen of CAIR-s (~6.2). If the anionic form
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is preferentially solvated in deuterium oxide, the change in solvation could cause the
change in the observed rate because the anionic form is not known to decarboxylate (8).
Table 2.3: Solvent isotope effect on CAIR-s decarboxylation
Solvent
Rate (min-1)a
H2O
0.00288
D2O
0.00221
a
Determined in 100 mM Potassium phosphate buffer pH 6.8 (pD 6.4). Rate estimated
using Δε260 for the reaction of CAIRN5-CAIR

Mixed solvent experiments. The effect of solvent polarity on the decarboxylation
of CAIR-s was examined (Table 2.3). Increasing the amount of ethanol from 0 to 90%
caused an approximately 2.5 fold decrease in the rate of CAIR-s decarboxylation. This is
the opposite of the substantial rate increase observed for the model of thiaminedependent α keto acid decarboxylation (12, 13). This suggests that that CAIR-s
decarboxylates by a different mechanism.
A reduction in rate suggests that the ground state of the decarboxylating species
is stabilized in reference to the transition state. However, caution is advised in
interpreting this small change due to the significant change in the solvent. The decrease
in rate may be due to selective solvation of one or more CAIR-s forms present in
solution. The pH of the buffer (4.95) is intermediate between the pKa values for CAIR-s,
which are 6.2 for the imidazole ring, and 3.0 for the carboxylic acid moiety at 30 °C (20).
At pH 4.95, the zwitterion (16) is the majority species in aqueous solution; however, that
may change as the amount of ethanol is increased and minor tautomers (18 and 19)
may be favored.
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Table 2.3: Decarboxylation of CAIR-s in mixed water-ethanol solvent.a
% Ethanol (v/v)
kobs (min-1)
0
0.122
0
0.112
10
0.113
10
0.112
20
9.78 X 10-2
30
8.88 X 10-2
40
7.60 X 10-2
50
7.21 X 10-2
50
7.55 X 10-2
70
6.11 X 10-2
70
6.55 X 10-2
80
5.53 X 10-2
90
4.68 X 10-2
a
Reactions contained 50 µM CAIR-s, 0.94 M LiCl, 25 mM acetic acid and 10.5 mM sodium
acetate at 30°C.

2.4 Discussion
CAIR-s decarboxylation. The initial rates of change in absorbance at 260 nm for
solutions of CAIR-s were monitored over a pH range of 2.0-9.0. This profile shows two
increases in the rate of change in absorbance. This indicates either an increase in the
rate of decarboxylation, or a change in the molar absorptivity of CAIR-s or AIR-s.
In previous studies of the nonenzymatic decarboxylation of CAIR-s over a range
of pH, the rates were monitored by the change in absorbance, and were performed at
longer time periods so the data could be fit to a single exponential, and the rate
constant determined (8). Those data show an increase in the rate of decarboxylation
from pH 7.6 to 5.0 at 50 °C, which is consistent with the increase observed here at 30 °C
from pH 8.0 to 5.0 (Figure 2.12). The increased rate of decarboxylation is likely due to
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protonation of the imidazole ring of CAIR-s, which has a reported pKa of 6.34 at 20 °C
(20).
The previous study of CAIR-s decarboxylation at 50 °C shows that the rate
constant for decarboxylation decreases as the pH is decreased from pH 5 to pH 2 (8).
This indicates that the second increase in the ΔA260 min-1 seen at 30 °C in Figure 2.12
from pH 4 to 2 is due to a change in the extinction coefficient of CAIR-s, AIR-s, or both.
UV spectra of CAIR and a model compound (4-carboxy 1-cyclohexyl 5-aminoimidazole)
at pH ~0.4 and ~3.5 show an increase the absorbance of both compounds above 255 nm
at the more acidic pH (20). The increase in absorbance suggests that the increase seen
in from pH 5 to 2 in Figure 2.12 is due to an increase in the extinction coefficient of
CAIR-s. The change in extinction coefficient is likely due to the protonation of the
carboxylic acid, which has reported pKa values of 3.00, 3.21 and 3.18 in CAIR-s, CAIR and
a model compound of CAIR in which the ribose has been replaced with a cyclohexyl ring,
respectively (20).
Mixed solvent experiments. The rate of decarboxylation of CAIR-s is reduced
slightly as the amount of ethanol is increased. The change in rate may be due to the
effect of increasing ethanol on the ionization state of CAIR-s, or may be due to the effect
of increasing ethanol on the energy of the ground state versus that of the transition
state of decarboxylation. Similar experiments have shown a large increase (~104) in the
rate of decarboxylation of 2-(1-carboxy-1-hydroxyethyl)-3,4,-dimethylthiazolium (3) as
the amount of ethanol is increased (12). It seems unlikely that the effect of increasing
ethanol on the ionization constants of CAIR-s would be large enough to mask a large
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increase in the rate of decarboxylation. The lack of a large increase suggests the
decarboxylation of CAIR follows a different mechanism than that of 2-(1-carboxy-1hydroxyethyl)-3,4,-dimethylthiazolium (12, 13).
Possible mechanisms of decarboxylation. As illustrated in Figure 2.12 and in the
previous study of CAIR-s (8), the decarboxylation rate increases as the N3 ring nitrogen
of the imidazole ring becomes protonated. This indicates that the most rapid
decarboxylation is from the CAIR-s zwitterion (16), or a species in equilibrium with it (18
and 19). If a direct ring protonation mechanism were to occur, the rate would not
plateau with the population of the zwitterion (16), but would continue to increase as
the pH is lowered.
C-4 protonation mechanism. One possible mechanism involves the
decarboxylation of species 19 (Figure 2.13). This is one of the several possible
mechanisms proposed by Litchfield et al (8). In this species, the ring is protonated at C4
instead of N3, and this C4-protonated intermediate is the species that decarboxylates.
Species 19 could either be in equilibrium with the zwitterion (16), or be formed from the
zwitterion (16) or another species in equilibrium with the zwitterion (18). Regardless
the rate of decarboxylation would be proportional to the population of the zwitterion.
This mechanism is similar to the amine catalyzed decarboxylation of β-keto acids such as
acetoacetic acid and oxaloacetic acid (27, 28).
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Figure 2.13: C-4 protonation mechanism for CAIR zwitterion.

In this view, the observed solvent kinetic isotope effect could be due to partly
rate limiting proton transfer to form 19. In this case, a larger isotope effect might be
expected. However, it is not possible to predict what effects the transfer to deuterium
oxide would have on the ionization constants of CAIR. A larger isotope effect may be
obscured if the anion (15) is not as well solvated as the zwitterion (16).
If the formation of species 19 is rate limiting, the transfer to less polar solvent
would have an uncertain effect. In this mechanism, catalysis by anions could be
explained by stabilization of the developing iminium ion promoting protonation at C4.
If the decarboxylation of species 19 is rate limiting, an increase in the rate of
decarboxylation would not be expected upon the transfer to a less polar solvent. The
transition state for decarboxylation is likely to be more polar than the ground state of
the intermediate, as it requires disruption of the hydrogen bond between the iminium
and carboxylate. In this mechanism, catalysis by anions could be explained by
stabilization of the iminium ion.
At lower pH, the cation of CAIR (12) may decarboxylate by a similar C4protonation mechanism (Figure 2.14). This would result in a species similar to species 19
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with a proton on either the ring nitrogen or the carboxylate (20). Owing to the
additional proton, protonation at C4 should be more difficult. The rate of
decarboxylation at the pH where 17 is the major species in solution, is lower than the
rate seen when the zwitterion of CAIR (16) dominates (8).

Figure 2.14: C-4 protonation mechanism for decarboxylation of the CAIR cation.

The above C-4 protonation mechanism can be used to explain the
decarboxylation of the zwitterion (16) and the cation (12) of CAIR-s. The C-4
protonation mechanism is consistent with the observed catalysis by anions at moderate
pH, the observed solvent isotope effect, and the decrease in the rate of decarboxylation
in solutions of increasing ethanol. However, this mechanism cannot be used to explain
the previous report of catalysis by protons at low pH (8).
Decarboxylation at very low pH has been proposed to proceed via a direct ring
protonation mechanism (8) (Figure 2.15), and will not be discussed. This mechanism is
similar to the direct ring protonation mechanism of anthralinic acid (19) and pyrrole-2carboxylic acid (18).
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Figure 2.15: Direct ring protonation mechanism at low pH.
More recently the enzyme PurE was proposed to use a C4 protonation
mechanism (2, 3). Of the nonenzymatic mechanisms presented the C4-protonation
mechanism appears to be the most consistent with the data collected. The reported
observation of catalysis by formaldehyde may also implicate such a mechanism (8). The
addition of formaldehyde increases the rate of decarboxylation at pH 8.1 such that the
sample completely decarboxylates within minutes at room temperature (8). However,
the addition of formaldehyde at 40 °C and pH 4.5 only causes a 10 fold rate increase (8).
At 30 °C and pH 8.0 the decarboxylation of CAIR is vanishingly small (Figure 2.12); the
rate acceleration by formaldehyde is, therefore, extremely large. One of the incredible
number of mechanisms that can be written, is for the formation of a carbinolamine that
can protonate C4 (Figure 2.16). The authors noted a large elevation in pH upon addition
of formaldehyde, which is consistent with the formation of a carbinolamine, among
many other possibilities.

Figure 2.16: One of the many possible mechanisms for formaldehyde decarboxylation.
Loss of formaldehyde shown as concerted with protonation at C4.
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Hammick type mechanism. An alternate mechanism for decarboxylation of CAIRs is analogous to the Hammick mechanism for the decarboxylation of picolinic acid
(Figure 2.17) (29-31). In this mechanism, decarboxylation of the neutral or zwitterionic
species (25) of picolinic acid produces a nitrogen ylide (26). (Note that the ionizations of
the carboxylate and ring nitrogen are reversed relative to CAIR. A proton transfer from
the carboxylic acid to the ring nitrogen precedes or is concerted with decarboxylation.)

Figure 2.17: Hammick type mechanism. A) Hammick mechanism shown for picolinic
acid; protonation of the ring nitrogen stabilizes the carbanion that results from
decarboxylation. B) Protonation of the N3 ring nitrogen stabilizes the carbanion formed
by decarboxylation. The resulting intermediate is then protonated at C4, shown here as
the addition of a proton from the solvent.

The maximal rate for a mechanism involving a zwitterion occurs when the
population of the zwitterion is highest. This occurs at a pH value that is the average of
the two pKa values (31). This is seen for the decarboxylation of the CAIR zwitterion (16).
However, catalysis by anions has been noted in previous studies of CAIR and CAIR-s over
the pH range at which the zwitterion dominates (8). In the Hammick-type mechanism,
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there is no clear role that an anion or catalytic base could play. This suggests that the
zwitterion of CAIR (16) decarboxylates by a different mechanism.
Additionally, in the Hammick mechanism, decarboxylation is inhibited when both
the carboxylate and ring nitrogen are protonated. Because the cation of CAIR (12) is
known to decarboxylate (8); this suggests that the Hammick mechanism could not apply
to the cation of CAIR (12).

Figure 2.18: Hammick type mechanism, part 2. A) The anion of picolinic acid has been
shown to decarboxylate (31). B) The cation of picolinic acid does not decarboxylate (31).
C) The anion of CAIR is not known to decarboxylate (8). D) The cation CAIR is known to
decarboxylate (8).

Furthermore, it was also shown that the anion of picolinic acid (30)
decarboxylates (31). The anionic species of CAIR (15) does not appear to decarboxylate.
If the zwitterion of CAIR-s (16) decarboxylates by a Hammick-type mechanism,
protonation of the ring nitrogen should be necessary, because the anion of CAIR-s (15)
does not decarboxylate appreciably at 30 °C. Because the cationic species of CAIR (12) is
known to decarboxylate (8), and the anionic species (15) does not, the Hammick
mechanism could only apply to the CAIR zwitterion.
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Implications for mechanism of PurEs. It has been proposed that Class I PurEs
may catalyze the decarboxylation of CAIR and N5-CAIR by sequestering the carboxylate
in a hydrophobic pocket in the enzyme (2-4, 32). This is similar in manner to the
decarboxylations of N(1’)-carboxybiotin and the thiamine-catalyzed decarboxylation of
α keto carboxylic acids. The lack of an increase in the rate of decarboxylation with the
transfer to ethanol indicates that a decrease in polarity is not sufficient to accelerate the
nonenzymatic decarboxylation of CAIR. This suggests that PurE catalyzes the
decarboxylation of CAIR via a different route.
PurE may increase the proportion of a species 19 by directing protonation to C4
(Figure 2.19). Crystal structures of PurE with bound aminoimidazole nucleotides
indicate that the active site residue Ser57 (A. aceti numbering) forms a hydrogen bond
with the N3 of the imidazole ring. Such an interaction would prevent protonation at this
position, directing protonation at C4. Crystal structures of PurE with bound nucleotide
indicate that the nucleobase is isolated in the active site of the enzyme. We therefore
expect there to be an active acid that allows for protonation of C4, and propose that the
conserved active site residue His59 as a likely candidate.

Figure 2.19: Possible role of PurE Ser57 and His59.
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The carboxylate of N5-CAIR (33), the actual substrate for Class I PurE, lacks the
internal hydrogen bond that could prevent direct decarboxylation. Direct
decarboxylation would also result in a resonance stabilized anion (34) (Figure 2.20). The
decarboxylation of N5-CAIR (33) would therefore be expected to be accelerated simply
by sequestration into the hydrophobic pocket. PurE may therefore catalyze the
conversion of N5-CAIR to CAIR by destabilizing the substrate N5-CAIR to yield AIRazaenolate (34) + CO2 in the enzyme active site, while providing an environment that
lowers the activation energy for the formation of CAIR.

Figure 2.20: Decarboxylation of N5-CAIR.
In this manner, N5-CAIR can be regarded as a CO2 carrier similar to N(1’)carboxybiotin. For both N5-CAIR and N(1’)-carboxybiotin, an amine is carboxylated using
ATP and bicarbonate, likely through a fleeting carboxy-phosphate intermediate. In a
separate active site, both decarboxylate to provide CO2. The enzyme bound CO2 is
attacked by a nucleophilic carbon in both enzymes. The difference in these two CO2
carriers is that biotin remains tethered to the carboxylase multienzyme complex by
covalent linkage, while N5-CAIR is able to diffuse to the next enzyme, PurE. The
possibility of direct N5-CAIR transfer, by metabolite channeling, is considered in Chapter
4.
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2.5 Future Directions
By far the most interesting prospect is to study the formaldehyde catalyzed
decarboxylation reaction (8).
The modest solvent kinetic isotope effect (KIE) seen at pH 6.8 is suggestive of a
proton transfer or a change in hydrogen bonding during the rate limiting step of CAIR
decarboxylation. The possibility that the rate decrease might be due to a change in
solvation cannot be ruled out until KIEs are determined at multiple pH values. The
magnitude of the KIE will help distinguish the rate limiting step for decarboxylation. For
such a study, CAIR-s would likely be the best model as the data will not be complicated
by the ionizations of the phosphate group of CAIR.

38

2.6 References
1.

2.

3.

4.

5.

6.

7.

8.

9.

10.

11.

12.

13.

Firestine, S. M., and Davisson, V. J. (1994) Carboxylases in de novo purine biosynthesis.
Characterization of the Gallus gallus bifunctional enzyme, Biochemistry 33, 1191711926.
Hoskins, A. A., Morar, M., Kappock, T. J., Mathews, I. I., Zaugg, J. B., Barder, T. E., Peng,
P., Okamoto, A., Ealick, S. E., and Stubbe, J. (2007) N5-CAIR mutase: Role of a CO2 binding
site and substrate movement in catalysis, Biochemistry 46, 2842-2855.
Constantine, C. Z., Starks, C. M., Mill, C. P., Ransome, A. E., Karpowicz, S. J., Francois, J.
A., Goodman, R. A., and Kappock, T. J. (2006) Biochemical and structural studies of N5carboxyaminoimidazole ribonucleotide mutase from the acidophilic bacterium
Acetobacter aceti, Biochemistry 45, 8193-8208.
Mathews, I. I., Kappock, T. J., Stubbe, J., and Ealick, S. E. (1999) Crystal structure of
Escherichia coli PurE, an unusual mutase in the purine biosynthetic pathway, Structure
7, 1395-1406.
Meyer, E., Kappock, T. J., Osuji, C., and Stubbe, J. (1999) Evidence for the direct transfer
of the carboxylate of N5-carboxyaminoimidazole ribonucleotide (N5-CAIR) to generate 4carboxy-5-aminoimidazole ribonucleotide catalyzed by Escherichia coli PurE, an N5-CAIR
Mutase, Biochemistry 38, 3012-3018.
Mueller, E. J., Meyer, E., Rudolph, J., Davisson, V. J., and Stubbe, J. (1994) N5carboxyaminoimidazole ribonucleotide: Evidence for a new intermediate and two new
enzymic activities in the de novo purine biosynthetic pathway of Escherichia coli,
Biochemistry 33, 2269-2278.
Firestine, S. M., Misialek, S., Toffaletti, D. L., Klem, T. J., Perfect, J. R., and Davisson, V. J.
(1998) Biochemical role of the Cryptococcus neoformans ADE2 protein in fungal de novo
purine biosynthesis, Archives of Biochemistry and Biophysics 351, 123-134.
Litchfield, G. J., and Shaw, G. (1971) Part XXXVIII. A kinetic study of the decarboxylation
of 5-amino-1-β-D-ribofuranosyl imidazole-4-carboxylic acid 5'-phosphate and related
compounds., Journal of the Chemical Society (B), 1474-1484.
Litchfield, G. J., and Shaw, G. (1965) The mechanism of decarboxylation of some 5aminoimidazole-4-carboxylic acids and the influence of transition metals, Chemical
Communications (London) 22, 563-565.
Cusack, N. J., Shaw, G. and G. J. Litchfield (1971) Purines, Pyrimidines, and Imidazoles.
Part XXXVI. Carboxylation of some 5-aminoimidazoles and related compounds,
including nucleosides, with potassium hydrogen carbonate in aqueous solution, Journal
of the Chemical Society (C), 1501-1507.
Alenin, V. V., Kostikova, T. R., and Domkin, V. D. (1987) Detection of products of Ncarboxylation of N1-substituted 5-aminoimidazoles in aqueous of potassium
bicarbonate, Zhurnal organicheskoi khimii 57, 692-701.
Crosby, J., and Lienhard, G. E. (1970) Mechanisms of thiamine-catalyzed reactions.
Kinetic analysis of the decarboxylation of pyruvate by 3,4-dimethylthiazolium ion in
water and ethanol, Journal of the American Chemical Society 92, 5707-5716.
Crosby, J., Stone, R., and Lienhard, G. E. (1970) Mechanisms of thiamine-catalyzed
reactions. Decarboxylation of 2-(1-carboxy-l-hydroxyethyl)-3,4-dimethylthiazolium
chloride, Journal of the American Chemical Society 92, 2891-2900.

39

14.

15.

16.

17.

18.

19.
20.

21.

22.
23.

24.

25.

26.

27.
28.

Acevedo, O., and Jorgensen, W. L. (2006) Medium effects on the decarboxylation of a
biotin model in pure and mixed solvents from QM/MM simulations, Journal of Organic
Chemistry 71, 4896-4902.
Rahil, J., You, S., and Kluger, R. (1996) Solvent-accelerated decarboxylation of N-carboxy2-imidazolidinone. Implications for stability of intermediates in biotin-dependent
carboxylations, Journal of the American Chemical Society 118, 12495-12498.
Kemp, D. S., Cox, D. D., and Paul, K. G. (1975) Physical organic chemistry of
benzisoxazoles. IV. Origins and catalytic nature of the solvent rate acceleration for the
decarboxylation of 3-carboxybenzisoxazoles, Journal of the American Chemical Society
97, 7312-7318.
Acevedo, O., and Jorgensen, W. L. (2005) Influence of inter- and intramolecular
hydrogen bonding on Kemp decarboxylations from QM/MM simulations, Journal of the
American Chemical Society 127, 8829-8834.
Dunn, G. E., and Lee, G. K. J. (1971) Kinetics and mechanism of the decarboxylation of
pyrrole-2-carboxylic acid in aqueous solution, Canadian Journal of Chemistry 49, 10321035.
Dunn, G. E., and Dayal, S. K. (1970) Mechanism of decarboxylaiton of substituted
anthranilic acids at high acidity, Canadian Journal of Chemistry 48, 3349-3353.
Litchfield, G. J., and Shaw, G. (1971) Purines, pyrimidines and imidazoles. Part XXXV.
Potentiometric and spectroscopic studies of some imidazoles related to intermediates in
the biosynthesis de novo of purine nucleotides, Journal of the Chemical Society (C), 817820.
Massoud, S. S., and Sigel, H. (1988) Metal ion coordinating properties of pyrimidinenucleoside 5'-monophosphates (CMP, UMP, TMP) and of simple phosphate monoesters,
including D-ribose 5'-monophosphate. Establishment of relations between complex
stability and phosphate basicity, Inorganic Chemistry 27, 1447-1453.
Schendel, F. J. (1986) Ph.D. Thesis, Department of Biochemistry, University of Wisconsin,
Madison, WI.
Srivastava, P., Mancuso, R., Rousseau, R., and Robins, R. (1974) Nucleoside Peptides. 6.
Synthesis of Certain N-[5-Amino-1-(β-D-ribofuranosyl)imidazole-4-carbonyl] amino acids
related to naturally occurring intermediates in the purine biosynthetic pathway, Journal
of Medicinal Chemistry 17, 1207-1211.
Meyer, E., Leonard, N. J., Bhat, B., Stubbe, J., and Smith, J. M. (1992) Purification and
characterization of the purE, purK, and purC gene products: identification of a previously
unrecognized energy requirement in the purine biosynthetic pathway, Biochemistry 31,
5022-5032.
Ellis, K. J., Morrison, J. F., and Daniel, L. P. (1982) [23] Buffers of constant ionic strength
for studying pH-dependent processes, in Methods in Enzymology, pp 405-426, Academic
Press.
Lumry, R., Smith, E. L., and Glantz, R. R. (1951) Kinetics of Carboxypeptidase Action. I.
Effect of Various Extrinsic Factors on Kinetic Parameters, Journal of the American
Chemical Society 73, 4330-4340.
Pedersen, K. J. (1929) The ketonic decomposition of beta-keto carboxylic acids, Journal
of the American Chemical Society 51, 2098-2107.
Guthrie, J. P., and Jordan, F. (1972) Amine-catalyzed decarboxylation of acetoacetic acid.
The rate constant for decarboxylation of a β-imino acid, Journal of the American
Chemical Society 94, 9136-9141.

40

29.

30.

31.

32.

Dyson, P., and Hammick, D. Ll.,. (1937) Experiments on the mechanism of
decarboxylation. Part I. Decomposition of quinaldinic and isoquinaldinic acids in the
presence of compounds containing carbonyl groups, Journal of the Chemical Society,
1724-1725.
Ashworth, M. R. F., Daffern, R. P., and Hammick, D. Ll. (1939) The mechanism of
decarboxylation. Part II. The production of cyanide-like ions from α-picolinic,
quinaldinic, and isoquinaldinic acids, Journal of the Chemical Society, 809-812.
Dunn, G. E., Lee, G. K. J., and Thimm, H. (1972) Kinetics and mechanism of
decarboxylation of some pyridinecarboxylic acids in aqueous solution, Canadian Journal
of Chemistry 50, 3017-3027.
Kappock, T. J., Ealick, S. E., and Stubbe, J. (2000) Modular evolution of the purine
biosynthetic pathway, Current Opinion in Chemical Biology 4, 567-572.

41

Chapter 3
N5-Carboxyaminoimidozole Ribonucleotide Mutase from
Acetobacter Aceti
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3.1 Introduction
Class I and Class II PurEs show a great level of sequence and structural similarity
to each other and contain ‘universally’ conserved residues among the classes (1). Each
class, however, has ‘class specific’ residues that are conserved and different in each
class. Histidine 59 (A. aceti numbering) is a universally conserved residue in the “forties
loop” of both classes of PurE (“forties loop” refers to EcPurE numbering) and has been
suggested to serve as an active site acid/base. Histidine 89, however, is a Class I-specific
conserved residue. Histidine 89 is part of a four histidine chain that connects the two
active sites on opposite faces of the PurE octamer (His 59, His 89, His89’, His59’ where
the ‘ denotes a separate subunit). Owing to the proximity of histidine 89 to histidine 59
and the different reactions catalyzed by Class I and Class II PurEs (Scheme 3.1), it has
been suggested that His89 could serve as a “proton wire’ between active sites (2).

Scheme 3.1: Reactions catalyzed by Class I and Class II PurEs. The substrate of class I
PurE contains 1 less proton than the substrated of Class II PurEs.

In the E1 component of the pyruvate dehydrogenase complex, a string of polar
and ionizbale residues has been proposed to serve as a proton wire that allows for the
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introduction of a proton into the active site (3). His89 serving as a proton wire could
allow for the introduction of a proton into the active site of Class I PurE, joining the
reactions catalyzed by both classes. To explore the roles of His59 and His89, a series of
mutants was made at these positions, and the mutants were characterized. Crystal
structures were determined for many of these mutants by Courtney Starks of this lab.
This lab previously hypothesized that cytoplasmic proteins from A. aceti have
been subject to evolutionary selection for acid resistance by the acidic cytoplasm
routinely experienced by the organism (4-6). This selection could lead to cytoplasmic
proteins that are specifically suited for functioning at low pH. Thus, our goal has been to
determine if enzymes from A. aceti are intrinsically resistant to acid-mediated
inactivation, and if they have been catalytically adapted to function optimally at lower
pH.
The first reported crystal structure of AaPurE (2) had citrate bound in the active
site (citrate was present in the crystallization solution). Comparisons to other crystal
structures of PurE indicated that citrate interacted with several residues that are
involved in nucleotide binding (Figure . The extensive interactions between citrate and
the active site indicated that citrate might serve as an active site probe. The residues
involved in binding citrate are highlighted below, and the roles the residues play in
nucleotide binding are shown in parentheses. The citrate C1 carboxylate (pro-R arm)
interacts with AaPurE Ser30 (bound to ribose-5-phosphate (R5P) moiety phosphate
oxygen of AIR), Asp33 (bound to the 2’ and 3’ hydroxyls of AIR) and Gly85 NH amide
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(bound to the 3’-hydroxyl of AIR); the central C6 carboxylate interacts with His59 Nδ,
which has been identified as the active site acid involved in catalysis.

Figure 3.1: Crystal structure of AaPurE with AIR bound. Several active site residues
used in nucleotide binding are also used in binding citrate. Citrate interacts with Ser30,
Asp33, Gly85 and His59. Crystal structure determined by Courtney Starks (5).

This chapter reports the biophysical and biochemical characterization of PurE
from A. aceti and 11 mutants made at residue 59 and 89. These enzymes were
characterized kinetically and through active site probes to determine specific roles for
residues His59 and His89. A biophysical examination of the stability of EcPurE compared
to AaPurE at a number of pHs was also undertaken. pH-rate profiles constructed for
AaPurE-wt and an interesting, active mutant AaPurE-H59D allowed confirmation that
His59 serves as an active site base. Also reported is a proposal for how proteins from an
acidophile like A. aceti may be optimized to survive at low pH, based on the analysis of
several crystal structures of AaPurE.
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3.2 Methods
Materials and methods – All materials were from Sigma Aldrich or Fisher
Scientific and of the highest purity unless otherwise noted. Hydroxyapatite HTP and
Bradford reagent were obtained from Bio-Rad. Restriction endonucleases, Vent DNA
polymerase, and T4 DNA ligase were from New England Biolabs. Mutagenesis was
performed using Quikchange Mutagenesis kits from Stratagene. Oligodeoxynucleotides
(ODNs) were from Integrated DNA Technologies. PD-10 disposable columns were
obtained from GE Health Care (formerly Amersham Biosciences). Centrifugation steps
were performed using a Beckman Avanti J-20 centrifuge with a JLA-10.5 or JA-20 rotor.
Routine activity assays were performed on an Agilent 8453 diode array UV/vis
spectrophotometer. Kinetic characterizations including minimal activity assays were
performed on a CARY-100 UV/Vis spectrophotometer. Cell disruption by sonication was
performed using a Virsonic 100 sonicator. Proteins were routinely concentrated using
Amicon ultrafiltration devices with a 10 kDa molecular weight cutoff (YM-10).
Aminoimidazole carboxamide ribonucleoside (AICAR) was obtained from Toronto
Research Chemicals and used to synthesize CAIR by Hong Jiang of this lab by a published
method (7). Protein concentrations were determined by the method of Bradford (8),
using bovine serum albumin as a standard. Plasmids were sequenced by Sanger
sequencing at the Protein and Nucleic Acid Chemistry Laboratory at Washington
University in St. Louis. Protein masses were determined by ESI-MS on a Micromass QTOF Ultima quadropole-TOF mass spectrometer by Washington University Center for
Biomedical and Bioorganic Mass Spectrometry.
46

Bacterial Strains. Mutagenesis steps were performed using E. coli strains DH5α
and XL-10 Gold. For protein expression, strain BL21(DE3) was employed.
Construction of plasmids for AaPurE expression. Plasmid pJK175 was used for
the expression and purification of AaPurE, and was previously made by Christopher Mill
of this lab (5). Mutant AaPurE constructs for expression were made using Quikchange
mutagenesis kits with plasmid pJK175 as template, and the appropriate ODNs listed in
Table 2.1 to create plasmids pJK278 (AaPurE-H89N), pJK279 (AaPurE-H89D), pJK280
(AaPurE-H89F), pJK281 (AaPurE-H59F), pJK282 (AaPurE-H59D), pJK283 (AaPurE-H59N),
Table 3.1 Oligodeoxynucelotides (ODNs) used in this Chaptera
ODN
Sequence 5’3’
Mutation coded(cut site)
1002
GTGGAGCTGCAaATtTGCCGGGTATG
5’-H89N (ApoI)
1003
CATACCCGGCAaATtTGCAGCTCCAC
3’-H89N
1011
GTGGAGCTGCAgATCTGCCGGGTATG
5’-H89D
1012
CATACCCGGCAGATcTGCAGCTCCAC
3’-H89D
1013
GTGGAGCTGCAttTCTGCCGGGTATG
5’-H89F
1014
CATACCCGGCAGAaaTGCAGCTCCAC
3’-H89F
1015
CATTGTTTCAGCAttTCGTACGCCAGAC
5’-H59F
1016
GTCTGGCGTACGAaaTGCTGAAACAATG
3’-H59F
1017
CATTGTTTCtGCAgATCGTACGCCAGAC
5’-H59D (PstI)
1018
GTCTGGCGTACGATcTGCaGAAACAATG
3’-H59D
1019
CATTGTTTCAGCAaATCGTACGCCAGAC
5’-H59N
1020
GTCTGGCGTACGATtTGCTGAAACAATG
3’-H59N
1062
GTGGAGCTGCAGTTCTGCCGGGTATG
5’-H89V
1063
CATACCCGGCAGAACTGCAGCTCCAC
3’-H89V
1064
GTGGAGCTGCAGGTCTGCCGGGTATG
5’-H89G
1065
CATACCCGGCAGACCTGCAGCTCCAC
3’-H89G
1066
CATTGTTTCAGCACAaCGTACGCCAGAC
5’-H59Q
1067
GTCTGGCGTACGtTGTGCTGAAACAATG
3’-H59Q
1068
CATTGTTTCAGCAgcTCGTACGCCAGAC
5’-H59A
1069
GTCTGGCGTACGAgcTGCTGAAACAATG
3’-H59A
1070
CATTGTTTCAGCAagTCGTACGCCAGAC
5’-H59S
1071
GTCTGGCGTACGActTGCTGAAACAATG
3’-H59S
a
Letters shown in lower case code for mutatagenesis. In some cases, a silent mutation
was also included to create a restriction site for screening plasmids.
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pJK314 (AaPurE-H89V), pJK315 (AaPurE-H89G), pJK318 (AaPurE-H59Q), pJK319 (AaPurEH59A), and pJK320 (AaPurE-H59S).
Overexpression and purification of AaPurE. Glycerol stocks of BL21(DE3) cells
transformed with pJK 175 were streaked on LB plates supplemented with 100 µg/mL
ampicillin and were grown overnight at 37 °C. A single colony was used to inoculate a
starter culture of LB broth, supplemented with ampicillin as above, that was grown to
saturation. Starter cultures were diluted 1:50 into fresh media and the cultures grown
at 37 °C to an A600 = 0.6, and induced by the addition of IPTG to 0.4 mM. After 4 h of
induction, cells were harvested by centrifugation (10000g, 20 min). Cell pellets were
then frozen at -80 °C until used. All subsequent steps were performed at 4 °C.
Cell pellets were resuspended in 50 mM Tris-HCL, pH 8.0 (6 mL/g of cells). Cells
were disrupted by sonication, and debris was removed by centrifugation (37000 g, 20
min). Streptomycin was added to the lysate to 1% (w/v) from a 10% (w/v) stock and the
lysate gently mixed for 15 min on ice. Solids were removed by centrifugation (37000g,
60 min). The resulting supernatant was then adjusted to 35% saturation by the slow
addition of solid ammonium sulfate over 30 min. Following an additional 30 min, solids
were collected by centrifugation (37000 g, 10 min).
The 35% ammonium sulfate pellet was redissolved in a minimal volume of 10
mM potassium phosphate buffer, pH 8.0. The solution was then desalted in 2.5 mL
portions using a PD10 column equilibrated in 10 mM potassium phosphate buffer, and
applied to a hydroxyapatite column (2.5 X 1.5 cm) equilibrated in 10 mM potassium
phosphate buffer. The column was washed with the same buffer, and AaPurE was
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found in the flow through fractions. These fractions were pooled and concentrated to
>5 mg/mL using Amicon ultrafiltration devices with a YM10 membrane. The
concentrated protein solution was then stored in small single use aliquots at -80 °C.
Overexpression and purification of mutant forms of AaPurE. AaPurE mutants
were isolated by using the same procedure as described above for wild type AaPurE. To
avoid cross contamination, each mutant was purified using its own new column material
and ultrafiltration devices. Mutants were concentrated to >5 mg/mL using Amicon
ultrafiltration devices with a YM10 membrane. The concentrated protein solution was
then stored in small single use aliquots at -80°C.
Thermal denaturation of E. coli PurE monitored by circular dichroism (CD). Data
were obtained on a Jasco J-500A spectropolarimeter. A jacketed cylindrical quartz cell
with a 0.1 cm path length was heated from 24 °C to >75 °C in 1° or 2 °C steps (smaller
steps were taken near the melting transition), allowing 200 s for equilibration at each
temperature. The loss of structure of EcPurE was followed by monitoring the ellipticity
of the protein at 222 nm at 0.23 mg/mL EcPurE, 50 mM potassium phosphate buffer and
100 mM KCl at pH 4.0, 5.0, and 7.0. A trial at pH 3.5 indicated the protein unfolded at
the starting temperature (24 °C). The melting temperature (Tm) for each pH was
determined by the inflection point of each progress curve.
Carboxylic titrations of AaPurE. Spectra were obtained on a Spex FluoroMax
fluorimeter equipped with a thermostated stirred cell holder using a 1 cm fluorimeter
cell at 25°C (the temperature inside cuvette was measured using a thermocouple).
Titrations were performed in a starting solution of 2.0 mL 50 mM potassium acetate, pH
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5.2, 100 mM KCl and 3 µM AaPurE. The emission spectra was recorded from 300 to 420
nm (5 nm slit width, 0.5 s integration, 1 nm intervals), exciting at 295 nm (1 nm slit
width). The intensity of λmax of the unliganded protein was then measured after small
additions of a 100 mM stock solution of carboxylic acidss listed in Table 2.4. At the end
of each titration the pH of the solution was determined. Data were corrected for
dilution and inner-filter effect when needed. Fluorescence data (F) were fit as a
function of C= [titrant] to three parameters using equation 1 below where: Kd =
dissociation constant, F0 = F prior to addition of titrant, and ∆F = maximal change in F.
𝐹 = 𝐹 − ∆𝐹

𝐶
𝐶+𝐾

(1)

Citrate pH-affinity profile. Titrations with citrate were performed as above at a
number of pHs from pH 3.7 – 6.2 in 50 mM potassium acetate buffer, 100 mM KCl, and
3 µM AaPurE, and the value of Keq was determined, (Keq = 1 / Kd). These values were
plotted as a function of pH and fit to equation 2.

log (𝐾 ) = log (

𝐾
10
10

+

10
10

)

(2)

+ 1

Enzyme activity assays. All active forms of AaPurE were assayed in the reverse
direction (CAIRN5CAIR) by using the published method at 100 µM CAIR(9). Activities
for all active forms (see below) of AaPurE (except H59S, the activity of which was too
low for characterization) were determined in 50 mM Tris-HCl pH 8.0, in a total volume
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of 0.5 mL, in a stoppered 1 cm pathlength cuvette. For Michaelis-Menten plots, initial
rates were determined at varying CAIR concentration. At higher concentrations of CAIR,
a 0.5 cm pathlength cuvette was used. Reactions were initiated by the addition of
enzyme after a background rate of decarboxylation had been determined. The initial
rate of CAIR conversion (<10% conversion of CAIR) was determined at 260 nm, and
plotted as a function of CAIR concentration. Kinetic constants were obtained by nonlinear least squares fitting to the Michaelis-Menten equation by using KaleidaGraph 3.6
(Synergy software).
Determination of maximal activities for inactive AaPurE mutants. Standard
activity assays were altered to contain up to 0.9 mg/mL of protein in an attempt to
detect any activity in mutants that showed no activity during the purification steps. For
AaPurE-H59N, this procedure was also attempted in the three buffer system at pH 5.0,
6.0, 7.0 and 8.0. The maximal possible activity was calculated as twice the uncertaintity
of the slope in A260 over time.
pH-rate profiles. The initial rates of reaction for AaPurE-wt and AaPurE-H59D
were determined as above except that a triple buffer system was used at many pHs,
using the values of ∆ε260 of CAIR  N5-CAIR determined for each pH as described in
Chapter 2. Reactions contained 100 mM Tris-HCl, 50 mM MES, 50 mM acetic acid,
variable amounts of CAIR (0.4-400 µM) and either 0.54-4.3 nM AaPurE-wt or 36.5-365
nM AaPurE-H59D. Data at each pH were plotted as a function of [CAIR], and the data
were fit to the Michaelis-Menten equation by nonlinear least squares fit. Values of kcat
and kcat/Km were plotted as a function of pH and fitted by nonlinear least squares fit to
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equation 3, or equation 4 in the case of AaPurE-wt kcat/Km, which accounts for three
ionizations, two of which are indistinguishable.

log 𝑦 = log[

log 𝑦 = log[

𝑐
]
𝐻
𝐾
1+
+
𝐾
𝐻

𝑐
]
𝐻
𝐾
1+( ) +
𝐾
𝐻

(3)

(4)

CAIR titration of inactive mutants. The ligand-binding affinity of AaPurE mutants
H59N, H59F and H59A were monitored in titrations detecting changes in intrinsic
tryptophan fluorescence. Titrations initially contained 50 mM Tris-HCl, pH 8.0 and 3 µM
AaPurE. The emission spectrum was recorded from 300 to 420 nm (5 nm slit width, 0.75
s integration at every nanometer), exciting at 295 nm (1 nm slitwidth). Spectra were
recorded following small additions from a titrant solution of 100 µM CAIR in 50 mM TrisHCl pH 8.0. After corrections for dilution, fluorescence intensity data (F) were fit as a
function of the known values C= [CAIR], and E = 0.5 [subunit] to three parameters using
equation 5 below where: Kd = dissociation constant, F0 = F prior to addition of titrant,
and ∆F = maximal change in F. Half sites binding was used because it yielded a superior
fit to data.

𝐹= 𝐹 −

∆𝐹
(𝐶 + 𝐸 + 𝐾 ) −
2
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(𝐶 + 𝐸 + 𝐾 ) − 4𝐸𝐶

(5)

Acid Stability Assays. In an adaptation of a previously described method for
measuring the relative acid stability of A. aceti proteins were compared to mesophile
proteins (4); AaPurE and EcPurE were incubated at 30 µg/mL in the three buffer system
at 30 °C at pH 3.0 and 3.5, as well as in 25 mM potassium phosphate buffer with KCl
added to an ionic strength of 0.1 M at pH 2.5. Aliquots were removed and assayed for
activity in a standard reverse direction activity assay.
3.3 Results
Creation of AaPurE mutants. Mutants of AaPurE were made to investigate the
roles of universally conserved residues His59 and Class I conserved residue His89.
Quikchange mutagenesis allowed for the rapid construction of plasmids for expressing
these mutants. Sequencing indicated that all of the intended mutants were obtained,
usually in the first attempt. The successful mutations were obtained without the need
to screen the plasmids using the silent restriction sites that had been added in some
cases.
Purification of Recombinant AaPurE. The gene coding for AaPurE was originally
isolated in plasmid pJK173 by Christopher Mill of this lab, by functional
complementation of the E. coli purE auxotroph PC0135. This indicated that AaPurE is
expressed as an active protein in E. coli. For purification, AaPurE was expressed in
BL21(DE3) cells using plasmid pJK175. The purification of AaPurE (Scheme 3.2),
followed standard steps for the
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Scheme 3.2: Purification scheme for AaPurE

disruption of cells (sonication) and removal of polynucleotides by streptomycin
precipitation. Ammonium sulfate (AS) fractionation at 35% AS saturation provided a
quick means to enrich AaPurE as evidenced by the increase in specific activity (Table
3.2). After removing salts and small molecules using a PD-10 size exclusion column,
several contaminating proteins were removed by applying the protein solute to a
hydroxyapatite column. Flowthrough fractions containing protein, including AaPurE,
were pooled and concentrated using an Amicon ultracentrafugation device (YM-10).
The same purification scheme was successfully used for all mutants. A representative
gel analysis of one purification is shown in Figure 3.2. A gel analysis of all concentrated
final products is shown in Figure 3.3.
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Figure 3.2: SDS-PAGE analysis (15% polyacrylamide) of an AaPurE purification. Shown
above is the purification of mutant AaPurE-H89G. Lane 1, Uninduced cells; Lane 2, Cells
after 4 h induction at 400 µM IPTG; Lane 3, crude lysate; Lane 4, insoluble lysate; Lane 5,
soluble lysate; Lane 6, 1% streptomycin supernatant; Lane 7, 35% Ammonium sulfate
supernatant; Lane 8, 35% ammonium sulfate pellet; Lane 9, PD10 elutant; Lanes 10-12;
flowthrough fractions from hydroxyapatite column. Flow through fractions from
hydroxyapatite column were pooled and concentrated as described.

Figure 3.3: SDS-PAGE analysis of purified AaPurEs. (15% polyacrylamide, 3 µg of each
protein). Sigma low range marker is shown in the first lane, and molecular weights
associated with each are shown on the right in kDa. AaPurE-wt is denoted by the
abbreviation wt. All mutants are denoted by the corresponding one letter code above
each lane.

The purification of wild type and mutants yielded final products of similar purity
(Figure 3.3). The activity of purifications (when activity was detected during
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purification) was followed, and the specific activity of each step determined (Table 3.2).
The identities of proteins were further confirmed by ESI-MS (Table 3.3).
Table 3.2: Purification chart for mutants with detectable activity throughout
purification.
Soluble
Lysate
Streptomycin
35% AS pellet
PD10 column
Hydroxyapatite
a

Wt
355a
(16.4)b
268
(22.4)
132
(35.4)
107
(38.6)
86
(38.8)

H59D
109
(0.14)
79.4
(0.22)
50.0
(0.31)
50.1
(0.30)
39.1
(0.33)

H89N
68.8
(0.022)
45.8
(0.031)
12.8
(0.091)
11.0
(0.099)
9.1
(0.11)

H89D
76.8
(0.61)
57.9
(0.87)
19.8
(3.2)
13.6
(1.9)
14.5
(1.7)

H89F
72.6
(0.75)
46.0
(1.4)
10.8
(4.3)
7.2
(5.8)
6.7
(5.8)

H89V
62.9
(1.5)
39.5
(2.3)
15.3
(4.9)
14.0
(5.4)
11.3
(5.7)

H89G
66.8
(0.72)
47.3
(0.94)
27.5
(1.6)
24.9
(1.7)
19.5
(1.6)

Amount of protein in milligrams bspecific activity of protein determined Units/mg.

Table 3.3: Results of ESI-MS of purified wild type and mutant AaPurEs
MW (Da)
Expected (Da)
wild type
18865 ± 2
18865.8
H59N
18842 ± 2
18842.7
H59D
18844 ± 2
18843.7
H59F
18875 ± 2
18875.8
H59Q
18856 ± 2
18856.8
H59A
18799 ± 2
18799.7
H59S
18815 ± 2
18815.7
H89N
18841 ± 2
18842.7
H89D
18844 ± 2
18843.7
H89F
18875 ± 2
18875.8
H89V
18828 ± 2
18827.8
H89G
18785 ± 2
18785.7
Samples were diluted in water, bound to an inline C18 guard column, and desalted with
water. After a solvent change via a 1 min gradient to 1% acetonitrile 0.1% trifluoroacetic
acid and the protein eluted in a gradient to 60% acetonitrile 0.1% fluoroacetic acid on a
Micromass Q-Tof Ultima with Waters CapLC. Spectra were decharged to give a MW by
using MaxEnt.

Acid stability studies. A. aceti is an acidophilic bacterium that tolerates an acidic
cytoplasm (10), and should therefore contain proteins suited to functioning at low pH.
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Previously, the acid stability of proteins from A. aceti was characterized in reference to a
similar protein from a mesophile (4, 6). The thermal denaturation of EcPurE under the
same conditions as AaPurE indicated that EcPurE is far less thermostable at all assayed
pHs (Figure 3.4). Attempts to compare the acid stability of AaPurE and EcPurE by
monitoring the loss of enzyme activity when the enzymes were incubated under acid
conditions failed. Upon transfer to standard activity assays (pH 8.0), the activities for
both enzymes were found to increase while being assayed. This indicated that both
unfolded proteins may partially refold in the assay buffer. This prevented the
determination of a rate of inactivation for either PurE.

Figure 3.4: Comparison of E. coli and A. aceti PurE Tm values. Melting temperatures for
proteins (Tm) were determined following circular dichroism at 222 nm to monitor
thermal denaturation of protein. Tms were determined as a function of pH, EcPurE (filled
squares) was found to be far less thermostable than AaPurE (open circles) at all pHs
assayed. EcPurE unfolded at the starting temperature of 24°C at pH 3.5 (not shown).

Carboxylic acid titrations of AaPurE. Owing to the extensive interactions between
citrate and the AaPurE active site, fluorescence titrations were performed to determine
57

if a citrate complex might form in vivo. The binding of citrate leads to a decrease in the
intrinsic fluorescence of AaPurE. This decrease was used to determine the binding
affinity of citrate for AaPurE by following the decrease in fluorescence emission
intensity as a function of citrate concentration. The resulting data were then fit to
equation 1. The binding of citrate to AaPurE was determined over a broad range of pH.
The pH was measured at the start and at the end of each titration. In no case did this
value differ from the starting value by more than 0.11 pH units. A pH-affinity profile
was created by plotting the citrate affinities as a function of pH (Figure 3.5). This yields
a bell-shaped profile, with an optimum near pH 4.6. Both the basic and acidic arms of
the profile have a slope of 0.9, indicating that a single protonation is involved in
determining each arm of the profile. This is consistent with the binding of the citrate
mono- or di- anion (pKa1= 3.13; pKa2= 4.76; pKa3= 6.80)(11) assuming that one of the
ionizations of the profile derives from citrate. The data collected at each pH were fit to
equation 2 to determine apparent pKa values of the profile.
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Figure 3.5: pH dependence of wt AaPurE citrate affinity (Keq). Binding equilibrium
constants (Keq) were determined at 0.3 pH unit increments from pH 3.4 to 6.4.
Fluorescence titrations were performed at 25 °C using AaPurE-wt. The solid line
represents a fit of the log(Keq) to equation 2, with pK1 = 5.1 + 0.4 and pK2 = 4.7 + 0.4 and
a maximum pH independent Keq= 20 ± 10 mM-1. The strongest affinity was recorded at
pH 4.6 = 3.6 ± 0.2 mM-1 (Kd = 0.28 ± 0.02 mM).

The fluorescence quenching assay was used to screen several other common
citric acid cycle intermediates and amino acids for binding at pH 5.4. For compounds
that appeared to bind, the Kd was determined in the same manner as for citrate (Table
3.4). None of 13 metabolites screened bound AaPurE more strongly than citrate,
although isocitrate, DL-2-fluorocitrate, cis-aconitate, trans-aconitate and malic acid
showed measurable Kds. For DL-2-fluorocitrate, titrations were performed at 3 pHs.
None of these binding affinities is strong enough to suspect that AaPurE is regulated in
vivo by the compounds tested.
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Table 3.4: Carboxylic acids screened as possible AaPurE ligands
Compound
Counterionc
Final pH
Kd (mM)d
∆F
a
Citrate
Sodium
5.5
0.19 ± 0.02
Decrease
DL-isocitratea
Sodium
5.6
0.8 ± 0.2
Decrease
a
5.41
>3
Decrease
OAA
a
fumaric acid
4.9
>5
Decrease
4.98
>10
None
Succinic acida
α-ketoglutaratea
sodium
5.16
>5
None
a
L-glutamate
sodium
5.43
>30
None
5.43
>20
None
L-lactatea
a
cis-aconitate
5.45
~1
Increase
a
trans-aconitate
5.44
~1
Decrease
5.5
>1.5
Decrease
DL-apartatea
b
potassium
4.16
0.53 ± 0.04
Decrease
DL-2-fluorocitrate
4.78
0.70 ± 0.06
Decrease
5.39
1.0 ± 0.1
Decrease
b
DL-malate
5.23
2.8 ± 1.0
Decrease
L-malateb
5.23
3.8 ± 0.6
Decrease
a
Buffer for titration was 50 mM ammonium acetate, 100 mM potassium chloride,
b
Buffer was 50 mM potassium acetate, 100 mM potassium chloride, c The commercially
available or prepared salt (12) was used to make titrant solution, a (-) indicates the free
was acid used, dFrom fluorescence emission titration

Among the compounds surveyed, an interesting difference was seen in the
between cis-aconitate and trans-aconitate (Figure 3.6). The binding of cis-aconitate
caused an increase in intrinsic fluorescence of AaPurE, while the binding of transaconitate caused a decrease. The data at higher concentrations of cis- and transaconitate both show a sharp increase in the intrinsic fluorescence of AaPurE. This made
the data difficult to fit. To obtain approximate Kd values, only data collected below 5
mM were fit to equation 1. This yielded values of 0.7 ± 0.2 mM and 1.5 ± 0.8 mM for
trans- and cis- aconitate respectively. Because only a portion of the data was used, the
Kd for cis- and trans- aconitate has been shown as ~1 mM in Table 3.4. In both titrations,
data were corrected for the large inner filter effect of the respective titrants. Therefore,
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it is unknown if the increase in intrinsic fluorescence seen at higher concentrations of
titrant is real or an artifact of the correction.

Figure 3.6: Fluorescence titration of AaPurE with cis- and trans- aconitate. Fluorescence
emission intensity at 337 nm plotted as a function of [aconitate] for trans aconitate
(filled circles) and for cis aconitate (filled squares). Cis-aconitate causes an increase in
the intrinsic fluorescence of AaPurE while trans aconitate causes an initial decrease in
the intrinsic fluorescence of AaPurE. At higher concentrations, both cis and trans
aconitate cause an increase in the intrinsic fluorescence of AaPurE. Only data collected
under 5 mM (filled tokens) for both cis and trans aconitate were fit to Equation 1 to
yield an estimate of Kd. The solid line represents a fit of the data for trans aconitate
with Kd = 0.7 ± 0.2 mM; F0= 2.998 ± 0.006; and ΔF = -0.16 ± 0.02; dashed line represents
fit of the data for cis aconitate with Kd = 1.5 ± 0.8 mM; F0 = 3.027 ± 0.008; and ΔF = 0.19
± 0.04. Data collected at higher concentrations of aconitate are not included in the fits.

Kinetic characterization of wt AaPurE and mutants at pH 8.0. The kinetic
constants kcat and Km were determined for wild type and all of the active mutants, except
H59S, at pH 8.0 (Table 3.5). Although the H59S mutant had a barely observable activity
(see following section) that scaled with the amount of enzyme added, this activity was
too small for reliable determination of kinetic constants.
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Table 3.5: Properties of wt and mutant AaPurEs

wild type
H59N
H59D
H59F
H59Q
H59A
H59S
H89N
H89D
H89F
H89V
H89G

Relative kcat/Kma
(units/mg)b
c
1 (39)
0 (<0.0005)
0.0016 (0.33)
0 (<0.0005)
0.000014 (0.00082)
0 (<0.0001)
ndd (0.0001)n
0.029 (0.11)
0.044 (1.7)
0.14 (5.8)
0.17 (5.7)
0.91 (1.6)

kcat (s-1)a
12.2 ± 0.6
nd
0.49 ± 0.03
nd
0.0006 ± 0.0001
nd
nd
0.063 ± 0.002
0.40 ± 0.02
1.97 ± 0.09
2.10 ± 0.09
0.97 ± 0.06

Km CAIR (µM)a
8.0 ± 1.2
nd
200 ± 30
nd
30 ± 20
nd
nd
1.4 ± 0.2
6±1
9±1
8±1
0.7 ± 0.5

Kd CAIR (µM)a

0.78 ± 0.07
0.46 ± 0.09
0.08 ± 0.02

Kd citrate(mM)
0.40 ±0.04
1.2 ± 0.1
7.1 ± 1.0
0.8 ± 0.3
2.8 ± 0.7
>10
>10
2.6 ± 0.4
2.7 ± 0.4
2.1 ± 0.2
0.49 ± 0.04
2.5 ±0.3

a

Determined at pH 8.0 and 30 °C in 50 mM Tris pH 8.0. bDetermined at 0.1 mM CAIR. c
wt kcat/Km = 1.5 X 106 M-1 s-1. nd= not determined.

Only three of the His59 mutants had detectable activity, indicating an important
role for this residue. The lack of a detectable activity for several mutants indicates that
contamination by host EcPurE does not occur. Of the mutants made at this position,
only the H59D, H59Q, and H59S mutants had any activity. Of these, only the H59D and
H59Q mutants had characterizable kinetics. All of the His89 mutants retained some
catalytic activity. Surprisingly several of the His89 mutants approach the kcat/Km of the
wt enzyme, most notably the H89G mutant. Mild substrate inhibition was noted for the
AaPurE-H89F mutant. Because this mutation results in a larger residue at this position,
the protein might be “overpacked” in the region between adjacent active sites. This
could cause negative cooperativity in substrate binding, either when both adjacent
active sites are occupied or during the conversion of occupied to vacant sites.
Minimally active mutant and inactive mutants. Activity was not detected during
the purification of several mutants (H59N, H59F, H59Q, H59A and H59S). To determine
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if these mutants lacked detectable activity, the standard activity assay was performed
using a large amount of the purified protein (up to 0.9 mg/mL final concentration in
reaction). These activity assays indicated that the mutants H59Q and H59S had a very
low specific activity that scaled with the amount of enzyme added (Table 3.5). For the
other mutants, no activity was detected at pH 8. The maximal residual activities for
these mutants were determined from detection thresholds; maximal residual activities
ranged from <0.0003 to <0.0008 units/mg. The term “inactive mutant” will be applied
to these mutants and is defined as not having activity that can be detected. Given that
these values are greater than the activity found for the barely active H59S mutant, they
can be taken as an upper limit of residual activity. For the H59N mutant, this minimal
activity assay was also repeated in the three buffer system at pH 5, 6, 7 and 8; again no
measurable activity was detected (Table 3.6). At lower pH, the detection threshold is
larger owing to the nonenzymatic decarboxylation of CAIR.

Table 3.6: Activity detection threshold for residual activity of AaPurE-H59N by pH
pH
Possible residual activity (units/mg)
8.0
<0.0002
7.0
<0.0002
6.0
<0.0003
5.0
<0.0004
a
Determined at 100 µM CAIR at 30°C in triple buffer system as described in methods
and materials.
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CAIR titrations of inactive mutants. For inactive mutants H59N, H59A and H59F,
fluorimetric titrations were performed using CAIR, at pH 8.0 in Tris-HCl buffer. While
the binding of citrate to AaPurE caused a decrease in intrinsic fluorescence, the binding
of CAIR caused an increase (Figure 3.7). This is an interesting distinction from EcPurE
mutants, which show a decrease in intrinsic fluorescence upon the binding of CAIR (13).
The data collected for each titration were fit to equation 5 with half of the sites binding.
Fitting to a half-sites model always gave a superior fit than full sites and will be
discussed later.
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Figure 3.7: Fluorescence titration of inactive AaPurE mutants with CAIR. (A)
Fluorescence emission spectra for AaPurE-H59N mutant at 0 (black line), 0.78 µM CAIR
(dark grey line), 2.2 µM CAIR (grey line) and 19 µM CAIR (light grey line), for 2.7 µM
protein subunit, recorded at 25 °C with excitation at 295 nm, final pH 7.99. (B)
Fluorescence emission intensity at 338 nm as function of CAIR concentration, for
AaPurE-H59N (open circles), AaPurE-H59F (open squares), and AaPurE-H59A (filled
diamonds). Titrations were performed at 2.7, 2.9 and 2.9 µM protein [subunit]
respectively. Data were fit to equation 5, which yielded values of Kd,CAIR summarized in
Table 3.5.

pH rate profiles of AaPurE-wt and AaPurE-H59D. Due to the nature of the
reaction catalyzed, and the ability for the product N5-CAIR to undergo rapid degradation
to AIR and CO2, special care was taken in designing how the pH-rate profile would be
compiled. Simple buffer systems such as Tris-HCl or acetate buffer have a narrow
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buffering capacity, and to set the pH of a buffer, acid or base is added. This changes the
total ionic strength of the solution, requiring salt to be added to normalize the ionic
strength of each buffer at each pH. The use of a triple buffer system can avoid this
problem with the choice of the proper components by fixing the ionic strength of the
buffer at all pHs within the buffering capacity of the system (14).
Michaelis-Menten plots were determined for AaPurE-wt at 0.5 unit intervals
from pH 5.0 to 9.0, and for AaPurE-H59D from pH 4.5 to 8.0 using the ∆ε260 for each pH
(Chapter 2). The data collected at each pH were fit to equation 3 to determine the
values of kcat and kcat/Km. A semi-logarithmic plot of these values versus pH gives bellshaped profiles consistent with two or more pKas (Figures 3.8 and 3.9).
kcat/Km pH rate profile. The kcat/Km pH rate profiles of AaPurE-wt and AaPurEH59D yield bell shaped profiles that are slightly different in shape (Figure 3.8). The
AaPurE-H59D profile fit well to equation 4 (AaPurE-H59D pK1= 5.7 ± 0.2, pK2 = 6.5 ± 0.2).
However, the steeper acidic arm slope of the AaPurE-wt profile required fitting with
equation 5, which assumes that two ionizations occur on the acidic arm (pK1*) of the
profile (AapurE-wt pK1* = 6.0 ± 0.1, pK2 = 7.2 ± 0.1).
kcat pH rate profile. The log kcat versus pH profiles for AaPurE-wt and AaPurEH59D yielded bell shaped curves that were fit to equation 4 (Figure 3.9, AaPurE-wt pK1 =
5.1 ± 0.2, pK2 = 8.4 ± 0.1; AaPurE-H59D pK1= 4.4 ± 0.4, pK2 = 6.8 ± 0.2).
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Figure 3.8: kcat/Km pH-rate profiles. Log(kcat/Km) as a function of pH for AaPurE-wt (filled
squares) and AaPurE-H59D(open circles). Values of kcat and errors shown were
determined from initial velocity data obtained varying amounts of CAIR at each pH
indicated, fit to the Michaelis Menten equation. For most points, the error was smaller
than tokens used. Lines shown are the fit of H59D data to eq 3, and the fit of wt data to
eq 4, which accounts for a second protonation (second pK1) occurring on the acidic arm
of the profile.

Figure 3.9: kcat pH-rate profiles. Log(kcat) as a function of pH for AaPurE-wt (filled
squares) and AaPurE-H59D(open circles). Values of kcat and errors shown were
determined from initial velocity data obtained varying amounts of CAIR at each pH
indicated, fit to the Michaelis Menten equation. For most points, the error was smaller
than tokens used. Lines shown are fits of data to eq 3.
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3.4 Discussion
The foci of the study of AaPurE were two-fold: (1) to investigate the role of Class
I PurE conserved residues His59 and His89, (2) to characterize AaPurE over a range of
pHs to investigate how it might be adapted to function at low pH. There are three nonexclusive ways one can imagine for an enzyme to be adapted to function at low pH (46): (A) an enzyme may be catalytically optimized to function at low pH; (B) a protein may
have improved stability at low pH; (C) a protein may work with the aid of chaperone
proteins at low pH. Only B is supported by our data, through a comparison of AaPurE
and EcPurE, which was not expected to have a particular stability at low pH. In this work,
it has been shown that AaPurE is intrinsically stable to acid-mediated denaturation over
the range of pH experienced in the cytoplasm of A. aceti, which suggests that an acid
chaperone is not required for the functioning of AaPurE.

(1) Investigation into the roles of conserved residues His59 and His89
Purification of AaPurE. The purification scheme outlined in Scheme 3.2 provided
a rapid method of purifying AaPurE and mutants to >90% purity. The ammonium
sulfate fractionation procedure removes most EcPurE, which remains soluble at a much
higher level of ammonium sulfate saturation (>60% AS) (15). AaPurE is also
distinguished from EcPurE (and Cryptococcus neoformans Ade2) in its inability to bind
hydroxyapatite at pH 8.0 and low phosphate conditions (15, 16). These two differences
allowed AaPurE and mutants to be separated from any host EcPurE, as is evidenced by
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the complete lack of a detectable activity for the H59A, H59F and H59N mutants.
Although the purifications of most of these inactive mutants have only been performed
once, the lack of activity in these mutants is supported by results from a mutant EcPurE
with equivalent to AaPurE-H59N (13).
Carboxylic acid titrations. The first reported crystal structure of AaPurE indicated
that citrate was bound in the active site. This suggested that citrate might be used as an
active-site probe. The ability of citrate to serve as an active site probe was also used to
study the active site of AaPurE using REDOR with 13C labeled citrate (17). These studies
indicated that His59, under the conditions used, was found in a mixture of two
protonation states (17). Binding of citrate caused a diminution of fluorescence in
AaPurE, which was used to determine the Kd for citrate. To investigate whether citrate
or any common carboxylic acid metabolites had the potential to regulate AaPurE in vivo,
13 different compounds were titrated with AaPurE. Citrate was found to bind most
strongly but with a modest affinity (Kd = 0.19 ± 0.02 mM). None of the compounds
appeared to bind strongly enough to suggest they regulate AaPurE in vivo. It is
interesting to note that some carboxylic acids had different effects on the fluorescence
of AaPurE: binding of cis-aconitate led to an increase in fluorescence, while the binding
of trans-aconitate led to a decrease. Of all of the compounds that bound, and those
that did not, no clear structure-affinity relationship could be discerned.
The affinity of AaPurE for citrate allowed citrate to be used as an active site
probe in most cases. Only two of the mutants failed to show binding of citrate by the
fluorescence titrations. Given that the two mutants that do not appear to bind citrate
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were shown to either bind CAIR (H59A) or to have a detectable activity (H59S), the
active sites of each mutant does appear to be intact. The failure to bind citrate
detectably could be due to a couple of reasons: (1) these mutants may bind citrate, but
the binding causes no measurable change in their intrinsic fluorescence. (2) different
portions of AaPurE are used to bind citrate and CAIR; namely His59, which is not
required for the binding of CAIR but does have an interaction with citrate.
Citrate pH-binding profile. To further investigate the binding of citrate to AaPurE,
titrations were performed at a number of pHs (0.3 pH unit intervals) from pH 3.5 to 6.4,
and used to construct a pH binding profile, which was fit to equation 2 (Figure 3.5). This
analysis was consistent with a single protonation on each arm of the profile, and yielded
pKa values (pK1 = 4.7 ± 0.2 and pK2 = 5.1 ± 0.2) that were very close to each other and to
the known pK2 of citrate (4.76). The value of pK1 is consistent with AaPurE binding to the
mono-anionic or di-anionic of citrate. The value of pK2 may correspond to Asp 33.
Binding CAIR. Thus far there is no direct evidence to indicate that more than half
of the active sites of the AaPurE octamer are occupied by CAIR at any given time. All of
the crystal structures of AaPurE with a bound nucleotide have only half of the active
sites occupied. However, recent crystal structures of EcPurE with nucleotide bound,
showed all eight sites of the octamer occupied (13). Fitting the data collected for
AaPurE mutants with half-sites binding yielded superior fits because the majority of
fluorescence change occurred at a concentration of CAIR that was lower than the
concentration of enzyme. Whether this difference between these enzymes is real is
unknown. If the determined value for the concentration of AaPurE is actually higher,
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this could result in the requirement of fitting the data to half sites binding. When fit
under the half-sites requirement, all three mutants bind CAIR with sub-micromolar
affinities (Table 3.5). If full-sites binding does occur and the determined concentrations
of AaPurE are too high, this would likely mean that the affinity for CAIR is even stronger.
The fact that all of the mutants bind CAIR or have an activity indicates that the active
site for all forms of AaPurE studied remains largely intact.
Role of conserved Histidine 59. Mutagenesis studies reported herein suggest an
acid/base role for this residue, as only the mutant with an ionizable residue at this
position (H59D) is active. All other mutants at this position are inactive or nearly so. The
pH-rate profiles that will be discussed in the following section suggest that residue 59
serves as an active-site acid in the reverse direction. The consistently sub-micromolar
Kd,CAIR for the inactive His59 mutants along with the slight steric clash seen in the wtAaPurE-AIR structure (2fwj) indicate that His59 does not contribute to the high affinity
binding. In the AaPurE-wt-AIR structure, the aminioimidazole ring of AIR is wedged
between the edge of His59, a hydrophobic pocket, and two backbone amides. In the
barely active mutants (H59S, H59Q), water may serve in the active site as an acid, as
either of these residues serving as an acid seems unlikely.
Role of conserved residue His89. Owing to the difference in reactions catalyzed
by Class I and Class II PurEs, it was hypothesized that His89 might serve as part of a
“proton wire” that could move protons into and out of an occupied active site (2),
similar to the role of His64 in carbonic anhydrase (18) or the extended proton wire in
the E1 component of the pyruvate dehydrogenase complex (3). Mutagenesis studies
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reported herein show that His89 is not catalytically essential. The replacement of this
residue with many other amino acids, some of which would preclude the ability to form
a proton shuttle such as the H89F mutant, still results in active enzymes.
All of the His 89 mutants have a decreased activity in comparison to wt AaPurE;
however, the most efficient substitution, with nearly wt kcat/Km, is AaPurE-H89G. In this
mutant the Km for CAIR is ~10 fold lower than that of the wild type (wt) enzyme and
approaches the values of Kd,CAIR determined for the inactive His59 mutants. This lower
affinity may indicate that AaPurE-wt exerts some ground-state destabilization on the
bound nucleotide. The replacement of His89 with the much smaller glycine would
alleviate this destabilization. Although substitution of His89 with other amino acids led
to some changes in the value of Kd,citrate, all mutants bind citrate.
If His89 serves as a proton shuttle, it is clearly not needed for the functioning of
AaPurE. It is interesting to compare the two different reactions catalyzed by Class I and
Class II PurEs (Scheme 3.3). While in the forward direction His59 is proposed to serve as
an active site acid in Class I PurEs, the equivalent histidine is proposed to serve as an
active site base in Class II PurEs. The conserved role of His89 in Class I PurEs may be to
stabilize protonated His59, as is indicated by the relatively high pKa of His59 (7.2 ± 0.1).
Owing to the different reactions, Class I PurEs require a protonated histidine, while the
opposite is true for class II PurEs. The equivalent residue for His89 in animals is a
conserved glycine, which would not be expected to stabilize a protonated His59.
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(2-A) Investigation into the catalytic properties of AaPurE and AaPurEH59D
kcat/Km profile - The value of Km is the concentration of substrate at which the
enzyme functions at half of its maximal activity (kcat). The value of Km is therefore
dependent on the affinity of the free enzyme for the free substrate and is dependent on
the enzyme-substrate complex. Thus the pH profile of Km for enzymes can be difficult to
interpret. However, the value of kcat/Km is only affected by the affinity of free enzyme
for free substrate. Changes in this value as a function of pH are indicative of ionizations
of moieties involved in enzyme-substrate binding.
The value of pK1 for both the AaPurE-wt and AaPurE-H59D pH profiles is similar
(6.0 ± 0.1 and 5.7 ± 0.2 respectively), suggesting some common feature is responsible. If
the substrate does not ionize, these similar values might be associated with an enzyme
side chain that must be unprotonated for substrate binding, such as the side chain of
Asp33, which is involved in binding of the ribose moiety (Figure 3.1). If the substrate
does ionize, a plausible candidate is the N3 nitrogen of CAIR which has a pKa of 6.11 at
30 °C (19). The N3 nitrogen of CAIR interacts with Ser57 (Figure 3.1). Serine can serve
as a hydrogen bond donor or acceptor; therefore, pK1 may be due to CAIR N3
protonation if Ser57 functions as a hydrogen bond donor. Alternatively, pK1 may be due
to the protonation of the substrate ribose 5-phosphate (R5P) group (pKa2 for R5P = 6.3
(20)).
The value of pK2 in the pH profiles of AaPurE-wt and AaPurE-H59D shows a large
shift, 7.2 ± 0.1 and 6.5 ± 0.2 respectively, that is dependent on the identity of residue
59. This assigns pK2 to His59. The shift that occurs from His59  Asp59 is due to the
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lower pKa of the Asp side chain. Alternatively pK2 may correspond to the protonation
state of His89, if its interaction with residue 59 plays a role in AaPurE being able to bind
CAIR productively.

Scheme 3.3: Possible mechanism of AaPurE. Individual steps shown may be concerted,
such as steps a1 and a2 or a3 and a4

kcat profile. kcat is the value of the maximal rate of catalysis for an enzyme at
saturating substrate concentration. Thus, the effects of substrate and enzyme binding
steps are eliminated, and all of the enzyme is taken to be in the form of the enzymesubstrate complex. Changes in this value, as a function of pH, are indicative of
protonations of key catalytic moieties in the enzyme-substrate complex (21).
The large difference in the value of pK2 for the AaPurE-wt and AaPurE-H59D
mutant, 8.4 ± 0.1 and 6.8 ± 0.2 respectively, indicates that a protonated residue 59 has a
key role in catalysis. These values are higher than the pK2 determined for the kcat/Km
profiles, which indicates that the pKa of residue 59 is higher in the enzyme–substrate
complex.
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Compared to the values of pK2, the values of pK1 for both the AaPurE-wt and
AaPurE-H59D pH profiles are similar in value (5.1 ± 0.2 and 4.4 ± 0.4 respectively),
indicating that residue 59 may not affect the acidic arm of the profile. The hydrogen
bond that forms between Ser 57 and the N3 of CAIR would likely make CAIR more
difficult to protonate, and would cause the pKa of the N3 of CAIR to be lower than that
of the free nucleotide (pKa=6.11) as is observed.
Assignments of pK2 in the kcat versus pH profile. It has been previously
postulated that Class I PurEs function in the reverse direction by catalyzing the
protonation of CAIR C4 (22). While protonation of this carbon might seem like a
candidate for the pK2 (basic arm) of the kcat pH-rate profile, the shift noted in the
profiles of His  Asp indicates the basic arm in the pH-rate profile is due to residue 59
in the enzyme-substrate complex. A structure determined from a crystal of the inactive
AaPurE-H59N mutant soaked in CAIR (structure 2fwp), exhibits what is likely a mixture
of AIR + CO2 and the tetrahedral intermediate isoCAIR in the active site (5, 13). This
species is likely formed due to the introduction of a proton into the active site of the
inactive mutant at the pH which the crystal structure was determined (pH 5.4). This
indicates that a residue capable of acid/base chemistry is required to catalyze the
conversion of CAIR to N5-CAIR.
A possibility for pK2 is that a protonated His59 is required in the first step of the
reaction (step a1), in which the C4 position of CAIR is protonated to form the isoCAIR
zwitterion. The isoCAIR zwitterion could decarboxylate to form AIR and CO2 in the
active site (step a2, Scheme 3.3). The enzyme bound AIR and CO2 would seem equally
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capable of forming N5-CAIR or CAIR, depending on whether the CO2 molecule is attacked
by the AIR exocyclic amino group or C4, respectively. The product formed from the
enzyme-bound CO2 intermediate may be determined by movement of the
aminoimidazole moiety of AIR (13).
The active H59D mutant shows that Asp is an acceptable substitute to catalyze
the reaction. One possible problem with the hypothesis that residue 59 protonates
CAIR is the difference in charge between protonated histidine and a protonated aspartic
acid. However, crystal structures of AaPurE-H59D indicate that Asp59 forms a hydrogen
bond with the neighboring His89. This interaction has no counterpart in the wild type
structure. The protonated His89 may facilitate protonation or binding of the substrate.
With such an interaction, requiring both His89 and Asp59 to be protonated, the pH-rate
profile would be determined by the second protonation, that of Asp59. This is consistent
with the lower pK2 seen with the Asp59 mutant. In contrast, protonation of His89 in the
wild type enzyme may lead to an inactive form of the enzyme, which is what we
hypothesize is part of the reason a two proton pK1 seen in the wt kcat/Km pH rate profile.
Comparison of kinetic constants for AaPurE-wt and AaPurE-H59D. The seemingly
non-conservative Asp mutant is a surprisingly efficient enzyme, with a maximal kcat
equal to ~40% of wt maximal kcat. Since pK1 and pK2 are closer together for AaPurEH59D, the actual pH-independent maximal mutant kcat is likely closer to 55% of wt. At
all pH values tested, the Km for AaPurE-H59D is much higher than that for AaPurE-wt, so
the kcat/Km for AaPurE-H59D is significantly lower than wt. This is consistent with the
proposal that the AaPurE-H59D mutant does not bind CAIR as effectively as AaPurE-wt.
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This would be expected if the mutant enzyme electrostatically repels the anionic
substrate. The anionic active site probe citrate shows a similarly lower affinity for the
mutant enzyme, with an 18 fold increase in the Kd from wt H59D.
Comparison of pH rate profiles of EcPurE and AaPurE. To date, the only other
PurE for which a pH-rate profile has been constructed is wt EcPurE (13). The data
reported by those authors yielded a bell shaped profile for both the kcat and kcat/Km.
They determined values of pK1 = 5.9 ± 0.4 and pK2 = 8.6 ± 0.4 from the EcPurE kcat pHprofile. The value determined for pK2 is very similar to the value determined herein for
AaPurE (pK2= 8.4 ± 0.1), while the value of pK1 is slightly higher than the value for
AaPurE (pK1 = 5.1 ± 0.2). They determined values of pK1 = 6.7 ± 1.6 and pK2 = 7.5 ± 1.5
for the EcPurE kcat/Km pH profile. The value determined for pK2 is very similar to the
value determined herein for AaPurE (pK2 = 7.2 ± 0.1), while the value of pK1 is slightly
higher than the value for AaPurE (pK1= 6.0 ± 0.1). These authors claimed that equation
4 was sufficient to fit their data, and that there was no need to fit the data to an
equation with three ionizations, as we found to be necessary for AaPurE-wt (two
ionization on the acidic arm). Regardless of the interpretation, much caution is
warranted for the interpretation of data on the acidic arm of the pH-rate profiles,
because of the high rate of nonenzymatic CAIR decarboxylation, and the lack of
extinction coefficients for N5-CAIR below pH ≤ 6.0.
While the absolute magnitude of kcat for AaPurE does not approach that of
EcPurE (AaPurE = 17 s-1 at pH 7.0, maximum rate from EcPurE plot ~26 s-1 at pH 7.3),
AaPurE has been shown to have a consistently lower Km, indicating that AaPurE may
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bind CAIR more tightly. A higher affinity is also seen in the Kd,CAIR determined for
equivalent mutants, AaPurE-H59N and EcPurE-H45N (0.78 ± 0.06 and 21 ± 2 µM
respectively). This higher affinity in AaPurE results in an enzyme which reaches a higher
kcat/Km, 6.2 X 106 M-1s-1 (pH 7.0) than EcPurE, ~3.6 X 106 M-1s-1 (pH 6.6).

(2B) – Structural analysis
It would seem that proteins that experience acidic conditions for prolonged
amounts of time would necessarily have adapted to survive under those conditions. It
would generally be expected that proteins from an acidophile would have increased
stability under acidic conditions. This is evidently the case for AaPurE. AaPurE appears
to be well suited for survival at acidic pHs as is evidenced by the thermal melt profile
constructed (Figure 3.5). Even at pH 3.5, AaPurE retains its structure while EcPurE
unfolds at room temperature. Similarly, increased stability under acidic conditions has
been seen in the cases of citrate synthase (4) and alanine racemase (6) from A. aceti, in
comparison to equivalent enzymes from the neutralophiles, pig and B.
stearothermophilus.
Stablilty of AaPurE compared to EcPurE. In the report of the initial crystal
structure for AaPurE (2), comparisons were made between it and its homologs from E.
coli, a mesophilic neutralophile, and T. maritima, a thermophilic neutralophile. While
one might expect that the crystal structure of AaPurE would share the most similarity in
structure to EcPurE, as both are mesophilic organisms and share 52% sequence identity,
the surface charge decoration and hydrogen bonding patterns were more similar to
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those of TmPurE. Interestingly, AaPurE was found not only to be more resistant to
acidic denaturation than EcPurE (EcPurE unfolded immediately at pH 3.5, while AaPurE
did not), but it was also far more resistant to thermal denaturation than EcPurE at all
pHs tested. The high Tms observed for AaPurE may be consistent with its structural
similarity to TmPurE. Similar experiments performed on A. aceti citrate synthase and
alanine racemase have shown that they are both acid-resistant and relatively
thermostable. This indicates that there may be general similarities in the development
of proteins that are stable under unusual conditions, as will be discussed in greater
detail below (4, 6).
Crystal structures of AapurE and mutants. To date, a total of 11 crystal
structures of AaPurE-wt and mutants have been determined over a range of pH from
5.4-8.5 (Table 3.7). Notably, there are only a few subtle differences among the
structures; in most cases these differences can be explained as a result of ligand binding
or as a result of a mutation. Some mutant crystal structures show a slight rotation of
residue Tyr154 that results in the residue forming a hydrogen bond of shorter length
with residue Asn78 when compared to AaPurE-wt structures. This rotation appears not
to occur as a consequence of a pH change. Other proteins, for which crystal structures
have been determined over a range of pH, show changes ranging from the reorientation
of a few side chains (23, 24), to large scale alterations of the entire protein structure
(25).
The cause of changes in the structure of any protein at different pHs will likely be
due to a change in the ionization state of one or more side chains. The lack of change
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noted in crystal structures of AaPurE may indicate that no changes in protonation state
have occurred. An examination of what changes might be expected over the range of
pH for which crystal structures have been determined highlights a possible way that
proteins from acidophiles may have evolved to survive an acidic environment. Proteins
from acidophiles may discourage changes in protonation state that could destabilize the
protein over the range of pH in which they grow.
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Table 3.7: Summary of AaPurE crystal structures
PDB code 1u11
2fwj
2fw1
AaPurE
wt
wt
wt
pH
pH 5.4
pH 7.0
pH 8.5
Liganda
citrate
AIR
-

2fwi
H59D
pH 7.0
AIR

2fwp
H59N
pH 5.4
AIR + CO2
‘citrate
Y

2fw6
H59N
pH 5.4
citrate

2fw7
H59N
pH 8.0
-

2fw9
H59F
pH 8.0
-

2fwb
H89F
pH 8.0
-

2fw8
H89G
pH 8.0
-

2fwa
H89N
pH 7.0
-

Tyr154b
N
N
Y
Y
N
Y
N
Y
N
rotation
a
symbol (‘) denotes different subunit. bMade in reference to orientation found in crystal structure 1u11. In crystal structure 1u11, the χ2
dihedral in reference to Cδ1 is 141.1°; In crystal structure 2fw6 this dihedral is 102.0°
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From pH 8.5 to pH 5.4, one might expect the following ionizations to occur: the
more acidic lysines in the protein become protonated (usually caused by being buried in
hydrophobic region), histidine becomes protonated, and the more basic aspartates
and glutamates become protonated. The above is only a broad guideline to the
ionizations expected, as the protonation state of any residue is dependent on the
environment in which it is found.
AaPurE contains a total of four lysines (Table 3.8). In the crystal structures, two
are in portions of the protein that are unstructured, so observations cannot be made.
The remaining two are exposed to solvent, and would thus be expected to be
protonated at all the pHs for which crystal structures have been determined. AaPurE
contains a total of 4 histidines, 2 of which are the conserved residues 59 and 89; the pKa
of His59 appears to be 7.2 as determined from the pH rate profile and is also consistent
with REDOR of the AaPurE-citrate complex (17). The other two histidines are on the
surface of the protein. His39 is near Arg38 (3.8 Å) and may have a depressed pKa owing
to electrostatic considerations and would not be expected to become protonated over
the pH range examined. His51 interacts with Asp41 and may be protonated over the pH
range examined (the Nε to carboxylate oxygen distance is 2.6 Å in 1u11, pH 5.4, and 2.7
Å in 2fw1 ,pH 8.5).
The remainder of residues that might ionize over the pH range examined are the
carboxylic acids aspartate and glutamate. AaPurE contains a total of 17 of these
residues, 4 which are always disordered, and 1 (Glu180) that is the last ordered residue
in a few structures, but disordered in most crystal structures. Any change in the
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unstructured residues cannot be observed. Of the remaining 12 carboxylic residues that
may ionize in the structure, 10 are involved in salt bridges with arginines (2), and an
eleventh salt bridge may exist between His 51 and Asp 41.
The interaction between two oppositely charged residues stabilizes the ionized
state of each, making the acidic residue more acidic and the basic residue more basic, in
comparison to the residues when lacking this electrostatic interaction. Experimentally
this stabilization results in a ∆pKa of 0.5 to 3.0 units for both residues (26-28). It has
been noted in the crystal structures of AaPurE (2) that the geometry of the salt bridges
appears ideal. Thus it seems reasonable to expect that the resulting shifts may be large.
Since almost all of the structured aspartate and glutamate side chains are involved in
salt bridges, it seems unlikely that they would ionize over the range of pHs for which
crystal structures have been determined. Further, these salt bridges may prevent
changes in the protonation state of AaPurE over the range of pH experienced in vivo.
Table 3.8: Comparison of A. aceti and E. coli crystal structures
AaPurE
EcPurE
AaCS∙OAA∙CMXb
EcCS∙NADHb
(1u11)
(1d7a)
(2h12)
(1nxg)
Structured His
4
6
9
15
Structured Lys
2
6
22
23
Structured Arg
9
6
21
23
a
Structured
13
16
38
51
Asp+Glu
10
13
9
Total Salt Bridges
11a
Asp+Glu not in
2
6
25
44
Salt Bridge
a
Glu180 is not structured in all crystal structures, but is included in the total for 1u11. 2Includes
possible salt bridge between Asp41 and His51. bSummarized from (4).

AaCS, another protein from A. aceti for which a crystal structure has been
determined, also shows an increased number of salt bridges in comparison to its
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counterpart from the mesophile E. coli (Table 3.8). AaCS also shows a decreased
number of the residues that would be expected to ionize over the range of pH
experienced in the cytoplasm of A. aceti. Thioredoxin, the only other protein from A.
aceti, for which a crystal structure has been determined (29), does not show the marked
differences that AaPurE and AaCS show to their E. coli counterparts. However, it has
been noted E. coli thioredoxin is an acid-stable protein (30).
Extension to salt bridges in thermophiles. The pKa values of nitrogenous bases
have been shown to be temperature-dependent (31-34), becoming weaker bases at
higher temperatures. While a vast body of work has been compiled on salt bridges in
thermophiles, there are few examples of investigating the temperature dependence of
protein side chain pKas (35). Over a 34 °C range, the pKas of six histidines in myoglobin
were found to decrease by 0.35-0.72 units. The lower values (~0.01 pKa unit per °C) are
similar to that seen in the temperature dependence of the second ionization of the free
amino acid histidine in aqueous solution (33), while the larger values (~0.02-0.025 pKa
unit per °C) are similar to the change seen for imidazole (32), the side chain of lysine
(33), and alkanoamines (34).
At the higher temperatures in which thermophiles grow, one role that some salt
bridges could serve is to hinder changes in the protonation state of the basic residues
involved. While even at high temperature, lysine will predominately be protonated, the
increase in population of unprotonated lysine may lead to a form of the thermophilic
protein that denatures. This is analogous to the proposed role that some salt bridges
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may serve in an acidophile such as A. aceti with salt bridges hindering changes in
protonation of carboxylic residues.
It is interesting to note that there is a lower fraction of histidine residues in
thermophile proteins (36-38). This preference has not been explained (36-39). One of
the causes for the reduction of histidine may be that at the higher temperatures of
thermophiles, the properties of histidine are quite different based on the temperature
dependences of the ionization of the imidazole ring.

3.5 Future Directions
It has been proposed in this chapter that the mutant AaPurE-H59D mutant may
require a protonated His89 in order to function. The characterization of a double
mutant such as AaPurE-H59D-H89F, should yield an answer to this proposal. If this
mutant has an activity near that of the AaPurE-H59D mutant, this would indicate that a
protonated His89 is not required. However, if very low or no activity is noted, and the
active site of the double mutant remains intact, this would indicate that a protonated
His89 is required.
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Chapter 4
The purE-purK operon of A. aceti

89

4.1 Introduction
The genes encoding purE and purK are usually adjacent in bacteria and appear to
form an operon. In E. coli and A. aceti, the purE and purK genes overlap (Scheme 4.1),
with the final four nucleotides of the purE gene comprising the first four nucleotides of
the purK gene. The purE start codons are different: GTG in A. aceti and ATG in E. coli. As
will be discussed in this chapter, there is an open reading frame (orf1) upstream of the
A. aceti purE gene that codes for a 68 amino acid protein of unknown function (Scheme
4.1).

Scheme 4.1: Organization of purE-purK operon in A. aceti and E. coli. Arrows represent
genes for purE, purK and orf1. The final two codons of purE and the first two codons of
purK are indicated. The bold text represents what the codons code for in their
respective proteins. The overlapping nucleotide sequence is underlined.

Overlapping start and stop codons in operons are often indicative of
translational coupling. In translational coupling, the translation of the downstream gene
(or genes) is dependent on the translation of the preceding gene (1, 2). One typical
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effect of translational coupling is a 1:1 stoichiometry for the translationally coupled
proteins (3, 4). A second feature of translational coupling is that mutations that cause
early termination, or frame-shift mutations, can have a “polar effect” on the translation
of downstream genes (1, 5). This polar effect is indicated by a reduction in the
translation of downstream genes. Even though these downstream genes are unaltered,
the proteins they encode are produced in diminished quantities. A polar effect is
evidence for translational coupling. Translational coupling and polar effects have been
seen in many operons, including the E. coli operons for tryptophan and histidine
biosynthesis (1, 5).
The biosynthesis of a compound in different organisms may contain pathway
alternates. Pathway alternates may use either altered chemistry or a different synthetic
route to obtain the same product. The divergent Class II PurE and Class I PurE/PurK
systems are the best known examples of pathway alternates in the biosynthesis of
purines; however, there are several other examples. There are two routes for the
conversion of 5’phosphoribosyl glycinamide to 5’phosphoribosyl-N-formylglycinamide
by the enzymes PurN or PurT (Scheme 4.2) (6). These enzymes are folate-dependent
and –independent, respectively. Another divergence is seen in the final two steps of
purine biosynthesis between archea and other bacteria and eukaryotes. Archea utilize
the enzymes PurP and PurO, while other bacteria and eukaryotes use the bifunctional
PurH enzyme. Another divergence involves FGAR-AT, the fourth step of purine
biosynthesis, in which a single protein (PurL) or a group of three proteins (PurL, PurQ
and PurS) performs the same enzymatic reaction.
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FGAR-AT converts 5’phosphoribosyl-N-formylglycinamide to 5’-phosphoribosylN-formylglycinamidine (Scheme 4.2). In the multiple-protein form, PurL is significantly
smaller, and it requires PurS, a small (~80 amino acid) protein that is homologous to the
N-terminal domain of larger PurL forms (7). Biochemical and structural studies
determined that the complex contains PurL:PurQ:PurS in a ratio of 1:1:2 (8, 9). Crystal
structures indicate that PurS interacts with portions of both PurQ and PurL (9).

Scheme 4.2: Other divergences in purine biosynthesis.

PurS was originally identified as an open reading frame amid the eleven
functionally characterized genes of the single purine biosynthesis operon in B. subtilis,
and was postulated to be a regulatory protein (10). The involvement of PurS in the
multi-protein FGAR-AT activity was identified recently using a single copy genomic
insertion strain (7). Simultaneous expression of all three B. subtilis genes in E. coli using
three different promoters proved problematic (8).
The study of strains of bacteria is an integral part of elucidating biosynthetic
pathways. The wild form of a bacterium is commonly referred to as “prototrophic.” A
prototrophic strain is able to grow when provided with essential minimal nutrients. In
the case of E. coli, these essential nutrients are a carbon source (e.g., glucose), a source
of nitrogen (e.g., ammonium salt), a source of phosphorous (e.g., phosphate), a source
of sulfur (e.g., sulfate), the cations potassium, calcium, sodium and magnesium, and
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smaller amounts of several transition metals. Provided with these essential nutrients, E.
coli is able to synthesize all of the compounds required for growth and division. Strains
that have an additional nutritional requirement are referred to as “auxotrophic.”
Depending on the strain, the auxotrophic phenotype may only appear under
certain conditions. These conditions may be environmental (temperature or
atmosphere) or nutritional (in the presence of a specific nutrient(s)). In the simplest
case, auxotrophy is caused by a mutation or deletion in a gene that eliminates the
activity of the enzyme encoded by that gene. In most cases, the introduction of a gene
that encodes for an enzyme with the same activity, or an activity that bypasses the
activity of the adulterated gene can lead to “functional complementation” of the
auxotrophic phenotype. Complementation of auxotrophy, or the restoration of
protrophy, means that the strain can now grow on minimal media. In some cases, the
functional complementation of a strain may occur under certain environmental or
nutritional conditions.
Purine auxotrophs that result from alteration of the purK gene provide a unique
example of many of the features described above. Under normal atmosphere, a purK
auxotroph requires a source of purines for growth; however, when a purK auxotroph is
grown in the environment of a “candle jar,” the strain is conditionally complemented. A
candle jar is a CO2 rich environment created by placing a lit candle into a sealable
container. Once the container is sealed, the candle is allowed to burn until it
extinguishes itself. It is proposed that purK auxotrophs are able to grow under such
conditions owing to the non-enzymatic production of N5-CAIR from AIR and the
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introduced CO2 (11) . This phenotype led early investigators to conclude that PurK
functions as a ‘CO2 carrier’ akin to the biotin-dependent components of fatty acid
synthesis (12). The introduction of a plasmid bearing a purK gene or a Class II purE gene
leads to complementation of the strain. The activity lost in the auxotroph is restored by
the purK gene, or is bypassed by the introduction of a Class II purE, which does not
require purK.
Reported herein are initial functional complementation studies of the E. coli purE
auxotroph PC0135, which were performed to assess the qualitative in vivo activity of
AaPurE mutants H59D and H59N. Although wild type and the enzymatically active
H59D mutant complemented the auxotrophy as expected, so did the apparently inactive
H59N mutant. This puzzling observation required the construction of an auxotrophic
strain with a less leaky phenotype.
This chapter also reports evidence that A. aceti purE is only able to
unconditionally complement purine auxotrophy if it is expressed in the orf1-purE-purK
gene context. This suggested the possibility that AaPurE does not function with EcPurK
as a source of N5-CAIR. The possibility that AaPurE may require AaPurK for activity
prompted the construction of new strains to explore the operons of A. aceti and E. coli.
Here we use a combination of stable deletion strains, and strains harboring precise gene
replacements to address this question.
Many functional complementation studies focus on either binary growth/no
growth determinations or on measuring the time required for the number of cells in
cultures of each strain to double (doubling time). Initial complementation studies
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showed that many strains had a prolonged “lag phase,” or delay of rapid growth,
following inoculation into minimal media. This lag, or acclimation phase, is unusual and
is the focus of these studies. The presence of orf1Aa profoundly affects strains which
express purEAa or purEAapurKAa, and its effects appear dependent on the identity of purE
and purK.
4.2 Methods and Materials
Materials. All materials were from Sigma Aldrich or Fisher Scientific and of the
highest purity unless otherwise noted. Vent DNA polymerase (New England Biolabs)
was used in all PCRs for cloning. Restriction endonucleases and T4 DNA ligase were
from New England Biolabs. Mutagenesis was performed using Quikchange Mutagenesis
kits from Stratagene (Pfu polymerase). Oligodeoxynucleotides (ODNs) were from
Integrated DNA Technologies (Tables 4.1 and 4.2). GoTaq polymerase (Promega) was
used in PCRs to confirm modifications to genomic DNA and to create products for
sequencing. DNAzol (Molecular Research Center) was used for isolation of genomic
DNA as noted. Plasmid Miniprep kits were from either Qiagen or Sigma. Large
quantities of plasmids were isolated using Qiagen Midikits. Other DNA purification kits
were from Qiagen. Chemically competent XL-10 Gold cells were from Stratagene.
Vectors pET23a and pUC118 were from Novagen. Vector pKOV was from George
Church’s lab (13, 14). Centrifugation steps were performed on a tabletop Eppendorf
5810R centrifuge; centrifugation of small aliquots was routinely performed in Eppendorf
5415D centrifuge. Cell disruption by sonication was performed using a Virsonic 100
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sonicator. DNA was sequenced by Sanger sequencing at the Protein and Nucleic Acid
Chemistry Laboratory at Washington University in St. Louis.
Table 4.1 Oligodeoxynucleotides (ODNs) used in the construction of deletion strains
ODN
Sequence (5’3’)a
1362 TAAAGCCGAGAGTTGTGCACCACAGGAGTTTTAAGACGCATGTCTTCCCGCAATAATC
CGgtgtaggctggagctgcttc
1363 CGTCGGTCTGGGCTTTGCGCCAGTCATTCAGACGCTGGTGCAGTTCTTTATCATGAGTC
Gattccggggatccgtcgacc
1364 CGTGCTATTCTCTGTGCCCTCTAAAGCCGAGAGTTGTGCACCACAGGAGTTTTAAGACG
Cgtgtaggctggagctgcttc
1365 TACCGGATCGGTAGGCCGGATAAGGCGTTTACGCCGCATCCGGCAAGAATAGAGCAC
CAGattccggggatccgtcgacc
1374 GGCGCAAAGCCCAGACCGACGAAGTGCTGGAAAACCCGGACCCGCGAGGTGCGGCAT
GAAgtgtaggctggagctgcttc
1375 GTACCGGATCGGTAGGCCGGATAAGGCGTTTACGCCGCATCCGGCAAGAATAGAGCA
CCAGattccggggatccgtcgacc
a
Sequence shown in upper case is homologous to target sites in the E. coli genome.
Sequence in lowercase is homologous to pKD13 and was used to amplify the Kan
cassette.

Table 4.2:
ODNs
601
617
1017
1018
1019
1020
1078
1079
1161
1162
1163
1164
1165
1166
1167
1269
1270

ODNs used in the construction of plasmids and sequencing
Sequence (5’3’)a,b,c
CGACGTTGTAAAACGACGGCCAGTG
CACACAGGAAACAGCTATGACATG
CATTGTTTCtGCAgATCGTACGCCAGAC
GTCTGGCGTACGATcTGCaGAAACAATG
CATTGTTTCAGCAaATCGTACGCCAGAC
GTCTGGCGTACGATtTGCTGAAACAATG
CATTGCCTGAATTCCTCCGTTACAGAC
GCATTGGGCTTAAGCTTAGAATGTAAG
CGGATGACGTTGAGCTGATTCATTTTCC
GAAGCCGTGGTAAACCCGCGTGGATTGG
GATCATCACCGACGGATTATTCAC
CAGCTCACCTAAACGATCAAACAC
CAGCTTTACCAATCGCCAGCGTAC
CATGAAACAGGTTTGCGTCCTC
CTATGTGGGCGTGATGGCGATG
AAAATAGCGGCCGCGTGGCGACACTCTTTATTG
GGCTTTGCGCCAGTCATTCGCCGGATTATTGCGGGAAG
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1271
GGCGGTTTCGCTCACGCGTCTTAAAACTCCTG
1273
CGACTCTAGAGGATCCTTAACCGAACTTACTCTGCGCCC
1274
CCCATTACCGAAGATAAATGAAACAGGTTTGCGTCCTCG
1275
CAGGAGTTTTAAGACGCGTGAGCGAAACCGCC
1276
CGAGGACGCAAACCTGTTTCATTTATCTTCGGTAATGGG
1301
CGACTCTAGAGGATCCTTAACCGAACTTACTC
1302
CTTCCCGCAATAATCCGGCGAATGACTGGCGCAAAG
1303
CGGTTTCGCTCACGCGTCTTAAAACTCC
1305
CAGGAGTTTTAAGACGCGTGAGCGAAACCG
1370
CTGCCCTCTGCTTCCAGTACATGGCGCGCATTGCAGACG
1371
CGTCTGCAATGCGCGCCATGTACTGGAAGCAGAGGGCAG
1372
CACAGGAGTTTTAAGACGCaTGAGCGAAACCGCC
1373
GGCGGTTTCGCTCAtGCGTCTTAAAACTCCTGTG
1386
TATTATTGGATCCATGAAAACACTGGTTGTGGCTC
1388
GAAGTGGTTTCTGCTaACCGCACCCCCGATAAAC
1389
GTTTATCGGGGGTGCGGTtAGCAGAAACCACTTC
1390
GATATACATATGTCTTCCCGCAATAATCC
1391
CAAGCTTGCATGCCTGCAGTTAACCGAACTTACTC
1394
CAGGAGTAAGCTTACGCGTGAGCGAAACCGC
1395
CAAGAATAGAGCTCCAGTTAACTGGCAGATTC
1396
GTTAACTGGAGCTCTATTCTTGCCG
1397
GACCCGCGAGGTGCGGGTCGACCTCCTTACATTC
1398
GAATGTAAGGAGGTCGACCCGCACCTCGCGG
1399
GACCCGCGAGGTGCGGcatGACCTCCTTACATTCTC
1400
GAGAATGTAAGGAGGTCatgCCGCACCTCGCGGGTC
1401
GAATCTGCCAGTTAACTGGtGCTCTATTCTTGCCG
1402
CGGCAAGAATAGAGCaCCAGTTAACTGGCAGATTC
1403
GATTGATTCGCTGCTG
a
Letters shown in lower case code for mutagenesis. bSequence shown in bold codes for
“introduced” cut sites used in cloning. cSequence shown in lowercase bold codes for
mutagenesis used to revert introduced restriction sites back to wild type sequence.

Method of naming strains. As reported in the following sections, a series of
unique strains of E. coli were made. The following strains will have the designation CC
followed by 4 digits. The first digit will denote the type of strain. A deletion strain will
be denoted by 0, and a precise gene replacement strain will be denoted by a 1. The
second digit will correspond to the method used to create the strain. Strains created by
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the method of Datsenko and Wanner (15) will be denoted by a 1, while strains created
using the pKOV precise gene replacement method (14) will be denoted by a 2. The final
two digits are used to differentiate strains.
Table 4.3: Description of strains
Strain
Descriptiona
Reference or Source
E. coli genetic Stock
PCO135
lacY1 purE55 glnV44(AS) gal-3
Center
rpsL117(strR) malT1 (LamR) xlyA7 mtlA2
thi-1
DH5α
supE44 ∆lacU169 (φ80 lacZ∆M15)
hsdR recA1 endA1 gyrA96 thi-1 relA1
XL-1 Blue
recA1 endA1 gyrA96 thi-1 hsdR17
Stratagene
q
supE44 relA1 lac [F´ proAB lacI Z∆M15
Tn10 (Tetr)]
XL-10 Gold
Tetr ∆(mcrA)183 ∆(mcrCB-hsdSMRStratagene
mrr)173 endA1 supE44 thi-1 recA1
gyrA96 relA1 lac Hte [F´ proAB lacIq
Z∆M15 Tn10 (Tetr) Amy Camr]
XL-10 Gold
Tetr ∆(mcrA)183 ∆(mcrCB-hsdSMRStratagene
KAN
mrr)173 endA1 supE44 thi-1 recA1
gyrA96 relA1 lac Hte [F´ proAB lacIq
Z∆M15 Tn10 (Tetr) Tn5 (Kanr) Amy]
W3110
LAM- In(rrnD-rrnE)1 rph-1
b
CC0101
W3110 ∆purEEc
This study
CC0102c
W3110 ∆purEEc∆purKEc
This study
d
CC0103
W3110 ∆purKEc
This study
e
CC1201
W3110 purEEc<>purEAa
This study
f
CC1202
W3110 purEEc<>purEAa(ATG)
This study
CC1203g
W3110 purKEc<>purKAa
This study
h
CC1204
W3110 purEEcpurKEc<>purEAapurKAa
This study
i
CC1205
W3110 purEEcpurKEc<>purEAa(ATG)purKAa
This study
a
<> symbol denotes precise gene replacement; subscript indicates origin of gene (Aa)
refers to A. aceti, (Ec) refers to E. coli. The purE gene of A. aceti begins with a GTG
start codon, subscript (ATG) denotes strains in which the start codon for purEAa has
been changed to ATG. b-iAlternate strain names: bCC0101 a.k.a. 1611, cCC0102 a.k.a.
2C311, dCC0103 a.k.a. DK111, eCC1201 a.k.a. Church 31, fCC1202 a.k.a Church ATG
61, gCC1203 a.k.a. Church K2121, hCC1204 a.k.a. Church EK 1111, iCC1205 a.k.a.
Church ATG EK 1131.
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Method for the creation of deletion strains. Deletion strains were made using
the λ-red recombinase system of Datsenko and Wanner (15) with guidance from Peter
Chivers, Department of Biochemistry, Washington University in St. Louis. The general
method is described below and illustrated in Scheme 4.3. A specific description for the
creation of each strain is given in the following sections.
The kanamycin resistance gene (Kan cassette) of plasmid pKD13 was amplified
by PCR using Vent DNA polymerase and the appropriate ODNs as described in the
following sections. ODNs were designed to amplify the Kan cassette with flanking 60-bp
sequences derived from regions flanking the genomic region being deleted. PCRs
contained 4 units of Vent, 0.4 pmol of both ODNs, 0.8 nmol of

Scheme 4.3: Method of gene deletion. Deletion strains created using λ-Red
recombinase system of Datsenko and Wanner (15), illustrated for deletion of purK.
Arrows above W3110 genome denote regions of homology used in ODNs for
amplification of Kan cassette for the creation of each strain as noted. Representations
are not to scale.
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each dNTP, at a total volume of 400 µL (for four 100 µL reactions). The PCR was
performed with an annealing temperature of 45 °C and melting, annealing, and
extension times of 30, 60 and 120 s for 30 cycles. Following PCR, 80 units of DpnI were
added, and the reaction was digested for 4 h at 37 °C. The entire reaction was run on a
1% agarose gel and the PCR product was extracted from the gel. The product was eluted
in a minimal volume of elution buffer. The purified PCR product (2-4 µL) was
electroporated into freshly prepared, arabinose induced, W3110/pKD46 cells. The
pKD46 plasmid contains the λ red recombinase system, which facilitates the
homologous recombination of the linear PCR product into the genome at the gene
targeted for deletion.
The electroporated cells were recovered in SOC broth at 37 °C for 3 h and spread
on LB plates supplemented with 50 µg/mL kanamycin (Kan). The plates were placed in a
37 °C incubator overnight. To select for genomic incorporation of the Kan cassette and
loss of plasmid pKD46, colonies were suspended in a small volume of LB broth (20 µL),
and 2 µL of the suspension was spotted on a LB plate supplemented with 100 µg/mL
Amp and an LB plate supplemented with 50 µg/mL Kan, and the plates were placed in a
42 °C incubator. Colonies that were Kan resistant and Amp sensitive were selected. The
spot grown on the Kan plate was used to inoculate 5 mL LB/Kan that was grown at 37 °C.
Whole colony PCR was performed to confirm the insertion of the Kan cassette into the
genome. Chemically competent cells of a culture containing the Kan cassette were
transformed with the plasmid pCP20. Cells were recovered in SOC broth and spread on
LB agar supplemented with either 20 µg/mL chloramphenicol or 100 µg/mL Amp and
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grown at 30 °C for 18 h to select for transformants containing plasmid pCP20. Several
colonies were selected and used to inoculate 5 mL LB cultures that were grown at 42 °C
for at least 3 h. Dilutions of each culture were made in LB, and a portion of dilutions
were placed on LB plates and LB/Kan plates. Plates were placed at 42 °C. From dilutions
that gave few to no colonies on LB/Kan/agar, single colonies from the corresponding LB
plate were used to inoculate 5 mL LB. Cultures were grown to turbitity, and glycerol
stocks were made. Whole colony PCR was performed on the turbid cultures to confirm
excision of the Kan cassette, and the PCR product was sent for sequencing.
Creation of E. coli ∆purEEc strain - ODNs were designed to delete the majority of
the purEEc gene, leaving the first 21 bp and the last 98 bp of the gene separated by the
82 bp scar left after excision of the Kan cassette. Primers were designed to leave the
purKEc gene in the same reading frame in reference to the start codon of purKEc. The
Kan cassette was amplified using ODNs 1362 and 1363, giving a product of 1.5 kb.
Insertion of the Kan cassette into the genome of W3110 was confirmed by whole colony
PCR, using ODNs 1161 and 1164 and Taq DNA polymerase, with 58 °C annealing
temperature and melting, annealing and extension times of 30, 60, and 120 s for 30
cycles, giving a product of 2.0 kb. Finally, excision of the Kan cassette was confirmed by
whole colony PCR, using the same conditions, and giving a product of 0.7 kb. The
process yielded the ΔpurEEc strain CC0101.
Creation of E. coli ∆purEEcΔpurKEc strain. ODNs were designed to delete all of
the purEEcpurKEc coding region in W3110, leaving only the 82 bp scar after excision of
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the Kan cassette. The Kan cassette was amplified by PCR using ODNs 1364 and 1365,
giving a product of 1.5 kb. Insertion of the Kan cassette into the genome of W3110 was
confirmed by whole colony PCR using ODNs 1161, 1162 and Taq DNA polymerase, with a
58 °C annealing temperature and melting, annealing and extension times of 30, 60, and
120 s for 30 cycles, giving a product of 2.0 kb. Finally, excision of the Kan cassette was
confirmed by whole colony PCR using the same conditions, giving a product of 0.5 kb.
The process yielded the ΔpurEEcΔpurKEc strain CC0102.
Creation of E. coli ∆purKEc deletion strain. ODNs were designed to delete the
majority the purKEc gene, leaving the first 6 bp of the gene upstream of the 82 bp scar
remaining after excision of the Kan cassette. The Kan cassette was amplified using
ODNs 1374 and 1375, giving a product of 1.5 kb. Insertion of the Kan cassette into the
genome of W3110 was confirmed by whole colony PCR using ODNs 1161, 1162 and Taq
DNA polymerase, with a 58 °C annealing temperature and melting, annealing and
extension times of 30, 60, and 180 s for 30 cycles, giving a product of 2.3 kb. Finally,
excision of the Kan cassette was confirmed by whole colony PCR using the same
conditions, giving a product of 0.8 kb. The process yielded the ΔpurKEc strain CC0103.
Method for construction of plasmids used in modifying genomic DNA. Two
methods were employed to construct the plasmids used in modifying the genomic DNA
of E. coli. As described in the following sections, the plasmid for the precise insertion of
purEAa and a plasmid constructed for deletion of purEEc were obtained by the technique
of cross-over PCR (16, 17). This technique allows for the joining of two separate pieces
of DNA (Scheme 4.4). For this technique, internal ODNs for the amplification of the two
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fragments of DNA were designed with at least 20 bp regions of identical sequence.
Initial PCR products were combined in a second PCR containing external primers. The
regions of identical sequence allowed for the joining of the two DNA fragments.

Scheme 4.4: Illustration of cross-over PCR.

The plasmids for the precise insertion of purEAapurKAa and purKAa were
constructed in parts by the use of existing restriction sites (MluI and NcoI) present in the
expected sequence of the final product, and by the use of introduced restriction sites
(SacI, SalI, and HindIII). The introduced sites were introduced by primers and were not
present in the expected sequence of the final product. The introduced restriction sites,
SacI and SalI, were then changed to the desired final sequence by Quikchange
mutagenesis. The introduced HindIII site was lost during subcloning.
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Table 4.4 Plasmids used in this Chaptera
Plasmid
pNC2
pKOV
pJK173
pJK324
pJK340
pJK346
pJK347
pJK348
pJK386
pJK388
pJK389
pJK390
pJK391
pJK412
pJK413
pJK414
pJK415
pJK418
pJK419
pJK420
pJK421
pJK426
pJK429
pJK430
pJK431
pJK432
pJK435
pJK440
pJK442
pJK443
pJK444
pJK446
pJK448
pJK455

Description
purEEcpurKEc ligated into NdeI and HindIII sites in pET23a
Gene replacement vector
orf1AapurEAapurKAa ligated into SphI site in pUC118
purEAa ligated into EcoRI and HindIII sites in pUC118
purEH59NAa ligated into EcoRI and HindIII sites in pUC118
purEH59DAa ligated into EcoRI and HindIII sites in pUC118
orf1AapurEH59DAapurKAa ligated into SphI site in pUC118
orf1AapurEH59NAapurKAa ligated into SphI site in pUC118
purEAapurKEc ligated into BamHI and filled SalI site in pET23a
lpxHEcpurE[30]Ec purKEc ligated into NotI and BamHI sites in pET23a
lpxHEcpurEAapurKEc ligated into NotI and BamHI sites in pET23a
lpxHEcpurE[30]EcpurK ligated into NotI and BamHI sites in pKOV
lpxHEcpurEAapurKEc ligated into NotI and BamHI sites in pKOV
orf1AapurEAa ligated into PstI and HindIII sites in pUC118
lpxHEcpurEAa(ATG)purKEc ligated into NotI and BamHI sites in pET23a
lpxHEcpurEAa(ATG)purKEc ligated into NotI and BamHI sites in pKOV
orf1AapurE[32]AapurKAa ligated into PstI site in pUC118
lpxHEcpurEEcpurKAaycbFEc ligated into NotI and BamHI sites in pET23a
purEEcpurK[62]Ec in pET23a
lpxHEcpurEAapurKAaycbFEc ligated into NotI and BamHI sites in pET23a
lpxHEcpurEAapurKAaycbFEc ligated into NotI and BamHI sites in pKOV
purEH45NEcpurKEc ligated into NdeI and HindIII sites in pET23a
purEAapurKAa ligated into HindIII and SacI sites in pET23a
ybcFEc ligated into SacI and BamHI sites in pET23a
purKAa ligated into SalI and SacI sites in pET23a
lpxHAapurEEc ligated into NotI and SalI sites in pET23a
purEH45NEcpurK[62]Ec in pET23a
purEAapurKAaybcFEcb ligated into HindIII and BamHI sites in pET23a
lpxHEcpurEAapurKAa ligated into NotI and SacI sites in pET23a
lpxHEcpurEEcpurKAab ligated into NotI and SalI sites in pET23a
purEAapurKAaybcFEc ligated into HindIII and BamHI sites in pET23a
lpxHEcpurEEcpurKAa ligated into NotI and SalI sites in pET23a
lpxHEcpurEEcpurKAaybcFEc ligated into NotI and BamHI sites in pKOV
orf1AapurE[64]Aa in pUC118

a

Source
(11)
(13, 14)
(18)
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study

Two letter subscript code indicates origin of gene, (Ec) E. coli or (Aa) A. aceti. The purEAa
gene begins with a GTG start codon, subscript (ATG) denotes strains in which start codon
for purEAa has been changed to ATG. In some plasmids the majority of a gene was deleted.
A number in [ ] represents number of amino acids from protein still encoded. bInserts
contain internal introduced restriction sites (SacI or SalI) that were introduced in cloning
and later reverted to wild type sequence by mutagenesis.
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Listed below are the conditions used to construct plasmids necessary for
obtaining the precise gene replacement plasmids pJK391, pJK413, pJK421, and pJK448.
Also described are the conditions to create plasmid pJK390, a plasmid initially created
for the precise deletion of purEEc. For clarity, plasmids will be reported under
subsections according to the product for which they were made: a) pJK391 and pJK414;
b) pJK421, c) pJK448 and d) pJK390

a) Construction of plasmid pJK391 and pJK414 for the precise insertion of purEAa into
the E.coli genome
The cloning strategy in this section is illustrated by Figure 4.1 shown on the
following page.
pJK386. The 1.1 kb purKEc gene was amplified by PCR from plasmid pNC2, using
ODNs 1273 and 1274, with an annealing temperature of 60 °C and melting, annealing,
and extension times of 30, 60 and 90 s for 25 cycles. The PCR (50 µL) contained 16.5
pmol each ODN, 10 nmol of each dNTP, and 1 unit of Vent DNA polymerase. The crude
product was used in subsequent cross-over PCR. The 0.6 kb purEAa gene was amplified
by PCR from plasmid pJK173, using ODNs 1275 and 1276, with an annealing
temperature of 55 °C and melting, annealing, and extension times of 30, 60, and 30 s for
25 cycles. The PCR (100 µL) contained 37 pmol each ODN, 20 nmol of each dNTP and 2
units of Vent DNA polymerase. A portion of crude product was saved, and the majority
was purified with a Qiagen PCR purification kit. The purified product was
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Figure 4.1: Illustration of method used to construct plasmid pJK389 for the precise
insertion of purEAa. Plasmid pJK386 was obtained by half-blunt ligation of the purEAa +
purKEc cross-over product, into pET23a using the BamHI restriction site. The lpxHEc +
purEAa cross-over product was then cloned into pJK386 using NotI restriction site of
pet23a and an internal AgeI restriction site present in purEAa. Plasmid pJK389 contains
the insert which was cloned into the pKOV vector to yield plasmid pJK391, and was
mutated to create plasmid pJK413 which contains the insert which was cloned into
pKOV vector to yield plasmid pJK414.

used in the subsequent cross-over PCR. A 1.7 kb cross-over product was obtained by
PCR using 1 ng of each of the purKEc and purEAa products as template, and ODNs 1273
and 1305 (ODN 1275 was replaced with 1305 to avoid primer dimers), with an annealing
temperature of 60°C and melting, annealing, and extension times of 30, 60 and 120 s for
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25 cycles. The PCR (50 µL) contained 10 pmol each ODN, 20 nmol of each dNTP and 1
unit of Vent DNA polymerase. The cross-over product was purified by Qiagen PCR
purification kit. The cross-over PCR product was digested with BamHI and purified
following digestion. Vector pET23a was prepared for ligation by digestion with SalI and
purification using a Qiagen PCR purification kit. The 5’ overhangs left by digestion were
filled in using Vent DNA polymerase in a reaction at a total volume of 107 µL that
contained 2 units of Vent, and 13 nmol of each dNTP, at 72 °C for 15 min. The filled-in
vector was purified using a Qiagen PCR purification kit, and then digested with BamHI
and treated with 1.2 units of calf intestinal alkaline phosphatase (CIP). The vector was
then purified with a PCR purification kit. The cross-over product was half blunt-ligated
into the BamHI restriction site of the prepared vector in a 10 µL reaction containing 200
units of T4 ligase at 15 °C to yield plasmid pJK386. Sequencing of plasmid pJK386
indicated the plasmid contained a deletion, but this was within a region not needed for
subsequent cloning steps.
pJK389. The 0.9 kb region upstream of purEEc, including the entire lpxHEc gene,
was amplified by PCR using gDNA and ODNs 1269 and 1271, with an annealing
temperature of 65 °C and melting, annealing and extension times of 30, 60, and 90 s for
25 cycles in a total volume of 50 µL. The PCR contained 16.5 pmol of each ODN, 10 nmol
of each dNTP, and 1 unit of Vent DNA polymerase. A 1.4 kb cross-over product was
obtained by PCR using 0.8 ng of the lpxHEc crude PCR product and 0.4 ng of the purEAa
crude PCR product as template, and ODNS 1269 and 1276, with an annealing
temperature of 65 °C and melting, annealing and extension times of 30, 60 and 90 s for
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30 cycles. The 200 µL PCR (four 50µL reactions) contained 40 pmol of each ODN, 80
nmol of each dNTP, and 4 units of Vent DNA polymerase. The cross-over product was
purified using a PCR purification kit. The product was sequentially digested with NotI
and AgeI, with enzyme removal using a PCR purification kit between digests. The
digested product was run on a 1% agarose gel and the 1.0 kb fragment was purified by a
Qiagen gel extraction kit. Plasmid pJK386 was sequentially digested with NotI and AgeI
as above. The digested plasmid was run on a 1% agarose gel, and the 3.9 kb fragment of
vector was purified by gel extraction kit. The purified 1.0 kb fragment of the cross-over
product was ligated into the prepared vector using the AgeI and NotI sites, yielding
plasmid pJK389. Sequencing of plasmid pJK389 indicated a point mutation that alters
the lpxH Ala7 codon (GCA) to a threonine codon (ACA).
pJK391. Plasmid pJK389 was digested with BamHI and NotI, and the insert was
purified by gel extraction. The insert was ligated into vector pKOV using the BamHI and
NotI restriction sites, yielding plasmid pJK391.
pJK413. The start codon of purEAa in plasmid pJK389 was changed from GTG to
ATG by Quikchange mutagenesis using plasmid pJK389 and ODNs 1372 and 1373. The
mutagenesis yielded plasmid pJK413. Sequencing indicated that the desired sequence
was obtained.
pJK414. Plasmid pJK413 was digested with BamHI and NotI, and the insert was
purified by gel extraction. The insert was cloned into vector pKOV using the BamHI and
NotI restriction sites, yielding plasmid pJK414.
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b) Construction of plasmid pJK421 for the precise insertion of purEAapurKAa into the
E.coli genome
The cloning strategy used in this section is illustrated by Figures 4.2 and 4.3.

Figure 4.2: Assembly of the insert of plasmid pJK421 (Part 1). “Introduced” restriction
sites are shown in Red. The vector pET23a does not contain an MluI restriction,
however, an MluI site is present at the junction of purEAa and the region upstream of
purEEc. This site was used for the assembly of the region upstream of purEEc and purEAapurKAa segments. The upstream region was initially cloned into a subclone of pJK429
that was found to have mutations. The NotI-MluI insert of pJK437 was cloned into
plasmid pJK429 using the NotI and MluI restriction sites to yield plasmid pJK442. The
“introduced” SacI site was used to assemble the purEAa-purKAa segment and the region
downstream of purKEc. The BamHI-SacI insert of plasmid pJK430 was cloned into pJK429
using the BamHI and SacI restriction sites to yield plasmid pJK440. Construction of insert
for pJK421 continued in Figure 4.3.
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Figure 4.3: Assembly of insert of pJK421 (Part 2). “Introduced” restriction sites shown in
red. Quikchange mutagenesis was used to revert the “introduced” SacI restriction site
to wild type sequence. The inserts of plasmids pJK444 and 442 were combined using a
unique NcoI restriction site present in purKAa. The BamHI-NcoI insert of pJK444 was
cloned into pJK442 using the BamHI and NcoI restriction sites to yield plasmid pJK420.
Plasmid pJK420 contains the insert which was cloned into the pKOV vector.

pJK429. A 1.8 kb product containing the purEAapurKAa genes was amplified by
PCR from plasmid pJK173 and ODNs 1394 and 1395, using an annealing temperature of
58 °C with melting, annealing and extension times of 30, 60, and 110 s for 30 cycles. The
100 µL PCR contained 60 pmol of each ODN, 20 µmol of each dNTP, and 2 units of Vent
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DNA polymerase. The PCR product was purified by gel extraction, and digested with
HindIII and SacI. The digested product was purified by PCR purification kit, and cloned
into the HindIII and SacI restriction sites of pET23a, yielding pJK429. ODN 1394
introduces a HindIII cut site immediately upstream of a unique MluI restriction site that
is created at the junction of purEAa and the region upstream of purEEc. The MluI site will
be used below. Sequencing of plasmid pJK429 indicated a silent point mutation that
alters the purK Arg215 codon CGA to CGG.
pJK437. A 0.9 kb product containing the region upstream of purEEc, including the
entire lpxHEc gene, was amplified by PCR from plasmid gDNA and ODNs 1269 and 1271,
and an annealing temperature of 65 °C with melting, annealing and extension times of
30, 60, and 60 s for 25 cycles. The PCR (100 µL) contained 66 pmol of each ODN, 40
µmol of each dNTP, and 2 units of Vent DNA polymerase. The PCR product was purified
using a gel extraction kit. The product was digested with NotI and MluI and cloned into
the restriction sites of a mutant subclone of pJK429, yielding pJK437. Sequencing
indicated that plasmid pJK437 contained the desired sequence.
pJK430. A 1.1 kb product containing the region downstream of purKEc, including
the entire divergently-oriented ybcFEc gene, was amplified by PCR from plasmid gDNA
and ODNs 1386 and 1396, and an annealing temperature of 50 °C with melting,
annealing and extension times of 30, 60, and 75 s for 30 cycles. The PCR (50 µL)
contained 30 pmol of each ODN, 20 µmol of each dNTP, and 1 units of Vent DNA
polymerase. The PCR product was purified using a gel extraction kit, and digested with
SacI and BamHI. The digest was purified by PCR purification kit and cloned into the SacI
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and BamHI restriction sites of pET23a, yielding pJK430. Sequencing indicated that
pJK430 contained the expected sequence.
pJK440. The SacI-BamHI insert of pJK430 was cloned into the SacI and BamHI
restriction sites of pJK429 to yield pJK440
pJK442. The NotI-MluI insert of pJK437 was cloned into the NotI and MluI
restriction sites of pJK429 to yield plasmid pJK442.
pJK444. Quikchange mutagenesis was used to revert the SacI of pJK440 back
wild type sequence using ODNs 1401 and 1402. Sequencing of pJK444 indicated the
desired sequence was obtained.
pJK420. The inserts of plasmids pJK444 and pJK442 were then combined using a
unique NcoI restriction site found in purKAa. The BamHI-NcoI insert of pJK444 was cloned
into pJK442 using the BamHI and NcoI restriction sites to yield plasmid pJK420.
pJK421. The BamHI-NotI insert of pJK420 was cloned into vector pKOV using the
BamHI and NotI restriction sites to yield plasmid pJK421.
c) Construction of plasmid pJK448 for the precise insertion of purKAa into the E.coli
genome
The cloning strategy used in this section is illustrated by Figures 4.4 and 4.5.
pJK432. A 1.4 kb product containing the region upstream of purKEc, including the
entire lpxHEc and purEEc genes, was amplified by PCR using E. coli gDNA and ODNs 1269
and 1398, with an annealing temperature of 62 °C and melting, annealing and extension
times of 30, 60, and 85 s for 30 cycles. The PCR (50 µL) contained 30 pmol of each ODN,
20 µmol of each dNTP, and 1 units of Vent DNA polymerase. The PCR product
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Figure 4.4: Assembly of insert of pJK448 (Part 1). “Introduced” restriction sites are
shown in red. The “introduced” SalI restriction site was used to assemble the purKAa
(pJK431) and the region upstream of purKEc (pJK432) segments. The NotI-SalI insert of
pJK432 was cloned into pJK431 using the NotI and SalI restriction sites to yield plasmid
pJK443. The “introduced” SalI site was reverted back to wild type sequence by
Quikchange mutagenesis to yield plasmid pJK446. Construction of insert for pJK448 is
continued in Figure 4.5.

was purified by a gel extraction kit, and was digested with NotI and SalI. The digest was
purified with a PCR purification kit and was cloned into pET23a using the NotI and SalI
restriction sites, yielding pJK432. Sequencing indicated that plasmid pJK432 contained
the expected sequence.
pJK431. A 1.2 kb product containing the purKAa gene was amplified by PCR using
plasmid pJK173 and ODNs 1395 and 1397, with an annealing temperature of 58 °C and
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Figure 4.5: Assembly of insert of pJK448 (Part 2). The inserts of plasmids pJK444 and
446 were combined using a unique NcoI restriction site present in purKAa. The BamHINcoI insert of pJK444 was cloned into pJK446 using the BamHI and NcoI restriction sites
to yield plasmid pJK418. Plasmid pJK418 contains the insert which was cloned into the
pKOV vector.

melting, annealing and extension times of 30, 60, and 75 s for 30 cycles. The PCR (100
µL) contained 60 pmol of each ODN, 40 µmol of each dNTP, and 2 units of Vent DNA
polymerase. The PCR product was purified by a gel extraction kit and was digested with
SalI and SacI. The digested product was purified with a PCR purification kit and cloned
into pET23a using the SalI and SacI restriction sites, yielding pJK431. Sequencing
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indicated that plasmid pJK431 contained the same silent point mutation in pJK429 that
alters the purK Arg215 codon CGA to CGG.
pJK443. The NotI-SalI insert of plasmid pJK432 was cloned into pJK432 using the
NotI and SalI restriction sites to yield plasmid pJK443.
pJK446. Quikchange mutagenesis was used to revert the SalI of pJK443 back wild
type sequence using ODNs 1399 and 1400. Sequencing of pJK446 indicated the desired
mutation had been obtained.
pJK418. The inserts of plasmids pJK444 and pJK446 were combined using the
BamHI restriction site, and a unique NcoI restriction site found in purKAa. The BamHINcoI insert of pJK444 was cloned into pJK442 using the BamHI and NcoI restriction sites
to yield plasmid pJK418.
pJK448. The BamHI-NotI insert of pJK418 was cloned into vector pKOV using the
BamHI and NotI restriction sites to yield plasmid pJK448.
d) Construction of plasmid pJK390 for the precise deletion of purEEc in the E.coli
genome
pJK388. A 0.9 kb product containing the region upstream of purEEc and the first
24 bp of the purEEc gene was amplified by PCR from gDNA using ODNs 1269 and 1270,
with an annealing temperature of 65 °C and melting, annealing and extension times of
30, 60, and 90 s for 25 cycles. The PCR (50 µL) contained 25 pmol of each ODN, 20 nmol
of each dNTP, and 1 unit of Vent DNA polymerase. A 1.2 kb product containing the last
66 bp of purEEc and the purKEc gene was amplified by PCR from plasmid pNC2 using
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ODNs 1301 and 1302, with an annealing temperature of 65 °C and melting, annealing
and extension times of 30, 60 and 90 s for 25 cycles. The PCR (50 µL) contained 50 pmol
of each ODN, 20 nmol of each dNTP and 1 unit of Vent DNA polymerase. A 2.0 kb crossover PCR product was obtained using crude products above as template and ODNs 1301
and 1269, with an annealing temperature of 60 °C and melting, annealing and extension
times of 30 60 and 150 s for 30 cycles. The PCR (50 µL) contained 25 pmol of each ODN,
40 nmol of each dNTP, 1 unit of Vent DNA polymerase, and the standard Thermopol
buffer supplemented with 200 nmol of MgSO4 to a 6 mM total concentration. The
product was purified by PCR purification kit, and the purified product was digested with
NotI and BamHI. The digested product was purified by PCR purification kit and was
cloned into pET23a using the NotI and BamHI restriction sites to yield plasmid pJK388.
Sequencing indicated that the plasmid contained a silent mutation that alters the purK
Gly31 codon from GGG to GGA.
pJK390. The NotI-BamHI insert of pJK388 was cloned into pKOV using the NotI
and BamHI restriction sites to yield plasmid pJK390.
Creation of insertion strains. Insertion strains were created using the pKOV
precise gene replacement vector system developed by the lab of George Church (13,
14). This plasmid allows for the selection of colonies that have inserted the plasmid into
the genome by homologous recombination, and allows for later selection of excision
and loss of the plasmid (Scheme 4.5). When the plasmid is excised from the genome, it
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may either leave the genome unaltered, or replace the genomic DNA with a portion of
the plasmid insert.

Scheme 4.5: Method for precise gene insertion using pKOV vector system. Illustrated
for the creation of purEAa insert strain. Unlabeled box and triangle shown for strain 1611
represents remainder of purEEc gene left in construction of strain as described in
experimental section. Representations are not to scale.

The replacement of genomic DNA with the plasmid insert will be referred to as “fruitful”
below. In principle, there is a 50:50 chance of obtaining fruitful and fruitless
recombination products, but additional selection factors may bias the ratio of products
obtained.
The pKOV vector contains: a chloramphenicol marker, that allows for selection of
cells containing the plasmid; a temperature-sensitive origin of replication, that allows
for selection of insertion of the plasmid at a non-permissive temperatures and excision
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at permissive temperature; and a counter-selectable marker, the B. subtilis sacB gene.
The sacB gene encodes for levansucrase, which is toxic in E. coli grown in the presence
of sucrose. The counter-selectable marker allows for selection of the loss of the
plasmid. The general method for the creation of the precise gene replacement strains is
described below, and illustrated in Scheme 4.5 for the creation of the purEAa insert
strain.
Insertion of plasmid into the genome of E. coli was selected for by growth on
chloramphenicol plates at a non-permissive temperature for plasmid replication (42 °C).
Insertion of plasmid was confirmed by PCR for each strain (individual conditions used for
each strain are listed below). Subsequent excision and concomitant loss of plasmid was
selected by growth at a permissive temperature for plasmid replication (30 °C) and
growth on LB agar plates supplemented with 5% sucrose (w/v). The loss of plasmid was
confirmed by sensitivity to chloramphenicol and by PCR.
Creation of precise purEAa insert strain CC1201. Several attempts were made to
obtain strain CC1201 by transforming W3110 cells with plasmid pJK391. After several
failed attempts, the ΔpurEEc strain CC0101 was used instead of W3110. This was done
owing to the possibility that the fruitless excision of the genome-integrated plasmid may
be favored. A fruitless excision of the plasmid would result in strain W3110, and might
have a selective advantage because it contains an unaltered copy of purE. The ΔpurEEc
strain CC0101 lacks the purEEc gene, and should therefore confer no advantage on
fruitless recombination products.
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Strain CC1201 was obtained by transforming pJK391 into strain CC0101. After
growth at a non-permissive temperature, insertion of the plasmid into the genome was
confirmed by whole colony PCR, using the size of products obtained with ODNs pairs
1161 and 1278, and 1277 and 1164, and an annealing temperature of 58 °C and a
melting, annealing and extension time of 30, 60 and 120 s for 30 cycles. ODN 1277 and
1278 are sequencing primers for vector pKOV, and ODN 1161 and 1164 are
complementary to a region upstream and downstream of purEEc. The 1.4 kb size of the
product obtained with ODNs 1161 and 1278 indicated that plasmid pJK391 had inserted
into the genome. The size of the product indicated that the deleted purEEc of strain
CC0101 had been amplified and not the purEAa of the plasmid. If insertion did not occur
or had occurred upstream of ODN 1161, a 1.8 kb product would have been obtained (if
the plasmid had inserted upstream of ODN 1161, the reaction with ODNs 1277 and 1164
would have indicated insertion had occurred). The PCR (25 µL) contained 8.25 pmol of
each ODN, 10 nmol of each dNTP, and 0.5 units of NEB Taq in Thermopol buffer.
Following selection at 30 °C on solid LB/5% sucrose media, colonies were re-passaged on
LB/5% sucrose to ensure single colonies were obtained. Whole-colony PCR was used to
confirm the excision of plasmid and insertion of purEAa into the genome with ODNs 1162
and 1378 and an annealing temperature of 50 °C and melting, annealing and extension
times of 30, 60 and 180 s for 30 cycles. The PCR (50 µL) contained 66 pmol of each ODN,
20 nmol of each dNTP, and 1 unit of NEB Taq in Thermopol buffer. Sequencing of the
2.8 kb product indicated the intended strain had been obtained.
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Creation of precise purEAa(ATG) insert strain CC1202. Strain CC1202 was obtained
by transforming pJK414 into strain CC0101. After growth at a non permissive
temperature, insertion of the plasmid into the genome was confirmed by whole colony
PCR, using the size of the product obtained with ODNs pairs 1161 and 1278; and 1164
and 1277 with an annealing temperature of 58 °C and a melting, annealing and
extension time of 30, 60 and 120 s for 30 cycles. The 1.3 kb size of the product obtained
with ODNs 1277 and 1164 indicated that plasmid pJK414 had inserted into the genome.
The size of the product indicated that the deleted purEEc of strain CC0101 had been
amplified and not the purEAa of the plasmid. If insertion had not occurred, or had
occurred upstream of ODN 1164, a 1.7 kb product would be obtained (if the plasmid had
inserted upstream of ODN 1164, the reaction with ODNs 1278 and 1161 would have
indicated insertion had occurred). The PCR (25 µL) contained 8.25 pmol of each ODN,
10 nmol of each dNTP, 25 nmol MgCl2, and 0.5 units of Taq (Promega) in GoTaq Flexi
buffer. Following selection at 30 °C on solid LB/5% sucrose, colonies were re-passaged
on LB/5%sucrose to ensure single colonies were obtained. Whole-colony PCR was used
to confirm the excision of plasmid and insertion of purEAa into the genome with ODNs
1162 and 1378 and an annealing temperature of 50 °C and melting, annealing and
extension times of 30, 60 and 180 s for 30 cycles. The PCR (50 µL) contained 66 pmol of
each ODN, 20 nmol of each dNTP, and 1 unit of Taq in Thermopol buffer. Sequencing of
the 2.8 kb product indicated the intended strain had been obtained.
Creation of precise purKAa insert strain CC1203. Strain CC1203 was obtained by
transforming pJK448 into strain CC0103. After growth at a non permissive temperature,
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insertion of the plasmid into the genome was confirmed by whole-colony PCR, using the
size of the product obtained with ODNs pairs 1161 and 1278; and 1162 and 1277 with
an annealing temperature of 58 °C and a melting, annealing and extension time of 30,
60 and 180 s for 30 cycles. The 1.9 kb size of the product obtained with ODNs 1277 and
1162 indicated that plasmid pJK448 had inserted into the genome. The size of the
product indicated that the deleted purKEc of strain CC0103 had been amplified and not
the purKAa of the plasmid. If insertion had not occurred, or had occurred upstream of
ODN 1162, a 2.9 kb product would be obtained (if the plasmid had inserted upstream of
ODN 1162, the reaction with ODNs 1277 and 1161 would have indicated insertion had
occurred). The PCR (50 µL) contained 33 pmol of each ODN, 20 nmol of each dNTP, 100
nmol MgCl2, and 1 units of Taq (Promega) in GoTaq Flexi buffer. Following selection at
30 °C on solid LB/5% sucrose, colonies were re-passaged on LB/agar/5%sucrose to
ensure single colonies were obtained. Whole-colony PCR was used to confirm the
excision of plasmid and insertion of purKAa into the genome with ODNs 1403 and 1378
and an annealing temperature of 50 °C and melting, annealing and extension times of
30, 60 and 240 s for 30 cycles. The PCR (50 µL) contained 66 pmol of each ODN, 20 nmol
of each dNTP, 100 nmol MgCl2, and 1 unit of Taq in GoTaq Flexi buffer. Sequencing of
the 3.8 kb product indicated the intended strain had been obtained.
Creation of precise purEAapurKAa insert strain CC1204. Strain CC1204 was
obtained by transforming pJK421 into strain CC0102. After growth at a non permissive
temperature, insertion of pJK421 into the genome was confirmed by whole colony PCR,
using the size of the product obtained with ODNs pairs 1161 and 1278; and 1162 and
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1277 with an annealing temperature of 58 °C and a melting, annealing and extension
time of 30, 60 and 180 s for 30 cycles. The 1.4 kb size of the product obtained with
ODNs 1278 and 1161 indicated that plasmid pJK421 had inserted into the genome. The
size of the product indicated that the deleted purKEcpurKEc of strain CC0103 had been
amplified and not the purEAapurKAa of the plasmid. If insertion had not occurred, or had
occurred upstream of ODN 1161, a 3.0 kb product would be obtained (if the plasmid had
inserted upstream of ODN 1161, the reaction with ODNs 1277 and 1162 would have
indicated insertion had occurred). The PCR (50 µL) contained 33 pmol of each ODN, 20
nmol of each dNTP, 100 nmol MgCl2, and 1 units of Taq (Promega) in GoTaq Flexi buffer.
Following selection at 30°C on solid LB/5% sucrose, colonies were re-passaged on
LB/5%sucrose to ensure single colonies were obtained. Whole-colony PCR was used to
confirm the excision of plasmid and insertion of purEAapurKAa into the genome with
ODNs 1403 and 1378 and an annealing temperature of 50 °C and melting, annealing and
extension times of 30, 60 and 240 s for 30 cycles. The PCR (50 µL) contained 66 pmol of
each ODN, 20 nmol of each dNTP, 100 nmol MgCl2, and 1 unit of Taq in GoTaq Flexi
buffer. Sequencing of the 3.8 kb product indicated the intended strain had been
obtained.
Creation of precise purEAa(ATG)purKAa insert strain CC1205. Strain CC1205 was
obtained by transforming pJK421 into strain CC1202. Strain CC1202 was used because it
already contained purEAa with an ATG start codon. After growth at a non-permissive
temperature, insertion of pJK421 into the genome was confirmed by whole colony PCR,
using ODNs pairs of 1164 and 1277; and 1167 and 1278 with an annealing temperature
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of 58 °C and a melting, annealing and extension time of 30, 60 and 120 s for 30 cycles.
ODNs 1164 and 1167 are complementary to portions of purKEc, and would only produce
PCR products if the plasmid had integrated into the genome. The 1.6 kb product
obtained with ODNs 1278 and 1167 indicated that plasmid pJK421 had inserted into the
genome. The PCR (50 µL) contained 33 pmol of each ODN, 20 nmol of each dNTP, 100
nmol MgCl2, and 1 units of Taq in GoTaq Flexi buffer. Following selection at 30 °C on
solid LB/5% sucrose, colonies were re-passaged on LB/5%sucrose to ensure single
colonies were obtained. Whole-colony PCR was used to confirm the excision of plasmid
and insertion of purEAapurKAa into the genome with ODNs 1403 and 1378 and an
annealing temperature of 50 °C and melting, annealing and extension times of 30, 60
and 240 s for 30 cycles. The 50 µL PCRs contained 66 pmol of each ODN, 20 nmol of
each dNTP, 100 nmol MgCl2, and 1 unit of Taq in GoTaq Flexi buffer. Sequencing of the
3.8 kb product indicated the intended strain had been obtained, with purEAa having an
ATG start codon.
Construction of purEAa plasmids for functional complementation studies. Plasmid
pJK173 was made by Christopher Mill of this lab (18). Plasmid pJK173 contains both
purEAapurKAa and includes a 318 bp 5’ upstream region containing orf1 and a 36 bp 3’
untranslated region, cloned into pUC118 via SphI. Plasmid pJK173 was used as the
template for all plasmids containing A. aceti sequence, as listed below.
Construction of orf-1AapurEH59DAapurK plasmid pJK347. The codon for His59 in
purEAa was changed to encode Asp by Quikchange mutagenesis of plasmid pJK173 using
ODNs 1017 and 1018. This process yielded plasmid pJK347.
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Construction of orf-1AapurEH59NAapurK plasmid pJK348 – The codon for His59 in
purEAa was changed to encode Asn by Quikchange mutagenesis of plasmid pJK173 using
ODNs 1019 and 1020. This process yielded plasmid pJK348.
Construction of purEAa single-construct plasmid pJK324. The purEAa region of
pJK173 (the purE gene, with a 39 bp 5’-UTR and 14 3’-UTR) was amplified by PCR from
pJK173 using ODNs 1078 and 1079, with an annealing temperature of 55 °C and melting,
annealing and extension times of 30, 60, and 60 s for 25 cycles. The PCR was performed
in a 100 µL Hot Start tube with Triton 100-X, and contained 31.3 pmol of each ODN and
2 units of Vent. The product was purified by Qiagen PCR purification kit, and digested
with EcoRI and NotI. The digested product was purified by PCR purification kit and
cloned into the EcoRI and HindIII restriction sites of pUC118 to yield plasmid pJK324.
Construction of purEH59DAa plasmid pJK346. The codon for His59 in purEAa was
changed to encode Asp by Quikchange mutagenesis of plasmid pJK173, using ODNs
1017 and 1018. This process yielded plasmid pJK346.
Construction of purEH59NAa plasmid pJK340. The codon for His59 in purEAa was
changed to encode Asn by Quikchange mutagenesis of plasmid pJK173 using ODNs 1019
and 1020. This process yielded plasmid pJK340.
Construction of orf1Aa-purEAa plasmid pJK412. The purEAa gene and all of the
region upstream of the gene in pJK173 was amplified by PCR from pJK173 using ODNs
617 and 1079, with an annealing temperature of 55 °C and melting, annealing, and
extension times of 30, 60 and 60 s for 30 cycles. The 200 µL (for 50 µL reactions) PCR
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contained 125 pmol of each ODN, 80 nmol of each dNTP, and 4 units of Vent DNA
polymerase. The product was purified using a Qiagen PCR purification kit, and was
digested with HindIII and PstI. The digested product was purified by gel extraction and
was cloned into the HindIII and PstI restriction sites of pJK173 to yield plasmid pJK412.
Constructs of purEEc for function complementation studies. Plasmid pNC2 was
previously made as reported (19). Plasmid pNC2 contains purEEcpurKEc cloned into
pET23a via NdeI and HindIII restriction sites.
Construction of purEH45NEcpurKEc plasmid pJK426. The codon for His45 in purEEc
in pNC2 was changed to encode Asn by Quikchange mutagenesis of plasmid pNC2 using
ODNs 1388 and 1389. This process yielded plasmid pJK426.
Construction of purEEc single construct plasmid pJK419. The majority of the
purKEc gene (bases 193-1066 of the gene) was removed from pNC2 using unique
restriction sites AscI and HincII. Plasmid pNC2 was digested with restriction enzymes
AscI and HincII and run on a 1% agarose gel. The 4.3 kb fragment was purified by gel
extraction. The 5’ overhang left by AscI in the purified fragment was filled in a 150 µL
reaction, containing 60 nmol of each dNTP and 3 units of Vent DNA polymerase in
Thermopol buffer, which was incubated at 72 °C for 15 min. The filled-in fragment was
purified by Qiagen PCR purification kit, and ligated to itself in a standard ligation
reaction run at room temperature for 3 h, to yield plasmid pJK419. In this plasmid the
first 64 amino acids of EcPurK are still encoded in an 86 amino acid protein, of which the
final 22 amino acid are coded for by the vector.
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Construction of purEH45NEc single construct plasmid pJK435. The majority of the
purKEc gene (bases 193-1066 of the gene) was removed from pJK426 using unique
restriction sites AscI and HincII. Plasmid pJK426 was digested with restriction enzymes
AscI and HincII, and run on a 1% agarose gel. The 4.3 kb fragment was purified by gel
extraction. The 5’ overhang left by AscI in the purified fragment was filled in a 100 µL
reaction, containing 20 nmol of each dNTP and 2 units of Vent DNA polymerase in
Thermopol buffer incubated at 72 °C for 15 min. The filled in fragment was purified by
Qiagen PCR purification kit, and ligated to itself in a standard ligation reaction run at
room temperature for 3 h to yield plasmid pJK435. The first 64 amino acids of EcPurK
are still encoded in an 86 amino acid protein, of which the final 22 amino acids are
coded for by the vector.
Construction of orf1AapurKAa plasmid pJK415. A product of the insert of pJK173
with an in-frame deletion removing a large portion of purEAa was made by cross-over
PCR. ODNs were designed to remove 151 residues of AaPurE. A 450 bp product
including the multi-cloning site and the first 36 bp of purEAa was amplified from pJK173
by PCR using ODNs 617 and 1371, with a 58 °C annealing temperature and melting,
annealing and extension times of 30 s each for 30 cycles. The PCR (50 µL) contained
16.5 pmol of each ODN, 20 nmol of each dNTP, and 1 unit of Vent DNA polymerase. The
product was purified using a PCR purification kit and was used as template (4 ng) in the
subsequent cross-over PCR. A 1.3 kb product containing the last 96 bp of the purEAa
gene, and all of purKAa and the HindIII site derived from pUC118 was amplified from
pJK173 by PCR using ODNs 601 and 1370, with a 62 °C annealing temperature, and
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melting, annealing and extension times of 30, 30 and 80 s for 30 cycles. The PCR (50 µL)
contained 16.5 pmol of each ODN, 20 nmol of each dNTP, and 1 unit of Vent DNA
polymerase. The product was purified using a PCR purification kit and was used as
template (4 ng) in the subsequent cross-over PCR.
A 1.7 kb cross-over PCR product was obtained using the above products as
template and ODNs 601 and 607, with an annealing temperature of 58 °C and melting,
annealing and extension times of 30, 30 and 110 s for 30 cycles. The PCR (100 µL)
contained 33 pmol of each ODN, 40 nmol of each dNTP, and 1 unit of Vent DNA
polymerase. The product was purified by gel extraction, and digested with HindIII and
PstI. Following digestion, the product was purified by gel extraction and was ligated into
pJK173. Sequencing indicated the plasmid contained a silent point mutation in purKAa
that has been seen previously (Arg215: CGACGG).
Construction of purKEc plasmid pJK427. A 1.2 kb product containing purKEc and a
truncated purEEc gene was amplified from pJK388, using ODNs 1390 and 1391 with an
annealing temperature of 58 °C and melting, annealing and extension times of 30, 60,
and 75 s for 30 cycles. The product was gel purified and digested with SphI and NdeI.
The digested product was purified using a Qiagen PCR purification kit and was ligated
into SphI and NdeI restriction sites of pNC2.
Construction of orf1Aa plasmid. A large portion of purEAa, and all of the purKAa
gene was removed from pJK173 by digestion with AgeI and HindIII. The 3.7 kb fragment
was purified by gel extraction. The overhangs left by digestion were filled in a 55 uL
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reaction, containing 20 nmol of each dNTP, 1 unit of Vent DNA polymerase in
Thermopol buffer, incubated at 72 °C for 10 min. The filled-in product was purified by
PCR purification kit and ligated to itself, in a standard ligation reaction run at room
temperature for 3 h. The plasmid encodes for orf1Aa and for the first 64 amino acids of
AaPurE fused to the α-LacZ fragment of pUC118.
Description of media. Two types of media lacking purines were used in liquid and
solid form (containing 1.5% agar). For all experiments, positive controls were run
containing exogenous purines. The addition of purines in the controls allows for the
growth of auxotrophic strains on minimal media. Minimal medium (A) was the media
described by Schrimsher et al. (20), further supplemented with 10 µM thiamine and 100
µg/mL carbenicillin. For all experiments involving medium A, the positive controls
contained 15 µg/mL hypoxanthine added to the media prior to autoclaving. Medium (B)
was composed of M9 minimal salts (21) with 0.4% glucose as a carbon source,
supplemented with 10 µM thiamine and 50 µg/mL carbenicillin. For all experiments
involving medium B, the positive controls contained 100 µg/mL adenine added from an
autoclaved 5 mg/mL stock solution of the chloride salt of adenine.
Initial strain PCO135 functional complementation experiments – Plasmids
pJK173, pJK324, pJK346, pJK347 and pUC118 (negative control) were transformed into
strain PCO135 cells and their ability to complement purine auxotrophy on solid media A
examined. Cells were grown for 12 h at 37 °C on LB/Amp plates and a single colony was
used to inoculate a 5 mL LB/Amp culture which was grown at 37 °C for 10 h. Using A600
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measurements, the culture was diluted in LB to a final A600 = 0.0004. A portion of this
diluted culture was then spread on medium A. For all plasmids except pJK347, a series
of plates were also grown in a candle jar (22). To create the candle jar, plates were
placed in a large glass desiccator. A lit candle was placed in the desiccator, and the
desiccator was sealed. The candle was allowed to burn until it extinguished, and the
desiccator was placed at 37 °C. Plasmids which complemented the purine auxotrophy
on solid medium A were also assessed for their ability to complement the purine
auxotrophy in liquid medium A.
Functional complementation of PC0135. Plasmids pJK173, pJK324, pJK412 and
pUC118 (negative control) were transformed into strain PCO135 cells and their ability to
grow on solid medium A was assessed. Cells were grown at 37 °C on LB/Amp plates for
12 h, and a single colony was used to inoculate a 5 mL LB/Amp starter culture, which
was grown to mid-log phase. The A600 of the cultures were measured and the value used
to make dilutions in LB to a final A600 = 0.00005. A portion of the diluted culture was
spread on solid medium A and grown at 37 °C. A duplicate set of plates was also grown
in a candle jar.
Solid medium functional complementation studies of strain CC0102 and PCO135
involving purEEc and purEH45NEc constructs. Strain CC0102 and PCO135 cells were
transformed with plasmids pNC2 (purEEcpurKEc), pJK419 (purEEc), pJK426
(purEH45NEcpurKEc); and pJK435 (purEH45NEc ), or pUC118 as a negative control.
Plasmids were assessed for their ability to restore prototrophy to those strains. LB/Amp
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cultures (5 mL) were inoculated from single colonies and grown for 12 h at 37 °C. Cells
were harvested by centrifugation (4000 g for 10 min), and resuspended in 5 mL medium
B. Cells were harvested by centrifugation again, and resuspended in a final 5 mL of
medium B. The A600 of the cultures were measured and the cultures were diluted in
minimal media B to a final A600 = 0.00005. A portion of the diluted culture was spread
on solid medium A and grown at 37 °C. For strain CC0102, a portion of the diluted
culture was also spread on solid medium B.
Functional complementation studies of CC0101 in liquid medium B. Plasmids
pJK173, pJK347, pJK348, pJK324, pJK412 and pNC2 were assessed for their ability to
restore prototrophy to strain CC0101. The negative control was CC0101/pUC118. Cells
were transformed with plasmids listed and placed on LB/Amp plates and incubated at
37 °C for 16 h. Satellite colonies were noted on the plates. A single large colony from
each plate was passaged on LB/Amp plates and incubated at 37 °C overnight. LB/Amp
cultures (5 mL) were inoculated from single colonies and grown for 12 h at 37 °C. Cells
were harvested by centrifugation (4000 g for 15 min), and were resuspended in 5 mL
medium B. Cells were harvested by centrifugation again, and resuspended in a final 5
mL of medium B. The A600 of the cultures was measured, and 50 mL medium B cultures
were inoculated to an A600 = 0.01. The adenine that was added to positive controls in
these experiments was sterile filtered. Cultures were grown at 37 °C with shaking at 200
rpm in a New Brunswick Scientific Innova 4430 shaking incubator. The growth of
cultures was monitored by measuring A600 over time. Cultures were observed for 186 h.
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Study purEEc and purEEcpurKEc constructs on strains CC0101 (ΔpurEEc), CC1201
and CC1202, on solid medium B. Strain CC1201, CC1201 and CC0101 cells were
transformed with plasmids pJK419 or pNC2. Plasmids were assessed for their ability to
restore growth on solid minimal medium A and solid minimal medium B. Cells were
placed on LB/Amp plates which were supplemented with 100 µg/mL adenine, 0.1 %
glucose and 10 µM thiamine and grown at 37 °C for 12 h. LB/Amp starter cultures (5
mL) supplemented with 100 µg/mL adenine, 0.1 % glucose and 10 µM thiamine, were
inoculated from a single colony, and grown for 19 h at 37 °C. The A600 of the cultures
was measured, and dilutions made in LB to a final A600 = 0.002. A portion of the diluted
culture was spread on solid medium A or solid medium B and grown at 37 °C. A
duplicate set of plates for CC0101/pJK419 on solid medium A was also grown in a candle
jar.
Functional complementation of strain CC0101 with single purEEc construct in
liquid medium B. Strain CC0101 cells were transformed with plasmids pJK419 (purEEc).
The negative control was CC0101/pUC118. Plasmid pJK419 was assessed for its ability
to restore prototrophy to strain CC0101 in liquid media. Transformed cells were placed
on LB/Amp plates and incubated at 37 °C for 11 h. LB/Amp cultures (5 mL) were
inoculated from single colonies and grown to mid log phase at 37 °C. Cells were
harvested by centrifugation (4000 g for 10 min), and were resuspended in 5 mL medium
B. Cells were harvested by centrifugation again, and resuspended in a final 5 mL of
media B. The A600 of the cultures was measured, and 50 mL medium B cultures were
inoculated to an A600= 0.005. Cultures were grown at 37 °C with shaking at 200 rpm in a
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New Brunswick Scientific Innova 4430 shaking incubator. The growth of cultures was
monitored by measuring A600 over time.
Functional complementation studies of CC0102 intended to assess the in vivo
activity of purEAa, purEH59DAa, purEH59NAa, and purEH45NEc. Plasmids pJK173, pJK347,
pJK426, pNC2 and pJK348 were assessed for their ability to restore prototrophy to strain
CC0102. The negative control was CC0102/pUC118. Cells were transformed with
plasmids listed and a single colony was used to inoculate a 5 mL LB/Amp starter culture
which was grown to mid-log phase. Cells were harvested by centrifugation at 4000 g for
10 min. Cell pellets were resuspended in 5 mL of medium B, harvested as before, and
resuspended in 5 mL of medium B. The A600 of resuspended cells was measured, and 50
mL medium B cultures were inoculated to an A600 = 0.005. Flasks were incubated at 37
°C with shaking at 200 rpm in a New Brunswick Scientific Innova 4430 shaking incubator.
The growth of cultures was monitored by measuring A600 over time.
Growth of strains CC0102 (ΔpurEEcΔpurKEc), CC0103(ΔpurKEc), CC1203
(purKEc<>purKAa), CC1204 (purEEcpurKEc<>purEAapurKAa) and CC1205
(purEEcpurKEc<>purEAa(ATG)purKAa) on solid medium B. All strains were transformed with
pUC118 and their ability to grow on solid medium B was assessed. Strain CC0102 was
also transformed with pJK173 as a positive control. Following transformation cells were
spread on LB/Amp plates, and grown for 11 h at 37 °C. LB/Amp starter cultures (5 mL)
were inoculated from a single colony and grown at 37 °C to mid log phase. Cells were
harvested by centrifugation (4000 g, 10 min) and resuspended in 5 mL of medium B.
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Cells were harvested again by centrifugation (4000g, 10 min), and resuspended in 5 mL
of medium B. The A600 of the cultures were measured, and the cultures were diluted in
minimal medium B to a final A600 = 0.0001. A portion of the dilution was spread on solid
media B and the plates grown at 37 °C.
Initial functional complementation studies for CC1203, CC1204, and CC1205 in
liquid medium B. The ability of the purKAa, purEAapurKAa, and purEAa(ATG)purK insert
strains to grow in medium B was assessed in reference to strain W3110. All four strains
were transformed with pUC118. Additionally the effects of pJK173 or pJK455 on the
growth of the purEAapurKAa, and purEAa(ATG)purK insert strains were assessed. Strain
CC0102/pUC118 was used as a negative control. Cells were transformed with the listed
plasmids. A single colony was picked from a plate grown at 37 °C for 12 h and used to
inoculate a 5 mL LB/Amp starter culture, which was grown to mid-log phase. Cells were
harvested by centrifugation at 4000 g for 10 min. Cell pellets were resuspended in 5 mL
of medium B, harvested as before, and resuspended in 5 mL of medium B. The A600 of
resuspended cells was measured, and 50 mL medium B cultures were inoculated to an
A600 = 0.005. Flasks were incubated at 37 °C with shaking at 200 rpm in a New
Brunswick Scientific Innova 4430 shaking incubator. The growth of cultures was
monitored by measuring A600 over time, and measurements taken only after growth was
observed. The negative control was observed for 1000 h.
Growth experiments involving strains CC1202 and CC1205. In separate
experiments for each strain, plasmid pJK348 and plasmids containing portions of pJK173
(pJK324, pJK412, pJK415, and pJK455) were assessed for their effects on the growth of
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strains in medium B (Scheme4.6). Strains were also transformed with plasmid pJK419 or
pUC118. For each growth experiment, a strain and plasmid combination that was not
expected to grow in medium B was used. For strain CC1202, CC0101/pUC118 was used
as a negative control. For growth experiments with strain CC1205, CC0102/pJK348 was
used as a negative control. Single colonies, picked from plates incubated for 12 h at

Scheme 4.6: Diagram showing inserts of plasmids. Plasmids were used in growth
experiments involving strains CC1202 and CC1205. Regions deleted from plasmids are
shown as dashed red line.

37 °C, were used to inoculate 5 mL LB/Amp starter cultures. Starter cultures were grown
at 37 °C to mid-log phase. Cells were harvested by centrifugation at 4000 g for 10 min.
Cell pellets were resuspended in 5 mL of medium B, harvested as before, and
resuspended in 5 mL of medium B. The A600 of resuspended cells was measured, and 50
mL medium B cultures were inoculated to an A600 = 0.005. Flasks were incubated at
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37°C with shaking at 200 rpm in a New Brunswick Scientific Innova 4430 shaking
incubator. The growth of cultures was monitored by measuring A600 over time, and
measurements taken only after growth was observed. Negative controls were observed
for 1000 h.
4.3 Results
Construction of plasmids. Standard molecular biology techniques were used in
the construction of almost all of the plasmids used in the functional complementation
studies. This process yielded plasmids that either contained the expected sequence, or
silent point mutations. To construct the plasmids for manipulation of genomic DNA,
two different approaches were taken to combine DNA products from different sources
(E. coli and A. aceti). The first approach used the technique of cross-over PCR. The
second approach relied on assembling PCR products amplified from different sources by
the introduction of restriction sites and cloning the products into pET23a. After the
pieces were assembled, mutagenesis was then used to remove the restriction sites and
revert the sequence to “wild type.” Both of these methods provided final plasmids with
the expected sequence, or contained a mutation that did not affect the strains. The
sequencing of strains indicated that no mutations present in a plasmid had been
incorporated into the flanking regions of genomic DNA (i.e., the mutation present in the
insert of pJK389 in the lphXEc Ala7 codon was not incorporated into the genome).
The inserts of plasmids pJK388 and pJK389 were constructed using cross-over
PCR. Attempts were made to construct the inserts of plasmids pJK418 and pJK420 by a
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similar method but were unsuccessful. While in theory it would seem that cross-over
PCR would provide the easiest route, in practice it can be difficult. The increased size
(~2.5 kb vs ~1.5 kb) of the cross-over products in the construction of purEAapurKAa and
purKAa insert plasmids likely contributed to the failure of cross-over PCR in the
construction of these plasmids. Cross-over PCR was very effective for rapidly creating
plasmid pJK388 and plasmid pJK415, each of which was built from comparatively smaller
pieces of DNA.
Construction of new strains. A schematic representation of the purEpurK region
for all strains is shown (Scheme 4.7). Initially plasmids were designed to create a precise
gene replacement strain purEEc<>purEAa and an in-frame deletion strain of purEEc, using
the pKOV system (13, 14). These plasmids were designed to install the purEAa gene in
the precise location of purEEc, and to create a precise in-frame deletion of purEEc without
a stop codon, in such a way as to not disturb translational coupling or regulatory control
of the targeted genes. After several failed attempts to use these plasmids to introduce
changes into the genome of strain W3110, an alternate route was designed to obtain
strains for study.
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Scheme 4.7: Schematic representation of the purEpurK region of strains used in this
study. The representations of genes are not to scale. Colored genes represent genes
from A. aceti. The dashed red line in strains CC0101, CC0102, and CC0103 represents
deleted region of genome and the small red box represents the exogenous 82 bp scar
left by the method used. Strain PC0135 is shown separately and in brackets because it is
not isogenic outside the region of the genome shown.

The method of Datsenko and Wanner (15) provided a rapid means to obtain
deletion strains, CC0101 (ΔpurEEc), CC0102 (ΔpurEEcΔpurKEc), and CC0103 (ΔpurKEc).
With this method, the desired strains were usually obtained on the first attempt, with
the exception of strain CC0102, which was obtained on the second attempt.
After the ΔpurEEc deletion strain CC0101 was created, it was used to obtain the
precise gene replacement strain CC1201 (purEEc<>purEAa). This was based on the
assumption that attempts to obtain the precise gene replacement strain CC1201
(purEEc<>purEAa) using W3110 cells may have failed because a fruitless excision might
confer a selective advantage. This is because a fruitless excision would contain an
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unaltered copy of the purEEc-purKEc operon. The ΔpurEEc strain CC0101 lacks the purEEc
gene, and should therefore confer no advantage on fruitless recombination products.
Using the deletion strain CC0101, we were able to obtain the precise gene replacement
strain CC1201.
A similar method was used to obtain strains CC1202 (purEEc<>purEAa(ATG)),
CC1203 (purKEc<>purKAa), and CC1204 (purEEcpurKEc<>purEAapurKAa), using the deletion
strains CC0101 (ΔpurEEc), CC0103 (ΔpurKEc), and CC0102 (ΔpurEEcΔpurKEc) respectively .
To obtain strain CC1205 (purEEcpurKEc<>purEAa(ATG)purKAa), the precise gene replacement
strain CC1202 was used because it already contained the purEAa gene with an ATG start
codon. The desired strain was obtained using this method, suggesting that the absence
of purEEc in the altered purEAa(ATG)purKEc operon did not convey the same benefit to
fruitless recombination as the unaltered purEEc in W3110 apparently did.
Functional complementation of strain PC0135 by A. aceti genes. AaPurE and
AaPurE His59 mutants were initially tested for their ability to restore prototrophy to
strain PC0135 cells on solid and liquid minimal media. This was done to correlate in vivo
activities with in vitro activities (or lack thereof) previously observed (Chapter 3). Based
on the detected in vitro activities, it was expected that AaPurE would be active, that the
AaPurE-H59D mutant would be less active, and that the AaPurE-H59N mutant would be
inactive. More definitive results were obtained with strain CC0102 (ΔpurEEcΔpurKEc) and
are reported in a following section.
In initial experiments, plasmids were based on pJK173 or pJK324, both of which
are derived from the high copy number pUC118 vector (Scheme 4.8). Plasmid pJK173
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was initially identified by functional complementation of PC0135 (18). It contains all of
the purEAapurKAa coding region and surrounding areas including orf1Aa. Plasmid pJK324
contains purEAa and a 39 nt portion of the 5’-untranslated region, which should contain
upstream regulatory elements needed for the transcription and translation of purEAa.
Cells transformed with pUC118 were used as a negative control. The results of the
initial findings are summarized below in Table 4.5.
For later experiments, plasmid pJK412 was created. Plasmid pJK412 contains
purEAa and the 318 bp 5’ upstream region present in pJK173 that contains orf1Aa. The
ability of pJK412 to complement the auxotrophy was assessed in comparison to pJK173,
pJK324 and pUC118.

Scheme 4.8: Illustration of the inserts of plasmids used in the functional
complementation studies of the purE strain PC0135. Plasmids pJK173 and pJK324 were
changed by mutagenesis to obtain the AaPurE-H59D and AaPurE-H59N mutants.

As expected, wild type AaPurE and the AaPurEH59D mutant were able to
complement the purine auxotrophy in strain PC0135; however, cells transformed with a
plasmid containing the apparently inactive mutant AaPurEH59N also complemented the
purine auxotrophy. A similar result has also been seen in EcPurE with the analogous
H45N mutant (23). The ability of these mutants, which have no detectable in vitro
activity, to complement the PC0135 auxotrophy is proposed to be due to the formation
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of heterooctamers that mix the truncated EcPurE encoded by PC0135 with the fulllength mutant (23).
Table 4.5: Functional complementation studies of purE deficient strain E. coli PC0135
Plasmid (A. aceti genes)
Medium A
Medium A Medium A Medium A
(solid)+
(solid)
(solid) +
(liq)
hypohigh CO2b
xanthinea
ef
pJK173 (orf1AapurEAapurKAa)
++++c
++++
+++
++++
pJK347 (orf1AapurEH59DAapurKAa)e +++
+++d
Nd
++d
pJK348 (orf1AapurEH59NAapurKAa)e +++
++d
++
ef
pJK324 (purEAa)
+++
++
e
pJK346 (purEH59DAa)
+++
e
pJK340 (purEAa)
+++
pJK412 (orf1AapurEAa)f
+++
+
++
Nd
ef
pUC118
+++
Nd
a
Minimal medium A as defined in Experimental Section. Hypoxanthine was added at 15
µg/mL. bPlates were placed in a candle jar as described in the Experimental Section. cKey
to symbols: ++++, large colonies/saturated culture at 24 h; +++ small colonies at 24 h;
++, large colonies/light turbidity at 72 h; +, small colonies at 72 h; -, no growth observed
at 144 h; Nd, not determined. dThe indicated plasmids was recovered from this culture,
and its DNA sequence was obtained to confirm that the purE region had not been
modified. eInitial experiments. fLater experiments.

Although the AaPurE and the AaPurEH59D mutant were able to restore
prototrophy, the ability to do so was only observed when they were co-expressed with
either orf1Aa or orf1Aa and purKAa. This suggests a necessary role for the product of
orf1Aa in the complementation of the purine auxotrophy.
All of the plasmids except pJK347 were also assessed for their ability to
functionally complement strain PC0135 in the CO2 rich environment of a candle jar.
Growth in the high pCO2 environment of the candle jar allowed for functional
complementation of strain PC0135 by plasmid pJK324, which was not observed in a
normal atmosphere. The phenotype exhibited by PC0135/pJK324 is reminiscent or very
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similar to that demonstrated by purK auxotrophs (12, 22), which is curious because
PC0135 contains an intact, endogenous purKEc gene and an exogenous purEAa gene
present on a high copy number plasmid.
The growth of PC0135/pJK324 under high levels of CO2 indicated that purEAa
from pJK324 was expressed in an active form. Given that PC0135/pJK324 gave the same
phenotype as a purK auxotroph, this suggested that AaPurE required AaPurK to function
properly. Such a requirement suggests that channeling of the substrate N5-CAIR may
occur. Channeling is the direct transfer of a metabolite between successive enzymes in
a metabolic pathway. While metabolite channeling is consistent with this result, it is not
the only possible explanation. It is inadvisable to interpret these results to imply
channeling (23), without performing further experiments to eliminate other possibilities.
What channeling would require. If channeling were to occur between PurE and
PurK, those enzymes must form a complex. This complex would not necessarily be
static, and could form a transient ternary complex with the shared metabolite N5-CAIR.
In either case, ‘matched’ enzymes from the same organism would have compatible
surface features. The simplest model is that a strain would grow on minimal medium if
it contains a PurE and a PurK from the same source (i.e., purEEcpurKEc or purEAapurKAa).
For strains containing a PurE and a PurK from different sources (i.e., purEAapurKEc or
purEEcpurKAa), a pur phenotype is expected on minimal medium. The formation of a
AaPurK-AaPurE channeling complex might also require AaOrf1, as will be discussed
later. Because E. coli lacks an orf1Aa homologue, the interaction between EcPurK and
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EcPurE might be different than that between AaPurK and AaPurE, leading to an inability
to recognize a mismatched partner.
Characterization of E. coli strain PC0135. Although strain PC0135 has been used
in elucidating the purine biosynthetic pathway and mapping the genes involved (24), no
published work has reported the molecular defect. Primers were thus designed to
amplify the purEEcpurKEc genes and surrounding areas. The resulting product was
sequenced in both directions and only a single nucleotide difference from wild type was
identified: a point mutation in purEEc that changes wt-EcPurE Trp151 to a stop codon
(TGG TGA). This mutation would cause the final helix of E. coli PurE to be deleted,
which might interfere with octamer assembly, and could explain the auxotrophic
phenotype.
Given that most of purEEc is still encoded by strain PC0135, including all active
site residues, the strain may have a leaky phenotype due to expression of the truncated
EcPurE. If the AaPurEH59N or EcPurEH45N mutants stabilize the truncated EcPurE, this
leaky phenotype explains functional complementation of the purine auxotrophy with
otherwise ‘dead’ mutants (Chapter 3)(23). The unusual observation that the apparently
inactive AaPurEH59N mutant and analogous EcPurEH45N mutant restore prototrophy to
strain PC0135 (23) has led to speculation that the truncated PurE encoded by PC0135
may be stabilized by the inactive PurEs thereby allowing for complementation. The
possible leaky phenotype necessitated the construction of better auxotrophic strains.
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Deletion strains CC0101, CC0102, and CC0103. Of the three deletion strains,
strain CC0102 (ΔpurEEcΔpurKEc) was selected for most studies because it contained a
complete deletion of the genomic genes, and interpretation of results would not require
a consideration of the effects of the genomic purKEc.
Functional complementation of strains PC0135 and CC0102 by purEEc genes. The
leaky PC0135 phenotype was examined by comparing the effects of purEEcpurKEc and
purEEc constructs, along with those plasmids with the EcPurEH45N mutation, on the
growth of strain PC0135 and deletion strain CC0102 (ΔpurEEcΔpurKEc) on solid minimal
medium A (Table 4.6). For strain CC0102, experiments were also performed on solid
minimal medium B (Table 4.6).
Table 4.6: Functional complementation studies of purEEc deficient strain PC0135 and
purEEcpurKEc deficient strain CC0102 by purEEc constructs on solid media.a
Medium B (solid)b
Plasmid (E. coli genes)
Medium A (solid)b Medium A
b
PC0135
(solid)
CC0102
CC0102
pUC118
-c
pNC2 (purEEcpurKEc)
+++
+++
+++
pJK426 (purEH45NEcpurKEc) ++
pJK419 (purEEc)
++
pJK435 (purEH45NEc)
+
a
A set of plates supplemented with exogenous purines in the form of 15 µg/mL
hypoxanthine for medium A or 100 µg/mL adenine for medium B. These controls gave
(+++) growth except for strain CC0102/pUC 118 which gave (++) growth. b minimal
media A and B as described in Experimental section. c key to symbols: +++, large
colonies at 36 h; ++, small colonies at 36 h; +, small colonies at 48 h; -, tiny colonies
which do not increase in size with time up to 144 h.

As expected, plasmids pNC2 and pJK419 were able to functionally complement
the auxotrophy in strain PC0135. Plasmid pNC2 was able to complement the
auxotrophy of strain CC0102. Because strain CC0102 does not contain a genomic copy
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of purKEc, plasmid pJK419 was not expected to, and did not, restore prototrophy to
CC0102.
Plasmids that contained the EcPurEH45N mutant (pJK426 and pJK435) restored
growth to strain PC0135. This was expected from previously reported studies (23), and
from the results we obtained for AaPurEH59N above. If the EcPurEH45N mutant is
active in vivo, plasmid pJK426 should restore prototrophy to strain CC0102. The lack of
growth of strain CC0102/pJK426 (purEH45NEcpurKEc) on solid minimal medium A and on
solid minimal medium B indicates that EcPurEH45N lacks the activity required to
complement the auxotrophy when all of purEEc is deleted. This result indicates that the
inactive mutant EcPurEH45N only restores prototrophy in strain PC0135 because it is
able to combine with the truncated PurE expressed by this strain.
In strain PC0135, growth is faster when either wild type or mutant EcPurE is coexpressed with EcPurK. This result suggests that the molecular lesion, which causes the
purE auxotrophy in strain PC0135, either has a polar effect on the expression of purKEc
or the selective overexpression of purEEc inhibits growth.
Functional complementation studies of strain CC0102 (ΔpurEEcΔpurKEc) in liquid
medium. Plasmids bearing orf1AapurEAapurKAa and purEEcpurKEc, or their respective PurE
H59N (E. coli: H45N) mutants, were assessed for their ability to restore prototrophy to
strain CC0102 in liquid medium B. Plasmid pUC118 was used as a negative control.
Positive controls contained exogenous purines in the form of 100 µg/mL adenine, which
had been used previously in the solid medium B experiments in Table 4.6 (15 µg/mL
hypoxanthine was used in medium A experiments). The results of these functional
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complementation studies are shown in Figure 4.6, which is a summary of the growth
curves shown in Figure 4.7. These results indicate that only PurE constructs with an in
vitro activity are able to restore growth.

Figure 4.6. Schematic representation of strain CC0101 growth curves. Summary of
results of minimal medium B growth curves shown in Figure 4.7. The first column gives
an entry number, and the strain used. The second column indicates proteins provided
by genomic DNA, PurE (rectangle) and PurK (rounded rectangle). Proteins are shaded
according to origin E. coli (white) and A. aceti (grey). For deletion strains, genes which
have been deleted are denoted by a large black X. The third and fourth columns report
the plasmids used, and the proteins provided by those plasmids. Proteins are
represented by different shapes, Orf1 (oval), PurE (rectangle), PurK (rounded rectangle).
Proteins are shaded according to origin E. coli (white) and A. aceti (grey). In the
‘Growth’ column is the time taken for each culture to reach A600 = 0.3.
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Figure 4.7: Growth curves of strain CC0102 in minimal medium B. Strain CC0102 was
transformed with plasmids pNC2 (purEEcpurKEc open squares), pJK173
(orf1AapurEAapurKAa open triangles), or pJK347 (orf1AapurEH59DAapurKAa open circles).
Growth was not observed in cultures of CC0102/pUC118, CC0102/pJK348
(orf1AapurEH59NAapurKAa) or CC0102/pJK426 (purEH45NEcpurKEc) through 1000 h.
Growth was noted in all positive controls which were supplemented at 100 µg/mL
adenine (not shown).

Functional complementation of strain CC0101 (ΔpurEEc) in liquid minimal medium
B. Plasmids pJK173, pJK347, pJK348, pJK324, pJK412 and pNC2 were assessed for their
ability to restore prototrophy to strain CC0101 in minimal medium B. Plasmid pUC118
was used as a negative control. Positive controls contained exogenous purines in the
form of 100 µg/mL adenine. The results of these functional complementation studies
are shown in Figure 4.8, which is a summary of the growth curves shown in Figure 4.9.
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Figure 4.8: Schematic representation of strain CC0101 growth curves. Results of minimal
medium B growth curves shown in Figure 4.9. In the ‘Growth’ column is the time taken
for each culture to reach A600 = 0.3.

Figure 4.9: Growth curves of strain CC0101 in minimal medium B. Strain CC0101 was
transformed with pNC2 (open diamonds), pJK173 (filled squares), and pJK342 (open
circles). Strain CC0101 was also transformed with pUC118, pJK324, pJK348 and pJK412
but no growth was measured.

As expected, plasmids which contained active forms of PurE (pNC2, pJK173 and
pJK347) were able to restore prototrophy to strain CC0101. However, constructs that
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contained an active PurE but lacked PurK (pJK324 and pJK412) failed to restore
prototrophy to strain CC0101. Although this might indicate that purEAa requires purKAa
to function, later experiments (see following sections) indicate that a plasmid containing
just purEEc restores prototrophy to strain CC0101 poorly on solid and in liquid media.
This suggests that expression of purKEc is affected in strain CC0101. Because cultures
were only observed for 186 h, it is uncertain if growth would have been observed at a
later time. Additionally these cultures were inoculated from stationary phase cultures.
For all other liquid medium experiments, cultures were inoculated from log phase
cultures. Growth was noted at later time for CC0101 than with CC0102 when the strains
were transformed with the same plasmids (pJK173, entries 1 and 7; pJK347, entries 2
and 8; pNC2, entries 5 and 12). Although these results are from different strains, this
may indicate that cells taken during the log-phase are healthier.
Effects of purEEc and purEEcpurKEc constructs on the growth of strains CC0101,
CC1201 and CC1202 on solid media. EcPurE constructs were tested for their ability to
restore prototrophy to strains CC0101, CC1201 and CC1202 on solid medium A or solid
medium B. Experiments were performed on both types of media so the results of the
candle jar experiment with CC0101/pJK419 could be directly compared to the identical
conditions used with PC0135. As expected, both plasmids pJK419 (purEEc) and pNC2
(purEEcpurKEc) restored growth to the strains (Table 4.7). However, the degree to which
plasmid pJK419 restored growth was dependent on the strain.
Plasmid pJK419 supported the growth of strain CC1202 at levels similar to pNC2.
In strain CC1201, plasmid pJK419 allowed for growth at a slightly lower level, with small
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colonies being noted at 24 h. In strain CC0101, plasmid pJK419 gave much slower
growth with small colonies being noted at 72 h. At 72 h, the growth of the duplicate
plate of CC0101/pJK419 on solid medium A from the candle jar was observed, and
significantly larger colonies were found. This indicates that the deletion of purEEc in
strain CC0101 may have a polar effect on purKEc expression.
Table 4.7: Functional complementation studies of strains CC0101, CC1201, and CC1202.a
pNC2
pJK419
Strain
Medium
Medium
Medium
Medium
Medium
Ab (solid) Bb (solid) A (solid)
A (solid) + B (solid)
high CO2
c
CC0101 (ΔpurEEc)
++++
++++
+
++
+
CC1201 (purEEc<>purEAa)
++++
++++
+++
Nd
+++
CC1202
++++
++++
++++
Nd
++++
(purEEc<>purEAa(ATG))
a
A set of plates supplemented with exogenous purines in the form of 15 µg/mL
hypoxanthine for medium A or 100 µg/mL adenine for medium B. These controls gave
(++++) growth. b minimal media A and B as described in Experimental section. c key to
symbols: ++++, large colonies at 24 h; +++, small colonies at 24 h; ++, large colonies at 72
h; +, small colonies at 72 h; Nd, not determined.

Functional complementation studies of strain CC0101 (ΔpurEEc) in liquid minimal
medium. Plasmid pJK419 was assessed for its ability to restore prototrophy to strain
CC0101 in minimal medium B. The results are summarized in Figure 4.10, which is
based on the growth curve in Figure 4.11. The results are shown in reference to strain
CC0102/pNC2. Plasmid pJK419 was found to complement the auxotrophy less well than
pNC2 complemented CC0102. This indicates that the deletion of purEEc in strain CC0101
either has a polar effect on purKEc expression or the selective over expression of purEEc
inhibits growth.
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Figure 4.10: Schematic representation of strain CC0101 growth curves. Summary of
minimal medium B growth curves shown in Figure 4.11. In the ‘Growth’ column is the
time taken for each culture to reach A600 = 0.3, dash denotes that no growth was
observed up to 1000 h.

Figure 4.11: Growth curves for strain CC0101 in minimal medium B. The strain was
transformed with plasmid pJK419 (purEEc) Also shown for comparison is the growth
curve for CC0102/pNC2 from Figure 4.7. Strain CC0101/pJK419 (open squares); Strain
CC0102/pNC2 (open circles).

Study of wild type strain W3110. For comparison to other strains, the wild type
strain W3110 was transformed with pUC118 and its growth was observed in minimal
medium B. Plasmid pJK455 (orf1Aa) was also assessed for its effect on the growth of
strain W3110. Results are shown in Figure 4.12, which is a summary of growth curves
shown in Figure 4.13.
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The level of expression of each protein is expected to be based on the copy
number of the gene. Strain W3110 contains a genomic copy of purEEc and purKEc, and
will express the enzymes encoded at a level that is sufficient to support growth. Plasmid
pJK455 is a high-copy number plasmid. This means that when transformed with pJK455,
W3110 will contain many copies of the orf1Aa gene, and should express a comparatively
high level of the encoded protein.

Figure 4.12. Schematic representation of strain W3110 growth curves. Results of
minimal medium B growth curves shown in Figure 4.13. In the ‘Growth’ column is the
time taken for each culture to reach A600 = 0.3.

Figure 4.13: Growth of strain W3110 in minimal medium B. W3110 was transformed
with pUC118 (open squares) or pJK455 (open circles).
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Strain W3110/pUC118 grew rapidly after a short lag phase in minimal medium B.
However, when strain W3110 was transformed with pJK455 (orf1Aa), the culture grew
more slowly (Figure 4.13). The effect of pJK455 on strain W3110 is different than in
other strains reported below.
Study of strains CC0102 (ΔpurEEcΔpurKEc), CC0103 (ΔpurKEc), CC1203
(purKEc<>purKAa), CC1204 (purEEcpurKEc<>purEAapurKAa) and CC1205
(purEEcpurKEc<>purEAa(ATG)purKAa) on solid medium B. The ability of strains CC0102,
CC1203, CC1204 or CC1205 to grow on solid medium B was assessed (Table 4.8). As
expected, strain CC0102/pUC118 and CC0103/pUC118 failed to grow without the
addition of exogenous purines. Surprisingly, strains CC1204/pUC118 and
CC1205/pUC118 failed to grow in the time that the plates were observed, while strain
CC1203/pUC118 and CC0102/pJK173 grew rapidly.
The difference seen between the purKAa replacement strain (CC1203/pUC118),
and the purEAapurKAa double replacement strains (CC1204/pUC118 and
CC1205/pUC118) could be due to several possibilities. The replacement of purEEc with
purEAa could change regulatory elements required for purK expression. However, the
expression level of purKEc in strains CC1201 and CC1202 (Table 4.7) is high enough to
support growth on solid medium B when a source of purEEc is provided. This suggests
that the level of expression of purKAa in the double replacement strains should be
adequate to support growth. Another possibility is that AaPurE is not as active as
EcPurE. However, both enzymes have been purified, and exhibit similar in vitro activities
(Chapter 3) (23).
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An alternate possibility requiring association of proteins in that PurE takes part in
a multi-enzyme complex with other enzymes in purine biosynthesis. The replacement of
EcPurE with AaPurE leads to a failure of the formation of this complex that can be
compensated by the increased expression of AaPurE from a plasmid. This would allow
for CC0102/pJK173 to grow, although CC1204/pUC118 and CC1205/pUC118 do not.
An additional possibility is that strains CC1204 and CC1205 do not contain all of
the genes which allow plasmid pJK173 to restore prototrophy to deletion strain CC0102.
Contained within the insert of pJK173 is the gene orf1. The product of this gene may be
required for the proper functioning of AaPurE and AaPurE as will be discussed in greater
detail later.

Table 4.8: Assessment of the ability of strains CC0102, CC0103, CC1203, CC1204 and
CC1205 to grow on solid medium B.
Strain/plasmid
Medium B
Medium B +
(solid)
Adenine (solid)
CC0102 (ΔpurEEcΔpurKEc)/pUC118
+++
CC0102 (ΔpurEEcΔpurKEc)/pJK173
+++
+++
CC0103 (ΔpurKEc)/pUC118
+++
CC1203 (purKEc<>purKAa)/pUC118
+++
+++
CC1204 (purEEcpurKEc<>purEAapurKAa)/pUC118
+++
CC1205
+++
(purEEcpurKEc<>purEAa(ATG)purKAa)/pUC118
a
key to symbols: +++, colonies noted at 30 h which become large (> 2mm) by 60h; -, tiny
colonies which do not increase in size with time up to 120 h.

Study of strains CC1201 and CC1202, strains with the precise gene replacement
of purEEc with purEAa. Strain CC1202 (purEEc<>purEAa(ATG)) was chosen for the focus of this
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study because it began with the same start codon as purEEc. This can affect expression
levels; generally, ATG gives a higher expression level than GTG or other codons (25).
Plasmids pJK348, pJK419, pUC118, pJK173 or plasmids containing portions of the
A. aceti genome contained in the insert of plasmid pJK173 (pJK324, pJK412, pJK415 and
pJK455) were assessed for their effect on insert strains CC1202 in minimal medium B. In
this experiment, the purEEc deletion strain CC0101 transformed with pUC118 was used
as a negative control. The results of these experiments are summarized in Figure 4.14,
which includes an illustration of the inserts for each plasmid. Figure 4.14 is a summary
of Figure 4.15, which was determined from the growth curves shown in Figures 4.16.
The level of expression of each protein is expected to be based on the copy
number of the gene and may be affected by the start codon of the gene. Strain CC1202
contains a genomic copy of purEAa(ATG). This gene starts with an ATG start codon and
should express AaPurE at similar levels to EcPurE in strain W3110. Strain CC1202
contains a genomic copy of purKEc and is expected to express EcPurK at a level similar to
W3110.
Plasmid pJK419 is derived from the moderate-copy number protein expression
vector pET23a. All of the plasmids carrying A. aceti genes are based on the high copy
number vector pUC118. These plasmids should provide many copies of the introduced
genes, and lead to an increased level of expression for the encoded proteins.
Strain CC1202/pUC118 grew after a prolonged lag phase indicating inefficient
synthesis of purines. Although growth after a prolonged period could indicate
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contamination by other bacteria, we note that the negative control CC0101/pUC118 did
not show growth at 1000 h.

Figure 4.14: Illustration of plasmids used in growth experiments and summary of lag
phases from Figure 4.15.
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Figure 4.15: Schematic representation of strain CC1202 growth curves. Results of
medium B growth curves shown in Figure 4.16. In the ‘Growth’ column is the time taken
for each culture to reach A600 = 0.3.

Figure 4.16: Growth curves for strain CC1202 in minimal medium B. Strain CC1202 was
transformed with pUC118 (empty vector control, filled triangles); pJK419 (purEEc, open
diamonds); pJK173 (orf1AapurEAapurKAa, open circles); pJK348 (orf1AapurEH59NAapurKAa,
open squares); pJK412 (orf1AapurEAa, open triangles); pJK324 (purEAa, filled circles);
pJK415 (orf1AapurKAa, filled squares); pJK455 (orf1Aa, filled diamonds).
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The CC1202/pJK419 culture was found to grow rapidly. The CC1202/pJK419
culture grew at a rate similar to that seen for the ∆purEEc∆purKEc deletion strain
CC0102/pNC2 (entry 4), and W3110/pUC118 (entry 16). This indicates that the
substitution of purEEc with purEAa does not have a polar effect on the expression of
genomic purKEc. This indicates that the cause of the prolonged lag phase seen in
CC1202/pUC118 is due to purEAa(ATG) and not to an unforeseen polar effect on purKEc.
The addition of plasmid pJK173 (orf1Aa purEAa purKAa) resulted in CC1202 having
a shorter lag phase than CC1202/pUC118. This was expected because plasmid pJK173
restores prototrophy to the ∆purEEc∆purKEc deletion strain CC0102. Clearly AaPurK and
AaPurE are functional in E. coli.
The addition of plasmid pJK324 (purEAa) resulted in CC1202 having a shorter lag
phase. The effect of pJK324 was similar to that of pJK173 (orf1Aa purEAa purKAa). This
indicates that increased expression of AaPurE allows for the cause of the prolonged lag
phase to be overcome. While at first it would appear that the cause of the prolonged
lag phase seen in CC1202/pUC118 could be due to either poor expression or low activity
of the genomic purEAa(ATG), a different result is seen when added purEAa is provided by
plasmid pJK412 (see next paragraph).
While the addition of plasmid pJK412 (orf1AapurEAa) resulted in strain CC1202
having a shorter lag phase than CC1202/pUC118, this plasmid complemented less
efficiently than pJK324 or pJK173.
The addition of plasmids that contain purKAa also decreased the lag phase of
strain CC1202. The addition of pJK348 (orf1Aa purEH59NAa purKAa) shortened the lag
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phase of strain CC1202 despite the presence of an entirely inactive AaPurE, and
complemented almost as well as pJK173. The addition of pJK415 (orf1AapurKAa) reduced
the lag phase, but this culture grew more slowly and to a lower total cell density than
CC1202/pJK348.
Plasmid pJK455 (orf1Aa) caused an increase in the lag phase of strain CC1202.
This indicates that AaOrf1 exacerbates the cause of the lag phase. In CC1202/pJK455,
the amount of AaOrf1 produced should be significantly higher than the AaPurE and
EcPurK produced from the genome.
Study of strain CC1203, a strain with the precise gene replacement of purKEc with
purKAa. Strain CC1203 (purKEc<>purKAa) was transformed with pUC118 and grown in
minimal medium B. The growth of CC1203/pUC118 was compared to W3110/pUC118
(Figures 4.17 and 4.18). Strain CC0102/pUC118 was used as a negative control.
Strikingly, CC1203/pUC118 grew rapidly, with a profile similar to W3110/pUC118. Thus
the substitution of EcPurK with AaPurK has almost no effect, in marked contrast with
the corresponding PurE substitution (entry #18).

Figure 4.17. Schematic representation of strain CC1203 and W3110 growth curves.
Results of minimal medium B growth curves shown in Figure 4.18. In the ‘Growth’
column is the time taken for each culture to reach A600 = 0.3.
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Figure 4.18: Growth of strain CC1203 and W3110 in minimal medium B. Strain W3110
(open squares) and strain CC1203 (open circles) were transformed with pUC118.

Study of strain CC1204, a strain containing a precise gene replacement of
purEEcpurKEc with purEAapurKAa. Plasmids pJK173, pJK455 and pUC118 were assessed for
their effect on strain CC1204 (purEEcpurKEc<>purEAapurKAa). These experiments were
performed at the same time as entries 26 and 16). The results of this experiment are
shown in Figure 4.19, which is a summary of the growth curves shown in Figure 4.20.
The level of expression of each protein is expected to be based on the copy
number of the gene and may be affected by the start codon of the gene. Strain CC1204
contains a genomic copies of purEAa and purKAa. Because purEAa begins with a GTG start
codon, the level of expression of AaPurE in strain CC1204 should be somewhat lower
than EcPurE in strain W3110. The reduced expression level of purEAa may cause a
reduction in the expression level of the genomic purKAa.
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Figure 4.19. Schematic representation of strain CC1204 and W3110 growth curves.
Results of minimal medium B growth curves shown in Figure 4.20. In the ‘Growth’
column is the time taken for each culture to reach A600 = 0.3.

Figure 4.20: Growth curves for strain CC1204 and W3110 in medium B. Strain CC1204
was transformed with plasmids pJK173 (orf1AapurEAapurKAa, open diamonds), pJK455
(orf1Aa, open triangles) or pUC118 (empty vector control, open squares). Strain W3110
was transformed with pUC118 (open squares). The growth curve for W3110/pUC118 is
also shown in Figure 4.18.

Plasmids pJK455, pJK173 and pUC118 are all high-copy number plasmids. When
transformed with pJK455 and pJK173, strain CC1204 will contain many copies of the
genes encoded by the plasmid, and thus should have increased expression of these
proteins.
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When transformed with pUC118, strain CC1204 grew but only after a very long
lag phase. This lag phase was longer than that seen with CC1202/pUC118, and was
longer than the lag phase seen with CC1205/pUC118 below. This is consistent with a
lower level of expression of purEAa.
Plasmid pJK173 reduced the lag phase in strain CC1204. The growth seen in
CC1204/pJK173 was similar to the growth seen previously in other strains transformed
with pJK173 and indicates that the increased levels of AaOrf1, AaPurE, and AaPurK
compensate for whatever deficiency causes the prolonged lag phase.
Surprisingly plasmid pJK455 caused an increase in the lag phase of strain CC1204.
This indicates that AaOrf1 exacerbates the cause of the lag phase. In strain
CC1204/pJK455, the amount of AaOrf1 produced should be significantly greater than
the AaPurE and AaPurK produced from the genome.
Study of strain CC1205, a strain containing a precise gene replacement of
purEEcpurKEc with purEAa(ATG)purKAa. Plasmids pJK348, pJK419, pUC118, pJK173 or
plasmids containing portions of the insert of plasmid pJK173 (pJK324, pJK412, pJK415
and pJK455) were assessed for their effect on replacement strain CC1205
(purEEcpurKEc<>purEAa(ATG)purKAa) in minimal medium B. The results of these
experiments are summarized in Figure 4.21, which includes an illustration of the inserts
for each plasmid. Figure 4.21 is a summary of Figures 4.22 and 4.24, which were
determined from the growth curves shown in Figures 4.21 and 4.23.
Strain CC1205 contains a genomic copy of purEAa and purKAa. In strain CC1205
the genomic purEAa has an ATG start codon, and should express purEAa at a similar level
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to EcPurE in W3110. Because the purEAa gene starts with an ATG start codon, this strain
would be expected to express purKAa at similar levels to purKEc in W3110 and CC1202.
Qualitatively similar results were obtained with CC1204 and CC1205 indicating the start
codon for purEAa has a relatively subtle effect.
Slightly different times were noted for strain and plasmid combinations in
separate experiments. This difference is likely due to the slight variation in disturbing
the shaking incubator. In experiments reported in Figures 4.24 and 4.25, more flasks
were being grown, requiring the shaking incubator to be disturbed more often.

Figure 4.21: Illustration of plasmids used in growth experiments and summary of lag
phases from Figure 4.22 (first growth column) and Figure 4.24 (second growth column).
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Figure 4.22. Schematic representation of strain CC1205 and W3110 growth curves.
Results of minimal medium B growth curves shown in Figure 4.23. In the ‘Growth’
column is the time taken for each culture to reach A600 = 0.3.

Figure 4.23: Growth curves for strain CC1205 and W3110 in medium B. Strain CC1205
was transformed with plasmids pJK173 (orf1AapurEAapurKAa, open diamonds), pJK455
(orf1Aa, open triangles) or pUC118 (empty vector control, open squares). Strain W3110
was transformed with pUC118 (open squares). The growth curve for W3110/pUC118 is
also shown in (Figure 4.18).
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Figure 4.24: Schematic representation of strain CC1205 growth curves. Results of
medium B growth curves shown in Figure 4.25. In the ‘Growth’ column is the time taken
for each culture to reach A600 = 0.3.

Figure 4.25: Growth curves for strain CC1205 in medium B. The strain was transformed
with plasmids pUC118 (empty vector control, filled triangles); pJK419 (purEEc, open
diamonds); pJK173 (orf1AapurEAapurKAa, open circles); pJK348 (orf1AapurEH59NAapurKAa,
open squares); pJK412 (orf1AapurEAa, open triangles); pJK324 (purEAa, filled circles);
pJK415 (orf1AapurKAa, filled squares); pJK455 (orf1Aa, filled diamonds).
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Plasmid pJK419 is derived from the moderate-copy number vector pET23a. All of
the plasmids carrying A. aceti genes are made from the high copy number vector
pUC118. All plasmids provide many copies of genes present, and should show an
increased level of expression for encoded proteins.
When transformed with pUC118, strain CC1205 grew after a prolonged lag
phase. While growth after a prolonged period may indicate contamination by other
bacteria, the negative control for each set of experiments did not show any growth at
1000 h (for Figure 4.23 the negative control was CC0102/pUC118, for Figure 4.25 the
negative control was CC0102/pJK348).
When strain CC1205 was transformed with plasmid pJK419, the culture grew
rapidly. This indicates the deficiency is in apparent PurE activity. The CC1205/pJK419
culture grew at a rate similar to that seen for the ∆purEEc∆purKEc deletion strain
CC0102/pNC2 (entry 4), the purEAa(ATG) insert strain CC1202/pJK419 (entry 25), the
purKAa insert strain CC1203/pUC118 (entry 26) and the wild type strain W3110/pUC118
(entries 16 and 35). A secondary result is that the substitution of purEEc with purEAa does
not have a polar effect on the expression purKAa, which is expressed in active form.
The addition of plasmid pJK173 (orf1Aa purEAa purKAa) to CC1205 resulted in a
shorter lag phase. This was expected as plasmid pJK173 restores prototrophy to the
deletion strain CC0102.
The addition of plasmid pJK324 (purEAa) to CC1205 conferred more rapid growth.
The effect of pJK324 was similar to that of pJK173. This indicates that increased
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expression of AaPurE allows for cross-complementation. This result is similar to the
result seen with CC1202/pJK324.
The addition of pJK412 (orf1AapurEAa) to strain CC1205 had a similar effect to the
addition of either pJK324 or pJK173. These results are different from those found in
CC1202. The subtle difference in results seen appear to be dependent on the form of
purK present in the genome of each strain.
The addition of plasmids containing both orf1Aa and purKAa also decreased the
lag phase of strain CC1205. The addition of pJK348 (orf1Aa purEH59NAa purKAa)
shortened the lag phase of strain CC1205, and allowed for complementation similar to
pJK173. The addition of pJK415 (orf1AapurKAa) reduced the lag phase, but the culture
grew more slowly and to a lower total cell density than CC1205/pJK348.
Plasmid pJK455 (orf1Aa) caused an increase in the lag phase of strain CC1205.
This indicates that AaOrf1 exacerbates the cause of the lag phase. In strain
CC1205/pJK455, the amount of AaOrf1 produced should be significantly higher than the
AaPurE or AaPurK produced from the genome. This is very similar to the comparable
results with CC1202 (entry #24) and CC1204 (entry # 29).
Observation of phenotype. When the insert and deletion strains are
transformed with plasmids that lack purEEc, satellite colonies begin to form after ~14 h
of growth on LB/Amp. Due to this, colonies for starter cultures were picked at or before
12 h incubation. Liquid minimal medium experiments also developed a light yellow
color at later time points in growth curves. This is probably due to contamination at
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later time points, but contamination does not affect the finding of when initial growth
was observed.
4.4 Discussion
Gene context and expression. To study the purE-purK operon of A. aceti in detail,
a series of new strains were needed. These strains were designed to create defined
systems that would contain a single copy of each gene. For the gene replacement
strains, the strains were designed to contain A. aceti genes in the precise location of
their E. coli counterparts. This was done to ensure that these genes would be expressed
at the same level and would be under the same regulation as their E. coli counterparts
in strain W3110.
The expression level of a gene will depend on several factors that were carefully
controlled in the current study. One is the number of copies of the gene present. For
genomic copies, there will be a single copy per cell. For W3110 and the replacement
strains, each contains one copy of a purE gene and one copy of a purK gene. When a
gene is contained on a plasmid, the number of copies of that gene present in a cell will
depend on the copy number of the plasmid.
The moderate- and high-copy number vectors pET23a or pUC118 were used for
all plasmids in the functional complementation (pET23a was used to construct pNC2,
pJK419, pJK426 and pJK435 all of which contain E. coli genes; pUC118 was used to
construct all plasmids containing A. aceti genes). The pET23a vector was used for E. coli
genes because they are homologous to wild type genes and should be expressed well.
Additionally, previous studies of PC0135 involved the pET23a derived pNC2. Cells
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containing the pET23a and pUC118 derived plasmids will contain hundreds of copies of
each gene present in the insert. The increased number of genes should give an
expression level that is significantly higher than that from single-copy genomic inserts.
The start codon of a gene will also affect the expression level of a protein. While
most bacterial genes start with an ATG start codon, some start with an alternative
codon. Among the alternative start codons, GTG is the most common (25). For the ATG
start codon, all three nucleotides are complementary to the Met initiator tRNA
anticodon (25). For the GTG start codon, only two of the nucleotides are complementary
to the initiator anticodon (25). Thus a gene with an ATG start codon should be expressed
at a higher level than the same gene with a GTG codon. Due to the difference in start
codons, replacement strains CC1201 and CC1204 would be expected to express less
purEAa than replacement strains CC1202 or CC1205.
Polar effects can significantly impact levels of expression. In the translationally
coupled trp operon, the early termination of one gene can lead to an up to 98%
reduction in the detectable activity of enzymes encoded by the genes that follow (1).
This was more difficult to control in the current experiments, given that the effects of
the different purK control sequences within purEAa are unknown.
Characterization of auxotrophic strains PC0135. The cause of the purE
auxotrophy in strain PC0135 has been found to be a single point mutation which
changes residue Trp151 in EcPurE to a premature stop codon (TGG  TGA). This results
in the deletion of the protein’s final helix, which has extensive interaction with the other
subunits in the octamer. This led to speculation that this truncated protein allows low168

level complementation by the apparently completely inactive mutants EcPurEH45N and
AaPurEH59N (18, 23).
To explore this possibility, strain CC0102 (∆purEEc∆purKEc) was designed to
remove the entire purEEcpurKEc coding region in the genome. This created a strain that
lacked any form of EcPurE. As expected, plasmids containing the completely inactive
mutants purEH59NAa (pJK348: orf1AapurEH59NAapurKAa) and purEH45NEc (pJK426:
purEH45NEcpurKEc) failed to restore prototrophy in strain CC0102. These results indicate
that these mutants lack sufficient in vivo activity to support growth, which was expected
from the lack of any detectable in vitro activity for these mutants (Chapter 3)(23).
The results from PC0135/pJK426 and CC0102/pJK426 are consistent with the
proposal that the truncated EcPurE encoded by PC0135 is stabilized by the expressed
inactive mutants EcPurEH45N leading to complementation. Although most of the
following work was done with minimal medium B, solid media experiments with
CC0102/pJK426 were also done on same medium as the other PC0135 experiments
(minimal medium A). Using this medium controls for the possibility that the difference
in media had an effect on functional complementation.
The outcome of the investigation of strain PC0135 also suggests that that the
point mutation has a polar effect on the expression of purKEc. The addition of single
construct EcPurE (pJK419) did not restore growth as well as the addition of the dual
construct purEEcpurKEc plasmid pNC2. Although the slow growth of PC0135/pJK419
could be due to the effect of increased expression of EcPurE, a similar effect is not seen
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with pJK419 in replacement strains CC1202 and CC1205 which contain an uninterrupted
purE.
Because strain PC0135 has been shown to have a leaky purE phenotype that
appears to have a polar effect on the expression of purK, no further studies were
performed with this strain.
Factors to consider from purine biosynthesis. The de novo biosynthesis of
purines is not an isolated pathway.
The biosynthesis of the cofactor thiamine uses an intermediate from purine
biosynthesis. Isotopic labeling experiments in E. coli have shown that the aminomethyl-pyrimidine ring of thiamine derives from AIR (26, 27). Although the
consumption of AIR in the synthesis of thiamine should be small, care was taken to
supplement the minimal media with thiamine. This was done to ensure that thiamine
deficiencies did not affect our results in any way.
Although IMP can be synthesized starting with 5-phosphoribosyl 1pyrophosphate, it is not the only inlet into purine biosynthesis. AICAR, the substrate of
the final enzyme in the synthesis of IMP, is also produced during the de novo synthesis
of histidine. If E. coli is grown in minimal media, and the final two steps of the purine
biosynthesis are blocked by chemical inactivation, AICAR accumulates.
Supplementation of the media with histidine causes a 45% reduction in accumulated
AICAR (28). This reduction is likely due to feedback inhibition of histidine biosynthesis,
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and indicates that histidine biosynthesis can have a significant contribution to purine
biosynthesis.
Assessment of growth experiments. Most of the strain and plasmid
combinations have only been grown once, so caution is advised. Experiments that have
been repeated more than once yielded similar lag times (W3110/pUC118, entries #16
and #27; CC1205/pUC118, entries #31 and #34; CC1205/pJK455, entries #32 and #40;
CC1205/pJK173, entries#33 and #39). Moreover, experiments in strain CC1202
(purEEc<>purEAa) and CC1205(purEEcpurKEc<>purEAapurKAa) generally yield similar results,
supporting conclusions obtained with these two closely related strains. In the case of
the difference in growth between CC1202/pJK412 (entry #20) and CC1205/pJK412
(entry #36), this observation has been observed once and should be confirmed.
Prolonged lag phase. Typically upon inoculation into minimal media, E. coli cells
quickly acclimate during a brief lag phase and begin to divide. During this lag phase,
bacteria produce the enzymes required for the production of all of the compounds
necessary for growth formally provided in the richer media in which they were first
grown. The lack of growth for some strain-plasmid combinations (CC0102/pJK348, entry
#3; CC0102/pUC118, entry #6; CC0102/pJK426, entry #5) and the different length of lag
phase for various strains and plasmid combinations in minimal media made it
impractical to inoculate observed cultures from starter cultures grown in minimal
media.
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Although it could be possible that contamination by another bacterium could
lead to growth seen at later time points, this seems unlikely for several reasons. 1)
Following inoculation, for all but one experiment, flasks were not opened until growth
was noted. 2) Several combinations of strains and plasmids in minimal medium B
reproducibly did not grow in 1000 h. 3) Strain CC1205 was transformed with pUC118
and pJK455 in two separate experiments, and in both experiments growth was noted at
a similar time. 4) Most cultures grew to a similar density. If contamination were to
cause the growth seen at later time points in the case of the replacement strains that
contain purEAa transformed with either pUC118 or pJK455, the results would still
indicate that there is a problem in purine biosynthesis, and that the addition of orf1Aa
from pJK455 does not remedy this problem.
Extended lag phases in E. coli are often noted as a response to environmental
stresses or toxic substances (29-31). The extended lag phase seen in purEAa insert
strains is unusual in that it is observed in minimal media under normal conditions. A
search of the literature found evidence of one other strain of E. coli, MH812, which
exhibits a prolonged lag phase when grown in minimal media (32). This strain contains a
mutation in the promoter region of the gene for dihydrofolate reductase (DHFR), folA,
which leads to an overproduction of DHFR. The extended lag phase in this strain is ~20 h
longer than the lag phase seen with wild type E. coli strain MG1655, and is observed
when the strain is grown at 42 °C.
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A possible cause of the lag phase. The replacement of purEEc with purEAa may
result in a decreased production of purines through purine biosynthesis. During the
acclimation to minimal media, these purEAa replacement strains may not adequately
supply enough purines to support rapid replication of DNA and synthesis of RNA for
newly transcribed genes, resulting in a prolonged lag phase. If histidine biosynthesis
increases once cells begin to divide, this may provide enough AICAR to supplement the
AICAR produced through purine biosynthesis and support rapid growth. For these
reasons we suggest that the lag phase is the most reliable indicator or a problem in
purine biosynthesis. However, there may be additional information that could be
gleaned from strains that grow slowly after the end of the lag phase, or that grow to
lower final densities.
Metabolite channeling. For channeling of a metabolite between two enzymes to
occur, a ternary complex of the two enzymes and the metabolite must form. This
means that the two enzyme must interact. This interaction may be transient and of a
duration that allows for metabolite transfer.
In vivo evidence of metabolite channeling is difficult to obtain. If proteins are
shown to associate in vivo, this only shows that channeling may occur. The best
evidence of channeling is found in vivo experiments using the technique of isotopic
dilution with either cell components (33, 34) or intact cells (35). This technique utilizes
an isotopically labeled precursor, and an unlabeled (or differently labeled) intermediate.
Low incorporation of the unlabeled intermediate into the final product suggests that the
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intermediate formed from the precursor does not freely dissociate into solution.
Evidence for metabolite channeling can also be found if a reaction results in a symmetric
intermediate (36). If an isotopically labeled precursor is converted to a symmetric
intermediate, non-random scrambling of the label in the final product suggests that the
intermediate is not free in solution.
The possibility that metabolite channeling may occur between PurE and PurK is
an appealing proposal. This is because PurK hydrolyzes ATP to produce the acid labile
N5-CAIR. If N5-CAIR were not used efficiently, decarboxylation of N5-CAIR to reform the
starting substrate AIR would waste energy. This is a particularly acute concern in the
acidophile A. aceti.
When the initial functional complementation studies of PC0135 with A. aceti
genes were published (18), great care was taken to say that the results of the
experiments suggest that AaPurK is needed for the proper functioning of AaPurE.
Another group interpreted those same results to imply that AaPurE could not accept N5CAIR from EcPurK (23). This was specifically not stated for many reasons. There are
several ways an enzyme could require another enzyme to function without channeling.
One possible requirement of a protein for another is that association of the two is
required in vivo for activity without channeling. However, the main reason we did not
claim to have evidence for channeling, is that strain PC0135 has a leaky phenotype.
Subsequently we realized that AaOrf1 might have a role in functional complementation.
At the time results were reported it was stated that experiments were planned to
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address the possible requirement of AaPurE for AaPurK. Those experiments are
discussed below.
The purEAa and purEAapurKAa replacement strains were created to explore the
unusual finding that PC0135/pJK324 has an unexpected purK- phenotype. This
suggested that the substrate of AaPurE (N5-CAIR) might not be produced in a usable
manner by EcPurK, and could be a sign of substrate channeling from PurK to PurE. One
way this could occur is if N5-CAIR does not freely dissociate from the enzyme in the
absence of EcPurE after it is produced.
Singly expressed AaPurE has been successfully isolated as active enzyme by
overexpression in E. coli (Chapter 3). This indicates that this enzyme should be
expressed as an active protein from the genome. The fact that the CC1202 (purEEc<>
purEAa), CC1204 (purEEcpurKEc<>purEAapurKAa), and CC1205 (purEEcpurKEc<>purEAa(ATG)
purKAa) replacement strains grow, albeit after a prolonged lag phase, indicates the
AaPurE is expressed as an active protein from the genomic level under normal
atmosphere.
Because the purKAa replacement strain CC1203 grows rapidly in minimal media,
AaPurK is expressed as an active enzyme from the genomic level. This also indicates that
AaPurK can serve as a source of N5-CAIR for EcPurE. This could occur either by AaPurK
releasing N5-CAIR into solution, or by EcPurE being able to accept N5-CAIR if channeling
is occurring. The identity of PurK seems to make no difference.
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Although the purKAa replacement strain CC1203 does grow well, the double
replacement strains that contained purEAapurKAa failed to grow better than the purEAa
single replacement strain CC1202. This means that the protein mismatch between
AaPurE and EcPurK is not adequate to explain CC1202 growth deficiency as would be
expected in a channeling model. While AaPurK provided adequate N5-CAIR for EcPurE, it
failed to provide adequate N5-CAIR for AaPurE. While these results do not preclude the
possibility of substrate channeling in E. coli PurE and PurK, they indicate that AaPurK can
partner with either EcPurE or AaPurE. These results suggest that the biosynthesis of
CAIR may be different in A. aceti, and they lead us to consider the possible involvement
of orf1Aa.
Reasons for the possible involvement of AaOrf1. The possibility of an additional
protein involved in the biosynthesis of CAIR raises several interesting possibilities. All of
these possibilities reduce the potential loss of N5-CAIR by decarboxylation.
There are several possible roles that AaOrf1 could serve:
(1) AaOrf1 could serve as an N5-CAIR binding protein. AaOrf1 would either bind
N5-CAIR in solution or accept it directly from AaPurK and protect it from
decarboxylation. AaOrf1 would then associate with AaPurE to deliver N5-CAIR.
(2) AaOrf1 could be an additional subunit of AaPurE. AaPurE would bind N5-CAIR
poorly in the absence of AaOrf1.
(3) AaOrf1 could bind AaPurE and prevent the production of CAIR in the absence
of AaPurK. The production of CAIR may thus be dependent on a three protein complex.
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(4) AaOrf1 could bind AaPurK and prevent the production of N5-CAIR in the
absence of AaPurE. The production of N5-CAIR may thus be dependent on a three
protein complex.
(5) AaOrf1 could serve as a scaffold for the assembly of a
AaOrf1:AaPurE:AaPurK complex. This complex could be transient and result in the
channeling of N5-CAIR, from AaPurK to AaPurE, without a direct interaction between
AaOrf1 and N5-CAIR. This complex could also be stable and result in the co-localization
of PurE and PurK activities.
(6) AaOrf1 is a transcriptional regulator of AaPurE.
Models 3 and 4 will be similar to model 5 if a three-protein complex of
AaOrf1:AaPurE:AaPurK is required. The main difference in these models is if AaOrf1
associates with AaPurK or AaPurE prior to complex formation
If AaOrf1 is required for the proper function of either AaPurE or AaPurK
individually (models 2-4), systems without orf1Aa paired with its partner would give a
pur phenotype.
If AaOrf1 were part of a three-protein complex with AaPurE and AaPurK (models
3-5), systems lacking any of the three would give a pur phenotype. In this case, the
relative amounts of AaOrf1, AaPurE, and AaPurK may be important.
If AaOrf1 serves as an N5-CAIR binding protein (model 1), the absence of AaPurE
or AaPurK could result in a pur phenotype.
If AaOrf1 allows for a complex of PurE and PurK to form (models 3, 4 and 5),
CAIR may be produced more efficiently. In this complex N5-CAIR could be transferred
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without dissociation into the cytoplasm. If AaOrf1 binds N5-CAIR, it could prevent
decarboxylation (model 1). If AaOrf1 prevents the activity of one component in the
absence of the other, energy would not be wasted by the production of N5- CAIR when it
is not needed (models 3 and 4).
Although much emphasis has been focused on the fate of N5-CAIR, the fate of
CAIR must also be considered. PurE catalyzes the readily reversible transfer of the
carboxylate of N5-CAIR from the exocyclic amino group, to the C4 position. PurE also
catalyzes the conversion of CAIR back to the more acid-labile N5-CAIR. This effect could
be more detrimental to A. aceti which maintains an acidic cytoplasm. If the activities of
these enzymes are coupled through channeling or association (models 3 and 5), an
additional benefit could occur. If AaPurE is only active in vivo in a complex, this would
reduce the possible loss of CAIR by the back-reaction to N5- CAIR  AIR + CO2.
Narrowing the possible role of AaOrf1. The possibility that orf1 affects purine
biosynthesis led to a series of experiments with the replacement strains CC1202
(purEEc<>purEAa(ATG)) and CC1205 (purEEcpurKEc<>purEAa(ATG)purKAa). For both strains, the
effect that different portions of the insert of pJK173 had on their growth was assessed,
along with plasmids pJK419, pJK348 and pUC118.
In both strains, the addition of pJK419 (purEEc) restored growth similar to that of
wild type strain W3110 (Figure 4.26), indicating there is a supply of N5-CAIR adequate to
support growth. The purKEc<>purKAa replacement strain also grew rapidly and at a rate
similar to strain W3110. Although this does not rule out any of the models, it does
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indicate that the reason the replacement strains that contain purEAa grow poorly is due
to impaired functioning of AaPurE in E. coli.

Figure 4.26: Comparison of growth curves of strains with a source of EcPurE. CC1202
(purEEc<>purEAa(ATG))/pJK419 (entry #25, open circles), CC1205
(purEEcpurKEc<>purEAa(ATG)purKAa)/pJK419 (entry #31, open squares),
CC1203(purKEc<>purKAa )/pUC118 (open diamonds), W3110/pUC118 (separate
experiments, open and filled downward triangles).

The effects of the addition of pJK173 will be used as a reference for the
comparisons that follow. The addition of plasmid pJK173 to strains CC1202 and CC1205
gave similar growth profiles (Figure 4.27). Although this finding does not rule out any of
the models, it does indicate that an increase in the products of orf1Aa, purEAa(ATG), and
purKAa compensates for the problem in replacement strains that contain purEAa.
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Figure 4.27: Comparison the effect of pJK173. The growth curves of replacement strains
CC1202 (entry #23, open circles) and CC1205 (entries #33 and #39, open and filled
squares respectively) transformed with pJK173 (orf1AapurEAapurKAa).

For both strains, the addition of pJK455 (orf1Aa) produced an increased lag phase
compared to pUC118 (Figure 4.28). Plasmid pJK455 contains the beginning portion of
the insert of pJK173 including orf1Aa and a portion of AaPurE (the first 64 amino acids of
AaPurE fused to the α-LacZ fragment of pUC118). This portion of AaPurE is too small to
contribute an activity. An increased lag phase was also seen in the double replacement
strain CC1204 with pJK455 in comparison to pUC118. These results are different from
the effect of pJK455 in strain W3110, which showed only a subtle growth inhibition
(Figures 4.12 and 4.13).
While pJK455 slowed the growth of W3110, it did not produce an increased lag
phase. This suggests that the effect of AaOrf1 is dependent on the identity of purE.
While plasmid pJK455 has the same effect on strains CC1202 and CC1205, one cannot
eliminate the possibility that AaOrf1 interacts with both AaPurE and AaPurK. It is
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unknown what the effect of increased concentration of one product would have if
association of the proteins occurs.

Figure 4.28: Comparison of effects of pUC118 and pJK455. Strains were transformed
with pUC118 (empty vector) or pJK455 (orf1Aa). W3110/pJK455 (entry # 17, filled right
triangles), W3110/pUC118 (entry #16, open right triangles), Strain CC1205/pJK455
(entries #32 and #40, filled circles and squares), Strain1205/pUC118 (entries #31 and
#34, open circles and squares), Strain CC1202/pJK455 (entry #24, filled isosceles
triangle), and Strain CC1202/pUC118 (entry #18, open isosceles triangles).

For both strains, the addition of pJK412 (orf1AapurEAa) caused a reduction in the
lag phase (Figure 4.29). Although plasmid pJK412 reduced the lag phase in both strains,
it had slightly different effects. In strain CC1205, which contains purKAa, the growth
obtained is comparable to fully complemented strain CC1205/pJK173. In strain CC1202,
which contains purKEc, slower growth was noted than in the fully complemented
CC1205/pJK173. This indicates the effect of AaOrf1 depends on the identity of purK but
to a lesser degree than on the identity of purE. These results coupled with the results of
pJK455 indicate that the effect of AaOrf1 depends upon the identity of both purE and
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purK. This is inconsistent with model 2, in which AaOrf1 is an additional subunit of
AaPurE (model 2). This model is also inconsistent with the observation that pure
AaPurE isolated from E. coli is as active as EcPurE.

Figure 4.29: Comparison of the effect of pJK412. Shown are the growth curves of
replacement strains CC1202 (entry #20, open circles) and CC1205 (entry #36, open
squares) transformed with pJK412.

The addition of pJK415 (orf1AapurKAa) had a similar effect in both single- and
double-replacement strains (Figure 4.30). Although the lag phase was reduced, both
strains grew slowly. A consideration of these results is included with those obtained
using pJK348 (below).
In both strain CC1202 and CC1205, the addition of plasmid pJK348
(orf1AapurEH59NAapurKAa) had a similar effect (Figure 4.30). The lag phase was reduced,
and both strains grew rapidly. The growth was similar to growth curves obtained using
the fully-complemented strains CC1202/pJK173 and CC1205/pJK173. If AaPurK activity
were inhibited by AaOrf1 in the absence of AaPurE, the production of the inactive but
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properly folded AaPurEH59N mutant would not be expected to improve growth. The
effect of pJK348 on both insert strains relative to pJK415 argues against model 4 in
which AaOrf1 serves to prevent N5-CAIR production by AaPurK in the absence of
AaPurE. Instead the results obtained with these plasmids suggest that similar
expression of all three components is beneficial.

Figure 4.30: Comparison of the effects of pJK415 and pJK348. Shown are the growth
curves of replacement strains in minimal medium B. CC1202/pJK415 (entry #21, open
circles), CC1202/pJK348 (entry #22, filled circles), CC1205/pJK415 (entry #37, open
squares), CC1205/pJK348 (entry #39, filled squares).

In both replacement strains, the addition of plasmid pJK324 (purEAa) improved
growth at levels similar to pJK173 (Figure 4.31). This indicates that increased levels of
AaPurE relative to AaPurK may compensate for the absence of AaOrf1. These results do
not distinguish between models 3 and 5.
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Figure 4.31: Comparison of the effect of pJK324. Shown are the growth curves of
replacement strains CC1202 (entry#19, open circles) and CC1205 (entry #35, open
squares) in minimal medium B.

Orf1. A search of the AaOrf1 protein using blastp (37) retrieved 21 hits with an E
value of ≤ 1 X 10-6. All of the hits were annotated as small hypothetical proteins or
proteins of unknown function (DUF 465). These hits were found throughout much of
the class α-proteobacteria and with two hits from the γ-proteobacteria genus
Thioalkalivibrio.
In most cases, the small hypothetical protein is immediately upstream or within
one gene of the purEpurK genes in these organisms. Among the 19 α-proteobacteria,
only four were found with a different synteny; in Erythrobacter sp SD-21, orf1 precedes
a probable AraC family transcriptional regulator; in two strains of Magnetospirillum
magnetotacticum, orf1 precedes a gene involved in the biosynthesis of tetrahydrofolate
(THF), 7,8-dihydroxymethylpterin pyrophosphokinase; and in Methylocella silvestris BL2,
orf1 is found divergently oriented from a gene for phosphatidylethanolamine N184

methyltransferase. In the γ-proteobacteria genus Thioalkalivibrio, orf1 precedes a gene
that encodes a FAD-dependent pyridine nucleotide-disulfide oxidoreductase.
AaOrf1 was aligned using ClustalW with BLAST for sequences that have orf1 in
the purE-purK cluster (Figure 4.32). Only 12 of the 14 proteins are shown because two
entries were subspecies. This alignment indentifies three highly conserved regions:
residues 16-23 (A. aceti numbering), RxEHRDLD; residues 43-48, RLKKxKL; residues 6468, PDxIA. There are also three other conserved residues: Leu12, Asp53 and Glu58. All
conserved residues are shown in bold in Figure 4.32.
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Figure 4.32: Sequence alignment of Orf1 from A. aceti and 12 close homologs.
Acetobacter_aceti_orf1
Granulibacter_bethesdensis_orf1
Gluconobacter_oxydans_orf1
Rhodospirillum_rubrum_orf1
Acidiphilium_cryptum_orf1
Stappia_aggregata_orf1
Roseovarius_TM1035_orf1
Roseovarius_217_orf1
Dinoroseobacter_shibae_orf1
Gluconacetobacter_diazotrophic_orf1
Methylobacterium_radiotolerans_orf1
Beijerinckia_indica_orf1
Rhodobacter_sphaeroides_orf1

-------------------MLR-DRDLLLAQLHELRSEHRDLDT
--------------MSFQAMLK-DRDALLRQLHELRSEHRDLDT
-------------------MMT-DDNAMLKRLHELRSEHRDLDT
-------------------MDDHELDGLRAKLEELRTEHRDLDA
-------------------MLT-DKDNLLRQLHGLRSEHRDLDS
-----------------------------MQLAQLRQEHRDLDA
-------------MNAFSDLSMKSEDVLRVELEEFRREHRDLDE
-------------MNAYSDLSMKSEDVLRVELEEFRREHRDLDE
-----------MGMNGTGAMSR--EEVLKYELEVLRREHRDLDE
-------------------MLT-DRDTLLRKLHELRSEHRDLDT
-MLSGDERSSGSQVTMADEAGEGAQSDLLGELARLREEHRDLDS
---------------MVDRLSEDERISLQTELEHLRQEHRDLDA
-------------MNASPELSF--EDMLRIRLEVLRREHRDLDE
.* :* ******

24
29
24
25
24
15
31
31
31
24
43
29
29

Acetobacter_aceti_orf1
Granulibacter_bethesdensis_orf1
Gluconobacter_oxydans_orf1
Rhodospirillum_rubrum_orf1
Acidiphilium_cryptum_orf1
Stappia_aggregata_orf1
Roseovarius_TM1035_orf1
Roseovarius_217_orf1
Dinoroseobacter_shibae_orf1
Gluconacetobacter_diazotrophic_orf1
Methylobacterium_radiotolerans_orf1
Beijerinckia_indica_orf1
Rhodobacter_sphaeroides_orf1

VINRMAHETTFIDQLYLQRLKKRKLLLKDQITKVESLLIPDDIA
VISRLADQGA-LDQLQLQRLKKRKLLIKDEVSRLESNLIPDNIA
VIERLVHH-P-LNQLQLQRLKKRKLQLKDEISWIETRLIPDNIA
VIARITENMP-FDMIQMQRLKKRKLALKDQISRLENRMIPDIIA
VIARLGDQPT-IDQLQIQRLKKRKLLLRDQILRLESRLIPDSIA
AVEALASTSN-QDALQLQRLKKKKLMIKDRITALEDQLFPDIIA
AIRALQDKGT-ADQLMIQRLKKKKLWLRDMIARIEDRLYPDIIA
AIRALQDKGT-ADQLMVQRLKKKKLWLRDMIARIEDRLYPDIIA
AIEALGERPA-PDQLTLKRLKKRKLALKDQIARIEDELFPDIIA
VISRLALH-P-MDQLQLQRLKKRKLLLKDEIAWLESRLIPDNIA
AIEALERSVA-GDQLQIQRLKKRKLTLRDRIFHIEDALTPDIIA
AIEALLHLST-TDRLQVQRLKKRKLVLRDRIVFIEDLLTPDIIA
AIAAIEAGGR-GDQLMLRRLKKQKLALKDQIVKIEDRLIPDIIA
.: :
: : ::****:** ::* : :* : ** **

68
72
66
68
67
58
74
74
74
66
86
72
72
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Because AaOrf1 is proposed to interact with AaPurE and AaPurK (models 3 and
5), these proteins from the orf1-containing organisms were also aligned and compared
to EcPurE.
Sequence alignments showed no obvious conserved differences from EcPurE,
except that EcPurE Lys50 is an arginine in orf1-containing organisms (AaPurE Arg64). In
A. aceti, PurE contains an additional ~20 N-terminal residues not found in EcPurE (38).
Although these residues would appear to be an important difference, they are not
present in the other PurEs from orf1-containing organisms.
Sequence alignments of PurK from orf1-containing organisms indicated three
conserved differences from EcPurK. Two of these differences are amino acid
substitutions. Residues Asp268 and Asp306 in E. coli PurK are replaced with Gly in all
PurKs from orf1-containing organisms. The third difference between the PurKs from
orf1-containing organisms and EcPurK is they all contained ~20 amino acids inserted
between residues Ser44 and Val45 in EcPurK (Figure 4.33).
Valine 45 in the EcPurK crystal structure (pdb 1B6S) is the beginning of a third
strand of a β-sheet (39). The sequence of AaPurK was submitted to Jpred3 (40), and the
20 amino acid insert was predicted to have a small β-strand comprised of residues Thr56
and Cys 57 followed by an α-helix comprised of residues Pro 63- Arg71.
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Figure 4.33: Sequence alignment of PurKs
Acetobacter_Aceti_PurK
Granulibacter_bethesdensis_Pur
Gluconobacter_oxydans_PurK
Rhodospirillum_rubrum_ATCC_Pur
Acidiphilium_cryptum_PurK
Stappia_aggregata_PurK
Roseovarius_TM1035_PurK
Roseovarius_217_PurK
Dinoroseobacter_shibae_PurK
Gluconacetobacter_diazotrophic_PurK
Methylobacterium_radiotolerans_PurK
Beijerinckia_indica_ATCC_PurK
Rhodobacter_sphaeroides_PurK
Escherichia_coli_PurK
Bacillius_subtilis_PurK
Cryptococcus_neoformans_Ade2

PEANGPAAQVSHAVTCGKYDD-----PTALDAFARAVDVVTFEFENISAD
DAPDSPAIQVSAAHTIGAYDD-----PQALRAFANAVDVVTFEFENVSAE
TEAPSPATEVAASVTVGAYDD-----PAALEDFASRCDVVTFEFENISAE
PEDNGPASQVCPMVTLAAYDD-----LDALSRFAASVDVITFEFENIPAA
PEPDAPASQVAAATTRADYDD-----NAALLRFADAVDVITFEFENVSAE
PDPNSPAFDVSAIFTVAPYED-----IDALDRFASSVAAVTYEFENVPGP
PGGDCPASHVAHQHIQADYTD-----EDALRRFAGIVDVITYEFENIPTA
PGGDCPASHVAHRHIQAEYSD-----EDALRRFAEAVDVITYEFENIPTT
PGAAPPAGQVAEAVTTAGYDD-----LDALRRFAEVVDVITYEFENIPTA
DEAEGPAAQVAHAVTVGAYDD-----PDVLRRFASSVDVVTFEFENISAD
PDADSPAFDVAARTTCAAYDD-----AAALADFARSVDVVTYEFENIPHA
PEADSPAFVVAAGHMLAAYED-----EEALAQFAAQVDVITYEFENVPAR
PSANPPAADVAHAVTTAPYED-----EAALRAFATSVDVITYEFENIPTS
LDAEPAAVPFQQS-------------------------VITAEIERWPET
PVKDSPCGQVADVEITAHYND-----REAIRKLAEISDIITYEFENIDYD
SGSYTPAKQTLLPPPPHSHPDGPFTSETHIRKLASACDILTVEIEHVNAD
..
:* *:*.
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86
83
84
91
84
85
83
83
83
87
84
83
83
56
84
84

While this insertion is not found in EcPurK or any annotated PurK in the order
Enterobacteriales, other organisms that lack orf1 contain a ~20 amino acid insertion in
this region of PurK. This insert is found in PurK from Firmicutes bacteria. The enzyme
Ade2, which is a bifunctional protein that contains the PurE and PurK activities in fungi,
also contains a ~20 amino acid insert in this region that is slightly larger. For examples
of the inserts contained in other organisms, B. subtilis and C. neoformans were chosen.
This is because B. subtilis is a well studied bacterium with a characterized purine
pathway, and the enzyme Ade2 from C. neoformans has been characterized (41). The
alignment indicates only two conserved residue in all of the ~20 amino acid inserts
corresponding to AaPurK Asp62 and Ala70. Because this ~20 amino acid insert is
present in other organisms, it is unknown if this insert might influence the function of
AaOrf1.
Summary. Whether A. aceti Orf1 is actually a new protein involved in the
function of PurE and PurK is not proven by these results. However, it does appear likely
that it is a new protein involved in purine biosynthesis. The conserved synteny of the
gene and the conserved residues present in the protein, along with the results of the
replacement strains, indicate has an effect that is dependent on the identity of both
PurE and PurK. One exciting possibility is that Orf1 is a channeling factor (model 5) The
possibility of the involvement of another protein in the activity of PurE and PurK raises
many interesting possibilities for the regulation and control of a set of reactions with
labile products.
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4.5 Future Directions
Under the current proposal, AaOrf1 appears to be required for the proper
functioning of AaPurE and AaPurK in E. coli. In order to better determine the role of
orf1, two routes present themselves. An in-frame deletion of orf1Aa in the host organism
would be most useful. Unfortunately A. aceti has difficult genetics, and no system is
available to create such deletions. While insertional inactivation methodology is
available for some acetic acid bacteria (42-44), any such insertion will have unknown
polar effects on the adjacent purE-purK genes. We predict that a Δorf1 strain would
require exogenous purines for rapid growth. We expect that an orf1AapurEAapurKAa
replacement strain in E. coli should grow on minimal media without a prolonged lag
phase.
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Citrate Synthase
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I.1 Introduction
Citrate synthase. Citrate synthase catalyzes the formation of citrate and
coenzyme A (CoA) from oxaloacetic acid (OAA) and acetyl CoA (AcCoA). This is the entry
point of AcCoA into the citric acid cycle (CAC). The rest of the CAC produces two
molecules of CO2 from the two carbons introduced by citrate synthase and regenerates
OAA. The CAC usually yields energy for the cell in the form of one nucleotide
triphosphate (ATP or GTP) and four reduced cofactors which can be used in oxidative
phosphorylation to produce ATP.

In A. aceti the CAC is also involved in acetate

removal (1).

Scheme I.1: Reaction of citrate synthase

Citrate synthase first catalyzes the formation of citryl-CoA (CitCoA) (Scheme I.1).
To accomplish this, CS catalyzes an aldol-Claisen condensation of AcCoA and OAA to
yield CitCoA, likely through an AcCoA enolate intermediate (2, 3). CS then catalyzes the
subsequent hydrolysis of the thioester of CitCoA to yield citrate, H+, and CoA.
When unbound by ligands, citrate synthase is found in an open conformation
with the active site exposed to solvent. Upon ligand binding, conformational shifts
completely sequester the substrate OAA. Citrate synthase (CS) destabilizes the
sequestered OAA via polarization of the carbonyl oxygen, which is stabilized by a
hydrogen bond with active site residue His320 (pig CS numbering). This polarization is
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evidenced by a change in the NMR chemical shift of the carbonyl carbon and by infrared
spectroscopy indicating a diminution of double bond character (4, 5). This polarization
prepares the carbonyl carbon for nucleophilic attack. Residue Asp375 of pig CS
catalyzes the deprotonation of the AcCoA methyl group, leading to an intermediate of
enolate character that interacts through one of the acetyl oxygens with His 274 (2, 3, 6).
Following the nucleophilic attack on the polarized carbonyl carbon of OAA by the AcCoA
enolate, CitCoA is formed. The same active site catalyzes the subsequent hydrolysis of
CitCoA to yield the product citrate, CoA, and a proton.
Crystal structures, mutagenesis studies, and substrate/transition state analogs
have yielded a great volume of information about the reaction and mechanism of CS (35, 7-13). In particular, mutation of the active site base Asp375 greatly diminishes
catalytic activity. However, the identification and detailed study of the kinetics steps
involved have proven difficult by virtue of the fact that in most CSs no step is clearly rate
limiting (13). This however is not the case for Thermoplasma acidophilum citrate
synthase (TpCS), in which hydrolysis of the CitCoA thioester has been shown to be rate
limiting. TpCS has also been shown to undergo several changes in fluorescence upon the
binding of substrates or substrate analogues (10, 12). The TpCS equivalent of pig CS
Asp375 is Asp317. In recent unpublished studies, Hong Jiang of this lab has noted that a
key mutant (TpCS-D317G) undergoes at least a 2 step binding of the substrate analogue
CMCoA. Experiments in the presence of glycerol or sucrose indicated that the rates of
these steps are independent of viscosity (changes in the viscosity of the buffer by the
addition of viscogens, glycerol and sucrose, can help identify steps which are dependent
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on conformational changes of a protein). A triple mutant (TM) form of TpCS, which is
catalytically active, has only a single Trp residue and much simpler fluorescence
responses. Recent unpublished studies by a collaborator have noted that TM also
undergoes at least a 2 step binding of CMCoA; however, the rate of one of these steps is
highly dependent on the viscosity of the buffer. The difference in viscosity-dependent
steps suggests that there may be at least a third step involved in the binding of the
AcCoA analogue in catalytically active enzymes that is unobservable by fluorescence.
The availability of TM, a large number of substrate and transition state analogues (7,
11), and a detailed understanding of the functions of several active site residues (11,
14), suggest that TpCS is an appropriate form of CS for detailed characterization of CS
reaction kinetics.
Herein is reported the determination of binding constants for TpCS-D317G, and
the creation and purification of a mutant TM-D317G made to help elucidate the kinetic
mechanism of TpCS.

I.2 Methods
Materials – All materials were from Sigma Aldrich or Fisher Scientific and of the
highest purity unless otherwise noted. Mutagenesis was performed using Quikchange
Mutagenesis kits from Stratagene. Oligodeoxynucleotides (ODNs) were from Integrated
DNA Technologies. PD-10 disposable columns were obtained from GE Health Care
(formerly Amersham Biosciences). Centrifugation steps were performed using a
Beckman Avanti J-20 centrifuge with a JLA-10.5 or JA-20 rotor. Routine activity assays
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were performed on an Agilent 8453 diode array UV/vis spectrophotometer. Circular
dichroism spectra were recorded on a Jasco J715 instrument. Cell disruption by
sonication was performed using a Virsonic 100 sonicator. Proteins were routinely
concentrated using Amicon ultrafiltration devices with a 10 kD molecular weight cutoff
(YM-10). AcCoA analogues were prepared by Hong Jiang and Jung Park. Plasmids were
sequenced by Sanger sequencing at the Protein and Nucleic Acid Chemistry Laboratory
at Washington University in St. Louis. Protein masses were determined by ESI-MS on a
Micromass Q-TOF Ultima quadropole-TOF mass spectrometer by Washington University
Center for Biomedical and Bioorganic Mass Spectrometry.
Mutagenesis of TM-D317G- The plasmid used for expression of TM was a gift
from the lab of Linda Kurz (12) and was given the designation pJK393. Plasmid pJK383
(TM-D317G) was created by Quickchange mutagenesis of plasmid pJK393 using and
oligodeoxynucleotides 982 (5’-TCCGAACACGGgTTACTTCTCC) and 983 (5’GGAGAAGTAAcCCGTGTTCGGA).
Purification of TM and TM-D317G- TM was purified by a published method (12),
except that streptomycin was used in place of polyamine-p. The protein-containing
solute was brought to 1% streptomycin from a 10% stock, following a 15 minute
incubation on ice, solids were removed by centrifugation. TM-D317G was purified using
the TM procedure except the final column, which was replaced with a Cibracon Blue 3GA agarose column (20 mL, 2.5

4cm, 250 drop fractions) equilibrated in 20 mM Tris

pH 8.0, 1 mM EDTA. The column was washed with 10 column volumes (CV) (200 mL) of
buffer, and the protein was eluted with 50 mM ammonium sulfate, 20 mM Tris pH 8.0, 1
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mM EDTA, fractions containing TpCS were pooled and concentrated using an Amicon
ultra filtration device to a volume of 2.5 mL. The protein solution was applied to a
disposable PD-10 column previously equilibrated in 20 mM Tris 1 mM EDTA pH 8.0, to
remove salts and small molecules, and the protein eluted with 3.5 mL of buffer. The
protein solution was concentrated by use of a new Amicon ultra filtration device. A
portion was saved for immediate use and stored at 4 °C, and the remainder of the
purified protein stored as an 85% ammonium sulfate suspension at 4 °C for future use.
OAA titration of TMD317G. Titrations were performed in a starting solution of
2.0 mL, 50 mM EPPS 0.1 mM EDTA pH 8.0 and 0.2 µM TM-D317G at 20 °C. The emission
spectra were recorded from 300 to 420 nm (5 nm slit width, 0.5 s integration, 1 nm
intervals), exciting at 290 nm (1 nm slit width). The intensity of λmax of the unliganded
protein was then measured after small additions from a solution of 20 µM OAA, in 50
mM EPPS, 0.1 mM EDTA pH 8.0. Titrant solution was made from a standardized stock
solution of OAA made in 50 mM EPPS, 0.1 mM EDTA at pH 8.5. Fluorescence data (F)
were fit as a function of C= [titrant] to four parameters using equation 1 below: K =
dissociation constant, E= concentration of enzyme, F0 = F prior to addition of titrant, and
∆F = maximal change in F.
𝐹= 𝐹 −

∆𝐹
(𝐶 + 𝐸 + 𝐾) −
2

(𝐶 + 𝐸 + 𝐾) − 4𝐸𝐶

(1)

Titration of TpCS-D317G and TpCS-D317N with AcCoA analogues. Titrations
were performed in a starting solution of 25 mL 50 mM EPPS 0.1 mM EDTA, 5 µM OAA,
and 0.5 µM [subunit] at 20 °C in a 10 cm path length cell. Titrations were also performed
in 20% glycerol or 30% sucrose as noted. The circular dichroism of the sample was
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measured 5 times from 300 to 250 nm, (1 nm step intervals, 10 nm/min acquisition, 500
µM slit width, 2 nm bandwidth, 10 mdeg sensitivity). Following all additions, the
solution was mixed by gentle rocking and the cell placed in the cell holder. The cell was
allowed to equilibrate for 10 min. The ellipticity of the sample was recorded after small
additions from a 1.5 mM stock solution of the titrant (CMX or CMCoA). The ellipticity of
the sample at 260 nm (θ260) was fit as a function of C = [titrant] concentration, to
equation 2 below, with the known constants, θi260 = initial ellipticity at zero titrant, E=
[subunit], and variables, Kd = dissociation constant, and ∆θ260 = maximal change in θ260.

𝜃

= 𝜃

−

∆𝜃
2

(𝐶 + 𝐸 + 𝐾 ) −

(𝐶 + 𝐸 + 𝐾 ) − 4𝐸𝐶

(2)

Titration of TM-D317G with CMCoA. Titrations were performed in a starting
solution of 2.0 mL 50 mM EPPS 0.1 mM EDTA, 100 µM OAA, and 8.98 µM [subunit] at
20°C in a 1 cm path length cuvette. The circular dichroism of the sample was recorded
from 300 to 250 nm, (1 nm step intervals, 2 nm/min acquisition, 500 µM slit width, 2 nm
bandwidth, 10 mdeg sensitivity). Following all additions, the solution was mixed gently
with a stirrer 20 times, so as not to disturb the cuvette, and the solution allowed to
equilibrate for 5 min prior to the next spectrum being recorded. The ellipticity of the
sample was recorded after small additions from a 1.0 mM stock solution of the CMCoA.
Following a small linear correction to account for the ellipticity of CMCoA, the ellipticity
of the sample at 260 nm (θ260) was fit to equation 2.
Quantum yield determination for TM-D317G - Values were determined using a
previously published method (12).
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Oligomerization state of TM-D317G- Initial titrations of TM-D317G with OAA or
CMCoA suggested that TM-D317G may purify with partial occupation of the OAA. To
examine this, TM-D317G was analyzed by gel filtration. TM-D317G (2.5 mg) was run on
a 120 mL 16/60 Superdex gel filtration column, (1 mL/min flow rate, 20 mM Tris 1 mM
EDTA 50 mM KCL buffer). Absorbance of the eluant was monitored as a function of
volume. The experiment was repeated including 500 µM OAA in the buffer and the
elution profiles were compared. BIO-RAD gel filtration standards (thyroglobulin 670,000
Da, bovine gamma globulin 158000 Da, chicken ovalbumin 44,000 Da, equine
myoglobulin 17,000 Da, Vitamin B12 1,350 Da) were run under the initial conditions to
generate a calibration curve, which was used to determine the molecular weights of the
peaks.
Stopped flow fluorescence. Experiments were performed in filtered 50 mM EPPS
0.1 mM EDTA at pHs 7.0, 8.0 or 8.9. Transients were collected using the following
parameters: 305 nm cut off filter, 20.0 °C, 1000 points, 285 nm excitation, 2 nm slits, PM
voltage = 400 V. Solutions in each syringe contained 200 µM OAA. The following
concentrations listed for components present in only one syringe, refer to the final
concentration in the cell (i.e. 40 µM CMCoA means that one syringe contained 80 µM
CMCoA). Transients were collected under a series of conditions including at pHs 7.0, 8.0
or 8.9 from 0.5  4 µM TpCSTMD317G against 40 µM CMCoA, or at pH 8.0 with varying
CMCoA concentrations (0 210 μM CMCoA). Transients were collected for CMX at 40
or 80 µM and 2 µM enzyme at pH 7.0, 8.0 or 8.9.
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I.3 Results
Purification- TM was purified several times according to published methods (12)
and yielded protein of high purity. The mutant TM-D317G was found to bind
irreversibly to the same column material used in the final step of purification of TM. A
series of agarose dye affinity column materials was screened (Cibracon Blue 3GA,
Reactive Brown 10, Reactive Green 19, Reactive Blue 4, Reactive Yellow 86, Reactive Red
120). Cibracon Blue-3GA was found to purify the protein and bind TM-D317G reversibly
(Figure I.1). The purified protein was analyzed by ESI-MS and found to have a mass of
42,765.0 ± 4 Da. This mass is consistent with the TMD317G – Met1, which has an
expected mass of 42,766.0 Da.
1

2
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4

5 6

7 8

9 10 11 12 13 14 15

Figure I.1: 9% SDS-PAGE analysis of Cibracon Blue 3-GA Agarose column purification of
TpCSTMD317G. Lane 1, Sigma high range marker; lane 2, 5.8 µg TM-D317G, lane 3,
concentrated Q sepharose eluant; lanes 4-6, Cibracon Blue 3-GA flowthrough; Lanes 713, Fractions eluted in buffer with 50 mM ammonium sulfate. Lanes 14 and 15, 1 M
ammonium sulfate wash. Fractions containing protein at 50 mM ammonium sulfate
were pooled and concentrated.
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CMCoA and CMX Titrations. The binding of AcCoA analogs CMX and CMCoA
cause a change in the circular dichroism spectrum of all TpCS forms due to the
immobilization of the adenine moiety in a chiral protein environment. This change
allowed for the determination of binding constants by monitoring the change in
ellipticity at 260 nm as a function of titrant (Figures I.2-I.9). Data collected were fit to
equation 2 to yield values of Kd (Table I.1). The binding affinities of TpCS-D317G for
CMCoA or CMX were determined, and the effects of the viscogens glycerol and sucrose
on the binding affinity assessed. The binding affinity of TpCS-D317N and TM-D317G for
CMX was also determined. All of the Kds determined are much lower than the
concentration of enzyme used in the titrations, so some caution is advised in
interpreting their values.
Table I.1. Acetyl-CoA analogues Kds Determined for TpCS mutants
Kd (CMCoA)
Kd (CMX)
Buffer
+20%
+30%
Buffer
+20%
Glycerol
Glycerol Sucrose
a
TpCS-D317G 16 ± 3 nM 3 ± 1 nM 5 ± 1 nM 11 ± 2 nM 5 ± 1 nM

+ 30%
Sucrose
8 ±3 nM

TpCS-D317Na

-

-

-

1 ±1 nM

-

-

TM-D317Gb

60 ± 10 nM -

-

-

-

-

1

- Titrations were performed at 20°C in 50 mM EPPS, 0.1 mM EDTA, 5 µM OAA and 0.5
µM enzyme in a 10 cm path length cell. Titrations were performed with the addition of
viscogens glycerol and sucrose as noted. 2- Titration was performed at 20°C in 50 mM
EPPS, 0.1 mM EDTA, 50 µM OAA and 8.98 µM enzyme in a 1 cm path length cell.
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Mutant TpCS-D317N bound the AcCoA-enolate analogue CMX more tightly than
TpCS-D317G. This higher affinity could be due to hydrogen bonding of the carboxylate
of CMX by the Asn side chain. Titrations for the TpCS-D317G mutant indicate that the
addition of the viscogens glycerol and sucrose caused TpCS-D317G to bind CMCoA more
tightly, while it had nearly the same affinity for CMX (Table I.1). The TM-D317G mutant
had the lowest acetyl-CoA analogue affinity of the enzymes studied (Table I.1).

Figure I.2: CMX titration of TpCSD317N. Ellipticity at 260 nm versus [CMX] for
TpCSD317N at 0.50 µM [subunit], 50 mM EPPS, and 0.1 mM EDTA pH 8.0 in a 10 cm
path length cell. The solid line represents a fit of data to equation 2 with constants E =
0.50 µM, θ i,260 = 0.3258 , and variables Kd,CMX = 1.1 ± 1.0 nM, ∆θ260 = -5.39 ± 0.06.

205

Figure I.3: CMX titration of TpCSD317G. Ellipticity at 260 nm versus [CMX] for
TpCSD317G at 0.50 µM [subunit], 50 mM EPPS, 0.1 mM EDTA pH 8.0 and 5 µM OAA in a
10 cm path length cell. The solid line represents a fit of data to equation 2 with
constants E = 0.50 µM, θ i,260 = - 0.0727, and variables Kd,CMX = 11 ± 2 nM, ∆θ260 = -5.41 ±
0.06.

Figure I.4: CMX titration of TpCSD317G in 20% Glycerol. Ellipticity at 260 nm versus
[CMX] for TpCSD317G at 0.50 µM [subunit], 50 mM EPPS, 0.1 mM EDTA pH 8.0, 5 µM
OAA and 20% glycerol in a 10 cm path length cell. The solid line represents a fit of the
data to equation 2 with constants E = 0.50 µM, θ i,260 = - 0.217 and variables Kd,CMX = 5 ±
1 nM, ∆θ260 = -5.39 ± 0.05.
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Figure I.5: CMX titration of TpCSD317G in 30% Sucrose. Ellipticity at 260 nm versus
[CMX] for TpCSD317G at 0.50 µM [subunit], 50 mM EPPS, 0.1 mM EDTA pH 8.0, 5 µM
OAA and 30% sucrose in a 10 cm path length cell. The solid line represents a fit of the
data to equation 2 with constants E = 0.50 µM, θ i,260 = 3.064, and variables Kd,CMX = 8 ± 3
nM, ∆θ260 = -5.46 ± 0.09.

Figure I.6: CMCoA titration of TpCSD317G. Ellipticity at 260 nm versus [CMCoA] for
TpCSD317G at 0.50 µM [subunit], 50 mM EPPS, 0.1 mM EDTA pH 8.0 and 5 µM OAA in a
10 cm path length cell. The solid line represents a fit of the data to equation 2 with
constants E = 0.50 µM, θi,260 = -0.150 and variables Kd,CMCoA = 16 ± 3 nM, ∆θ260 = -5.36 ±
0.06.
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Figure I.7: CMCoA titration of TpCSD317G in 20% Glycerol. Ellipticity at 260 nm versus
[CMCoA] for TpCSD317G at 0.50 µM [subunit], 50 mM EPPS, 0.1 mM EDTA pH 8.0, 5 µM
OAA and 20 % glycerol, in a 10 cm path length cell. The solid line represents fit of data to
equation 2 with constants E = 0.50 µM θi,260 = -0.074 and variables Kd,CMCoA = 3 ± 1 nM,
∆θ260 = -5.45 ± 0.06.

Figure I.8: CMCoA titration of TpCSD317G in 30% Sucrose. Ellipticity at 260 nm versus
[CMCoA] for TpCSD317G at 0.50 µM [subunit], 50 mM EPPS, 0.1 mM EDTA pH 8.0, 5 µM
OAA and 30 % sucrose, in a 10 cm path length cell. The solid line represents a fit of the
data to equation 2 with constants E = 0.50 µM, θi,260 = 2.968 and variables Kd,CMCoA = 5 ±
1 nM, ∆θ260 = -5.60 ± 0.05.
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Figure I.9: CMCoA titration of TpCSTMD317G. Ellipticity at 260 nm versus [CMCoA] for
TpCSTMD317G at 8.98 µM [subunit], 50 mM EPPS, 50 µM OAA, 0.1 mM EDTA pH 8.0, in
a 1 cm path length cell. The solid line represents a fit of the data to equation 2 with
constants E = 8.98 µM, θi,260 = -1.5938 and variables Kd,CMCoA = 60 ± 10 nM, ∆θ260 = -9.58
± 0.04.

Stopped flow fluorescence. The binding of CMCoA to the ternary complex of TMD317G (0.5 µM [subunit] and 200 µM OAA, 50 mM EPPS 0.1 mM EDTA pH 8.0) was
examined at varying concentrations of CMCoA. Attempts to fit the data to single,
double, triple and quadruple exponential equations, including attempts with a linear
correction, all gave fits with systematic inconsistencies. A double-exponential equation
yielded the best fit, as shown for a sample trace at 20 µM CMCoA (Figure I.10). The
residuals of the fit are also shown, and as can be seen in both the transient and the
residuals, the data from ~0.1-0.5 s and the data beyond 5 s deviate from the fit.
Therefore, a plot of the derived parameters k1 and k2 versus [CMCoA] cannot be
interpreted (Figure I.11). These trends are not seen for TpCS-D317G or TpCS-TM.
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Several conditions were surveyed for TM-D317G and CMCoA to find conditions
which would yield data that could be fit. These conditions included: 0.5-4.0 µM
TMD317G at 40 µM CMCoA at pH 8.0, at 0.5-3.0 µM subunit; and 2.5 µM subunit with
50 mM KCl at pH 8.9; and 0.5-4.0 µM subunit at 40 µM CMCoA at pH 7.0. Experiments
with CMX indicated that the transient fluorescence changes were much smaller in
magnitude. Traces were collected at pH 7.0 at 40 µM CMX and pH 8.0 or 8.9 at 80 µM
CMX. Attempts to characterize the kinetics of CMX binding proved even more difficult,
as the transients were of smaller magnitude and appeared more complex (Figure I.12).
None of the equations used above fit the data as well as a single exponential. The
residuals from this fit are also shown (Figure 5.13). No suitable conditions were found
for the study of CMCoA or CMX binding.
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Figure I.10: Stopped flow fluorescence of CMCoA binding TM-D317G∙OAA at pH 8.0.
Traces collected at 0.5 µM TM-D317G, 200 µM OAA and 20 µM CMCoA final mixed
concentrations. Voltages for time points shown as dots to highlight double exponential
fit to the data (solid line). Residuals of the fit are shown (X-token). Dashed line
represents y = 0. Double exponential fit to parameters Vf = 0.02798 ± 0.00004; ΔVk1 =
0.0101 ± 0.0003; k1 = 5.6 ± 0.3 s-1; ΔVk2 = 0.0233 ± 0.0004; k2= 82 ± 2 s-1.

Figure I.11: Values of k1 and k2 from double exponential fits of TM-D317G as a function
of [CMCoA]. Plot shown on log scale to highlight the change in k2 (filled squares), and k1
(open circles).
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Figure I.12: Stopped flow fluorescence of CMX binding TM-D317G∙OAA at pH 8.0.
Traces collected at 2 µM TM-D317G, 200 µM OAA and 80 µM CMX final mixed
concentrations. Voltages for time points shown as dots to highlight double exponential
fit of data (solid line). Residuals of the fit are shown (X-tokens). Dashed line represent y
= 0. Double exponential fit to parameters Vf = 0.04935 ± 0.00009; ΔVk1 = 0.0519 ±
0.0009; k1 = 333 ± 7 s-1.

Gel-filtration profile of TM-D317G. The inconsistent stopped flow fluorescence
data fitting led us to suspect an inhomogeneous aggregation state of the multiplymutated TMD317G protein. Upon purification, TM-D317G was initially titrated with a
solution of OAA. The resulting titration yielded an end point below the concentration of
enzyme in the cuvette (~70% [subunit]). A subsequent titration with CMCoA indicated
that this was not a result of the concentration of protein being incorrect. This suggested
that the enzyme co-purified with partial occupancy of OAA. Ordinarily this would be
confirmed by enzyme activity, but the D317G mutant is inactive.
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In order to investigate the possibility of partial occupancy of OAA, the protein
was analyzed by gel filtration and analyzed again with the addition of OAA to the buffer.
The gel-filtration profile indicated two peaks for the purified protein (Figure I.14). When
500 µM OAA was added to the buffer, the second peak decreased in magnitude (Figure
I.14). This is consistent with TM-D317G co-purifying with tightly bound OAA. Indeed,
D317G is known to bind OAA very tightly (12).

Figure I.13: Gel filtration profile of TM-D317G. TM-D317G (2.5 mg) was run on a gel
filtration column in 20 mM Tris 1 mM EDTA, and 50 mM KCl as buffer with (dashed line)
and without (solid line) 500 µM OAA in the buffer. TM-D317G yielded two peaks with
apparent molecular masses of 59 kDa and 31 kDa. The addition of OAA to the buffer
caused reduction in the peak at 80 mL (31 kDa), consistent with TM-D317G purifying in
two forms, unliganded and OAA-bound.

Quantum yield determinations of TM-D317G- The absolute quantum yield of TMD317G was determined following a published procedure previously used for other
forms of TpCS (12) (Table I.2).
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Table I.2: Quantum yield of TM-D317G
Unliganded protein OAA complex
Ternary complex
absolute Quantum
relative to
Yield in reference to unliganded protein
Trp (0.14) (relative
to Trp)
a
TM-D317G
0.11 (0.79)
0.30
0.46
b
TM
0.27 (1.99)
0.21
n.d.
a
-Protein purifies with partial occupancy of OAA. Therefore the actual value of absolute
quantum yield of completely unliganded protein should be higher and the ratio of OAA
complex relative to unliganded protein and ternary complex ratio to be lower. b-values
from(12)

I.4 Discussion
Purification of TM forms- The current method of growth and purification yields
very pure protein. However, the total yield of protein is typically low (~3 mg/L culture).
The small broth size used during growth of cells (300 mL in 2 L flasks), makes the
production of large quantities of protein difficult. If expression of large quantities of
protein is required, an alternative system may be needed.
The TM-D317G mutant irreversibly bound to the Reactive Red 120 CL-3000B
column used in the previous purifications of TM, necessitating a search for a new
method to purify the protein. This was accomplished by the use of a Cibracon Blue 3GA
column. This has the additional advantage of being commercially available in large
quantities.
The difference in purification for TM-D317G may be due to the enzyme purifying
in two forms (Figure I.13); TM does not co-purify with OAA (12). The cause of this
difference may be the removal of the catalytically important Asp317. The D317G mutant
214

cannot convert bound OAA to citrate, and this may lead to accumulation of OAA on the
enzyme during expression of the protein.
Stopped flow fluorescence. While the data collected for the TM-D317G mutant
failed to give the expected simplified kinetics, the data collected can be used to aid
qualitatively in the analysis of data collected from the TpCS-wt, TpCS-D317G, TpCSD317N and TM. The transient fluorescence change for both TpCSD317G and TM are
biphasic. TpCSD317G shows a large rapid increase, followed by a small slow decrease in
transient fluorescence upon binding CMCoA or CMX. However, TM shows a small rapid
increase, followed by a large slow decrease in transient fluorescence upon binding
CMCoA or CMX. The traces for TM-D317G resemble the traces of the TpCSD317G and
indicate that the transient fluorescence changes seen in TM are not due to the
replacement of three tryptophans with phenylalanine. The lack of a slow decrease in
the traces for TM-D317G suggests that the second phase seen in TpCSD317G is due to
the three tryptophans not present in TM-D317G.
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